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Summary 
Cardiovascular disease represents a significant socio-economic burden and 
minimally invasive therapies that address the needs of patients suffering with 
peripheral arterial disease and critical limb ischemia are needed. Cell therapies 
have been proposed as an alternative to pharmacological and surgical 
treatments, yet, have demonstrated somewhat limited efficacy. However, the 
unlimited capacity for self-renewal, and the ability to differentiate into cell 
types from all three germ layers, including endothelial cell (EC) forming 
mesoderm, make human embryonic stem cells (hESC) and human induced 
pluripotency stem cells a promising source for well-defined differentiated cell 
populations with high angiogenic capacity. 
Numerous endothelial differentiation protocols have been published with high 
differentiation efficiencies achieved recently. However, most of these 
approaches are not optimised for clinical purposes due to the use of poorly 
defined, non cGMP compatible reagents, or require additional processing steps, 
such as cell sorting, complicating the clinical approval of these therapies. 
Therefore, here it was aimed to develop and optimise a clinically compatible 
hESC-EC differentiation protocol that avoids using poorly defined reagents, and 
yields high percentages of cells expressing EC markers without the use of cell 
sorting. 
A novel, serum free hESC-EC differentiation protocol was developed in the lab. 
The use of Pluronic F-127 well coating was demonstrated as a low cost 
alternative to low adherence wells. Furthermore, inhibition of TGFB signalling 
during hESC-EC differentiation to increase the differentiation efficiency was 
evaluated and did not reveal any additional benefits and thus was not included 
in the optimised protocol. The optimised protocol consists of embryoid body 
based mesodermal induction phase, followed by plating and monolayer culture 
for vascular specification. By day 7, approximately 30% of cells express 
endothelial markers CD31 and CD144. In addition, transient induction of 
mesodermal gene, followed by induction of endothelial progenitor and 
endothelial gene expression was demonstrated, following the expected gene 
expression patterns. 
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It was proposed that high throughput screening using hESC lines carrying 
fluorescent reporter constructs could be used to optimise the differentiation 
protocol for increased efficiency, thus, avoiding the need of cell sorting prior to 
therapeutic use. Here, reporter constructs where ETV2, ROBO4 and CDH5 
promoter sequence fragments were cloned upstream from florescent reporter 
sequences were generated and preliminary validation was attempted in NCI60, 
HUVEC and HSVEC cell lines, and during the hESC-EC differentiation. Reporter 
gene expression was not observed in any of the validation experiments, 
suggesting that these constructs were not functional. Similarly, previously 
published CDH5 and commercially sourced ETV2 reporter constructs were 
validated during the hESC-EC differentiation. Preliminary testing of these 
reporter constructs showed non-specific reporter gene expression, therefore, 
the work with reporter constructs work was not pursued further. 
Next, rational targeting of novel signalling pathways that may contribute to the 
hESC-EC differentiation was employed as an alternative approach for the 
optimisation of hESC-EC differentiation. Firstly, it was hypothesised that 
intracellular cAMP levels could be targeted pharmacologically to increase the 
differentiation efficiency, and to induce expression of arterial and arterial 
phenotype associated genes, which could reduce the need for cell sorting and 
deliver arterial cell populations with a superior angiogenic profile. Forskolin 
treatments induced increased intracellular cAMP levels during the hESC-EC 
differentiation, yet, this did not result in increased arterial or arterial 
phenotype associated gene expression. However, an increase in the percentage 
of cells expressing EC markers was observed in Forskolin treated 
differentiations, mainly mediated via an increase in the CD144low CD31+ cell 
population.  
Additionally, it was hypothesised that angiotensin II (Ang II) signalling may play a 
role in hESC-EC differentiation and may be exploited to increase the endothelial 
differentiation efficiency. Indeed, differential renin angiotensin system receptor 
expression was demonstrated during hESC-EC differentiation, supporting a role 
for Ang II signalling in endothelial development. However, no significant 
differences in the differentiation efficiency and total cell numbers were 
observed when Ang II and AT1R antagonist Losartan treatments, in combination 
14 
 
or alone, were applied during the hESC-EC differentiation. In contrast, a 
significant reduction in total cell numbers and a trend of reduced differentiation 
efficiency was observed when AT2R antagonist PD-123319 was used in 
combination with Ang II. These observations highlight the negative effects of 
AT1R signalling during hESC-EC differentiation and show that signalling via AT2R 
counterbalances these effects.  
In summary, a novel endothelial differentiation protocol was developed and 
rational selection of signalling pathways for the optimisation of the hESC-EC 
differentiation was employed. Here, the role of cAMP and Ang II signalling during 
hESC-EC was demonstrated, highlighting the contribution of various signalling 
systems to endothelial differentiation. Both of these signalling systems can be 
easily manipulated in a clinically compliant manner, and therefore represent an 
attractive target during clinically compatible hESC-EC differentiation. Further 
research is needed to investigate the underlying mechanisms of the observed 
effects and to evaluate other, novel signalling pathways that may be targeted to 
enhance endothelial differentiation. The work described has highlighted the 
difficulties of establishing efficient, clinically compatible hESC-EC 
differentiation methods, which are needed to provide highly defined cell 
populations for future cell therapies and tissue engineering. 
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1.1 Cardiovascular Disease 
Cardiovascular disease (CVD) includes various diseases of the heart and 
circulation, and has four main types: coronary heart disease, stroke, peripheral 
arterial disease and aortic disease. According to the World Health Organisation 
(WHO), CVD is the main cause of deaths worldwide (WHO, 2015). In the United 
Kingdom (UK), CVD causes more than a quarter of all deaths with yearly costs 
relating to lost productivity and disease treatment estimated at £19 billion (BHF, 
2015). 
One of the fundamental processes in CVD is atherosclerosis, which is a slow 
disease process driven by endothelial dysfunction and low grade inflammation, 
leading to formation of a plaque, consisting of accumulated low-density 
lipoprotein, oxidized lipids, debris, immune cells and apoptotic cells (Weber and 
Noels, 2011). This leads to narrowing of arteries (Figure 1) and reduced blood 
supply to tissues, also known as ischemia. Ischemic tissues do not receive 
sufficient oxygen, glucose and other nutrients as well as have an accumulation 
of cellular waste products, leading to altered cell metabolism, remodelling and 
even tissue atrophy. 
Although, targeting behavioural risk, current pharmacological and surgical 
interventions have reduced CVD death rates in the UK by a third since 1961 
(BHF, 2015), there is still a need for novel therapies to address the needs for 
those patients who have had limited success with pharmacological treatments 
and don’t have an option of surgical interventions. 
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Figure 1: Atherosclerosis and blood flow. A. In a normal artery, blood flow is not 
limited and tissues receive adequate blood supply. B. Formation of a plaque can 
result in narrowing of an artery and subsequently abnormal blood flow and reduced 
blood supply to the tissues as seen in PAD and CLI. C. Cross section of a coronary 
artery where lipid rich atherosclerotic plaque can be seen. This blood vessel was 
blocked completely by a thrombus (in red) that formed due to the ruptured 
atherosclerotic plaque. Adapted from: Hansson (2005) and National Institutes of 
Health (2015).  
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1.2 Peripheral arterial disease 
Peripheral arterial disease (PAD), also known as peripheral vascular disease, is 
an ischemic disease associated with systemic atherosclerosis resulting in 
decreased tissue perfusion pressure and comprised capillary function as shown in 
Figure 2 (Lambert and Belch, 2013). PAD can affect arteries in different parts of 
the body, however, in the majority of cases PAD affects lower limbs. 
Intermittent claudication, which is pain and stiffness in calf muscle usually 
attenuated by rest, is a symptom of early stage PAD. Severe form of PAD is 
known as critical limb ischemia (CLI). PAD is associated with age, with estimated 
incidence increasing to 150 - 250 cases per 100 000 of over 85s population per 
year, depending on the classification system used (Howard et al., 2015). 
According to the National Institute for Health and Care Excellence (NICE) 
guidelines (2012), current treatments of PAD rely on behavioural changes, 
exercise programs, pharmacological treatments targeting disease cofactors, for 
example diabetes, high blood pressure or cholesterol levels, and invasive 
approaches, for example, endovascular therapy to restore blood flow to the 
tissues. In addition to pain management, the only pharmacological treatment 
offered for PAD in the UK is vasodilator naftidrofuryl oxalate, used only if 
revascularization is not considered.   
Two meta-analysis have shown that naftidrofuryl oxalate significantly improves 
pain free and maximum walking distances (Squires et al., 2011; Stevens et al., 
2012). However, these improvements are not deemed statistically significant in 
Cochrane analysis of eight clinical trials and it was also noted that amputation 
rates remained high with naftidrofuryl oxalate treatment (Smith et al., 2012). 
Other drugs used for their vasodilatory effects are naftidrofuryl and cilostazol, 
however, there is limited evidence for their efficacy in CLI (Lambert and Belch, 
2013). 
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Figure 2: CLI pathology. A. In the majority of cases PAD affects lower limbs. 
Severe form of PAD is known as CLI B. Magnetic resonance angiogram where near 
complete occlusion of the right superficial femoral artery can be seen as indicated 
by the thick arrow). C. Systemic atherosclerosis results in decreased tissue 
perfusion pressure and comprised capillary function. Adapted from: Annex et al. 
(2013) and Lamberth and Belch (2013).  
Another pharmacological approach is the use of prostanoids for their antiplatelet 
and vasodilatory properties. Due to lack of evidence showing efficacy, it is not 
currently not recommended in the UK (NICE, 2013). A recent meta-analysis by 
Vitale et al. (2015) presented some evidence that prostanoids were associated 
with a lower major amputation rate while total amputation and healing rate was 
not significantly affected by prostanoid treatment. However, they were unable 
to draw conclusions or recommend their use. 
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Approximately in one in five patients with PAD, the disease progresses to a point 
where the blood supply of limbs is severely restricted resulting in CLI. CLI 
represents a significant clinical and socioeconomic burden, especially when 
considering the consistently reported mortality and amputation rates of over 20% 
(Abu Dabrh et al., 2015; Henry et al., 2011; Howard et al., 2015). In addition, a 
recent UK based population study has estimated the five year CLI mortality rate 
of 29% and amputation rate exceeding 40% (Howard et al., 2015). 
It is clear that current drug therapies are insufficient for treating PAD and CLI, 
and surgical revascularisation strategies have been receiving increased clinical 
focus as additional approaches for increasing limb salvage rates and reducing 
PAD related mortality. 
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1.3 Current revascularization strategies for PAD 
There are two main revascularization strategies for PAD. Surgical bypass surgery 
is more suitable for younger patients with longer life expectancy and requires a 
bypass vessel, usually an autologous vein. In contrast, endovascular 
revascularization (angioplasty, stenting and atherectomy) is less invasive and 
costly and has become the preferred treatment (Goodney et al., 2009; Slovut 
and Sullivan, 2008).  
Both methods offer increased limb salvages rates. However, there is a lack of 
consensus on which is the best therapeutic approach. An attempt to address this 
was made in BASIL study (2005) which followed 452 patients with CLI and severe 
limb ischemia randomly assigned to either angioplasty or bypass surgery. The 
study reported similar medium term outcomes between the treatment groups 
with amputation-free survival at 3 years of 57% in bypass surgery group and 52% 
in angioplasty group. However, evidence was also provided suggesting that 
bypass surgery might have a favourable long term amputation and survival rate 
using post-hoc analysis (Bradbury et al., 2010). However, there have been 
multiple criticisms of the BASIL study, for example regarding to cohort and 
clinical endpoint (amputation free survival) selection (Conte, 2010) and a new 
BEST-CLI study has been designed to address these issues and evaluate the 
current CLI revascularization therapies (Farber et al., 2014). 
Another approach is hybrid revascularization which combines open surgery with 
endovascularization techniques promising similar early and long term efficacy to 
surgical bypasses but with reduced morbidity and hospitalization times (Huynh 
and Bechara, 2013). A recent, long term 57 patient study demonstrated no 
significant differences in limb salvage rates, major procedure-related 
complications, systemic complications and mortality between patients 
undergoing combined iliac endovascular therapy and infra-inguinal bypass, even 
though, preoperative limb ischemia was more severe in patients undergoing 
combined iliac endovascular therapy (Miyahara et al., 2015). This is in line with 
observations by Zhou et al. (2014) and one of the largest studies to date 
reporting 125 procedures by Dougherty et al. (2003). However, long term 
analysis with higher patient numbers is required to further explore any potential 
benefits of hybrid revascularisation. 
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While endovascular revascularization is an alternative for those patients who are 
not eligible for bypass surgery, there’s a significant patient population, for 
example patients with complex lesions, who are not suitable for either of the 
treatments. Therefore, minimally invasive therapies that address the needs of 
this patient group are needed. In addition, novel approaches, for example gene 
therapy, to revascularization have the potential to complement current 
therapies, offering limb salvage, quality of life and survival improvements. 
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1.4 Gene therapy for PAD 
Gene therapy aims target disease processes by introducing exogenous genes and 
has attracted increasing attention since the first therapeutic trials were 
performed in the beginning of 1990s. Even though the majority of the gene 
therapy trials focus on cancer treatment, cardiovascular gene therapy is the 
second largest area of interest (Edelstein et al., 2007, 2004; Ginn et al., 2013). 
There are two main approaches to gene delivery: viral and non-viral. Viral gene 
delivery can be further classified, depending on the use of non-integrative 
vectors, for example adenoviruses, or integrative vectors like retroviruses which 
offer higher transduction efficiencies and stable transgene expression. After 
initial promising proof of concept trials using retroviral vectors, concerns 
regarding preferential viral integration near oncogenes (Edelstein et al., 2007) 
became an important obstacle in the clinical progression of the viral gene 
therapies. Indeed, multiple high profile adverse effect reports have highlighted 
that additional precautions are required when considering viral gene therapy 
vectors (Check, 2005; Gansbacher and European Society of Gene Therapy, 2003; 
Hollon, 2000; Hughes, 2007; Marshall, 1999).  
The development of new human immunodeficiency (HIV) based lentiviral vectors 
(Dull et al., 1998; Naldini et al., 1996) has minimised these risks. In addition, 
methods have been developed for clinical grade lentiviral vector production 
(Ausubel et al., 2012) and, unsurprisingly, a large number of clinical trials have 
used lentiviral vectors for treatments of a wide range of diseases in the past 
years (Ginn et al., 2013). Yet, some risks of genotoxicity and immunogenicity 
remain, thus, non-viral gene delivery methods remain important alternative 
tools for gene therapy (Baum, 2014; Nayak and Herzog, 2010). 
Direct gene transfer in vivo was first demonstrated in mouse skeletal muscle by 
Wolff et al. (1990) and recently plasmid based vectors have gained more 
attention as an alternative to viral vectors with reduced adverse event risk, 
larger capacity of therapeutic deoxyribonucleic acid (DNA) and cheaper 
manufacture, albeit lower efficiency and concerns regarding the presence of 
antibiotic resistance genes (Edelstein et al., 2007; Vandermeulen et al., 2011). 
Plasmid mini-circles lacking antibiotic resistance gene have been developed to 
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overcome this (Mayrhofer et al., 2009; Vandermeulen et al., 2011), making 
plasmid based approaches highly suitably for clinical setting. 
Angiogenesis has been well characterised both in health and disease as reviewed 
by Carmeliet (2003) and a role for various signalling molecules, for example, 
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
hypoxia inducible factor (HIF) and platelet derived growth factor (PDGF), has 
been well documented. Several of these cytokines have attracted interest as 
potential therapies for CLI and numerous gene therapy trials using plasmids or 
adenoviruses have been completed (Cooke and Losordo, 2015; Ko and Bandyk, 
2014).  
There are 4 FGF receptor genes and 18 members in the FGF ligand family with 
several members expressed both on endothelial and vascular smooth muscle 
cells (Yang et al., 2015). Interestingly, FGF is involved both in vascular 
homeostasis, atherosclerosis, early and late angiogenesis and thus has received 
increased attention as a potential target for gene therapy.  
TAMARIS is the highest profile clinical trial to date and was set up after initial 
positive findings in an open label Phase I trial and a double-blind, randomized, 
placebo-controlled Phase II trial (Comerota et al., 2002; Nikol et al., 2008). 
TAMARIS followed 525 patients over a period of 12 months and evaluated the 
efficacy and safety of FGF1 encoding plasmid NV1FGF for CLI (Belch et al., 
2011). Unfortunately, NV1FGF did not achieve any improvement in major death 
or amputation rates, mainly due to lower than expected placebo major 
amputation or death rate when comparing Phase II versus Phase II trial (33% vs 
>50%). Safety was comparable to placebo at the end of the TAMARIS trial and 
subsequent follow up at 36 months confirmed these observations. Two cases of 
cancer were reported in the NV1FGF treated patient group, however, no 
conclusions could be drawn from this observation due to the small sample size 
(Belch et al., 2011; Niebuhr et al., 2012; Prokosch et al., 2014).  
HIF1 is the main transcriptional regulator expressed in response to hypoxia and is 
able to activate a range of genes via binding hypoxia response elements in gene 
promoters or enhancers (Zimna and Kurpisz, 2015). HIF1 upregulates gene 
families associated with cytokines and growth factors, including VEGF and PDGFB 
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and can support all stages of angiogenesis. Manalo et al. (2005) has shown that 
HIF1 carrying adenoviral vector is sufficient to induce endothelial tubule 
formation in vitro. In addition, it has been reported that low density lipoprotein 
(LDL) reduces hypoxia induced expression of HIF1A and HIF2A in vitro (Yao et 
al., 2015), this suggests that HIF expression might be reduced in patients with 
CLI and could be targeted in CLI therapies.  
The largest clinical study of HIF1 to date has been reported by Creager et al. 
(2011) and was a randomised, double blind, placebo controlled trial following 
289 patients with intermittent claudication over a 12 month period and tested 
adenovirus vector encoding constitutively active HIF1A gene (Ad2/HIF1/VP16). 
No improvement in any of the quality of life indicators was observed in the 
Ad2/HIF1/VP16 treated group. Safety was comparable between the groups, but 
it was noted that four cases of stroke were observed in the Ad2/HIF1/VP16 
treated group, while no cases were observed in the control group. Nevertheless, 
the small sample size limits the conclusions that can be drawn from this 
observation. It was speculated that the treatment might benefit patients with 
more severe PAD, or that another vector is needed for increased efficiency, 
however, this is yet to be tested in a clinical setting. 
Other, smaller clinical trials have evaluated VEGF, hepatocyte growth factor 
(HGF) and developmental endothelial locus-1 gene therapies with mixed results 
(Cooke and Losordo, 2015). While overall the data from clinical trials suggest 
acceptable safety of gene therapy in PAD and CLI, there is an overall trend of 
limited efficacy in larger, clinically relevant patient populations.  
Therefore, there is a clear need for alternative therapy strategies to 
complement or replace pharmacological and gene therapy approaches for the 
treatment of CLI and PAD. Cell therapies represent a novel approach for 
therapeutic angiogenesis and have been attracting more and more interest. 
Multiple clinical trials have attempted to use adult cell sources for therapeutic 
angiogenesis, which will be discussed in the following section. 
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1.5 Cell therapy for PAD 
Bone marrow contains not only hematopoietic stem cells but also a variety of 
other progenitor cells which have gained increased attention as potential 
sources for treatments of non-hematopoietic disorders (Prockop, 1997).  Further 
research has led to multiple adult cell types being trialled in a clinical setting 
for PAD – bone marrow derived or granulocyte colony-stimulating factor 
mobilized peripheral blood derived mononuclear cells (BM-MNC and PB-MNC), 
mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPC).  
The vast clinical experience with bone marrow and hematopoietic cell 
transplantation was seen as advantage as it promised simplified road to clinical 
setting with faster development and approval for these therapies. This was 
somewhat restricted by 2011 recommendations of Committee for Advanced 
Therapies of the European Medicines Agency which classified the use of BM-MNC 
and cell products derived from BM-MNC as advanced therapy medicinal products 
when used in non-hematopoietic applications (Cuende et al., 2013, 2012; Pirnay 
et al., 2013). However, this has not diminished the interest in bone marrow 
derived cells as clinically relevant therapies for PAD and multiple clinical studies 
have been undertaken as summarised in Table 1 and discussed in the upcoming 
sections. 
  
 
 
Study Phase Patients Cell Type Follow up Outcomes 
JUVENTAS (Teraa 
et al., 2015) 
I/II 160 BM-MNC 9 months 
No significant differences in major amputation rate when compared 
to placebo. 
Prochazka et al. 
(2010) 
n/a 96 BM-MNC 4 months 
A reduction in major limb amputation in BM-MNC treated patient 
group. 
RESTORE-CLI 
(Powell et al., 
2012) 
II 86 
BM-MNC 
derived 
Ixmyelocel-T 
12 months 
No significant differences in amputation free survival when compared 
to placebo. Significantly prolonged time to treatment failure (major 
amputation of injected leg, all-cause mortality, doubling of total 
wound surface area, de novo gangrene). 
Li et al. (2013) n/a 58 BM-MNC 6 months 
No difference in major amputation rate when compared to placebo. 
Improved rest pain, skin ulcers and ABI. 
Huang et al. 
(2007) 
n/a 150 
BM-MNC vs 
PB-MNC 
12 weeks 
No difference in amputation rates. Improvement of ABI, skin 
temperature, and rest pain in PB-MNC treated group. 
TACT 
(Tateishi-Yuyama 
et al., 2002) 
n/a 47 
BM-MNC vs 
PB-MNC 
24 weeks 
ABI, rest pain and pain free walking time was significantly improved 
in BM-MNC treated group compared to PB-MNC. Amputation rate 
comparison not reported. 
Zhang et al. 
(2016) 
n/a 53 
PB-MNC: 
CD133+ 
18 months 
No statistically significant differences in amputation rates when 
compared to placebo. Improved ulcer healing and ABI. 
Raval et al. 
(2014) 
n/a 10 
PB-MNC: 
CD133+ 
12 months 
No differences in overall survival, freedom from amputation or 
freedom from hospitalization at 12 months compared to placebo. 
 
Table 1: Key clinical studies evaluating cell therapies for PAD. Continued on the next page. 
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Study Phase Patients Cell Type Follow up Outcomes 
Kirana et al. 
(2012) 
n/a 24 
BM MSC vs 
CD90+ 
45 weeks Comparable safety and efficacy between the treatment groups.  
Perin et al. (2011) I 21 
MSC:  
ALDH+ vs  
BM-MNC 
24 weeks 
Improvement in Rutherford ischemic limb classification system score 
in ALDH+ treated patients when compared to BM-MNC. 
Gupta et al. 
(2013) 
I/II 20 
MSC: CD90+ 
CD73+ CD166+ 
CD106+ 
6 months 
No difference in serious adverse effects (death, infected gangrene, 
amputations) compared to placebo. 
Losordo et al. 
(2012) 
I/IIa 28 EPC: CD34+ 12 months No difference in major amputation rates when compared to placebo. 
Kawamoto et al. 
(2009) 
I/IIa 17 
EPC: CD34+ 
dose 
escalation 
12 weeks 
Demonstrated safety and improvement in efficacy score (total 
walking distance, TBI, and pain), placebo control not used. 
Skóra et al. 
(2015) 
n/a 32 
BM-MNC + 
VEGF 
expressing 
plasmid 
12 weeks 
Increase in ABI and reduction of pain observed in BM-MNC + VEGF 
expressing plasmid treated group when compared to control group 
receiving pentoxifylline. 
 
Table 1 (cont.): Key clinical studies evaluating cell therapies for PAD. 
 
 
1.5.1 BM-MNC and PB-MNC 
BM-MNC are a heterogeneous population of cells, including hematopoietic stem 
cells and MSCs, amongst other cell types. Multiple clinical trials of BM-MNC 
therapies for PAD have been conducted as reviewed by Liu et al. (2015) and 
Raval and Losordo (2013), often reporting positive findings. However, these 
studies enrolled small numbers of patients and lack statistical power, so the 
positive effects need to be validated in larger patient populations.  
This was attempted in a recent randomized, double-blind, placebo-controlled 
JUVENTAS trial which is the largest study to date, enrolling 160 patients (Teraa 
et al., 2015). JUVENTAS compared repeated intra-arterial infusion of BM-MNC 
versus placebo and did not find any significant differences in major amputation 
rates at 6 months and the extended follow up at 9 months between the patient 
groups. Safety of BM-MNC was comparable to placebo.  
Other large scale studies have provided conflicting evidence, both supporting 
the clinical efficacy of BM-MNC and showing a reduction in major limb 
amputation (Procházka et al., 2010) and showing no benefit in amputation free 
survival (Powell et al., 2012). However, an updated meta-analysis of the effect 
of cell therapy on major amputation rates in CLI (Teraa et al., 2015) reported 
that, when non-blinded studies were excluded, the positive effect of cell 
therapies was lost. While differences in patient population or doses used or cell 
isolation methods, which can be detrimental to BM-MNC (Pösel et al., 2012), 
could contribute to the observed discrepancies in treatment efficiency between 
blinded and non-blinded studies, this highlights the need for double-blind, 
placebo controlled studies with sufficiently large patient populations to 
determine the efficacy of BM-MNC treatments for PAD. 
Furthermore, DAMASCENE, a comprehensive evaluation of autologous bone 
marrow stem cell trials for treatment of ischemic heart disease (Nowbar et al., 
2014), has demonstrated a correlation between the number of discrepancies in 
trial reports and the reported clinical efficiency. Indeed, while studies without 
discrepancies did not report an enhancement of ejection fraction, studies with 
increasing numbers of discrepancies reported an increasing benefit of bone 
marrow stem cell therapies. The possible explanations for these observations – 
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pressure for results to match expectations, reporting of exciting results before 
full checking, consistency in applying the treatment or measuring the response, 
also apply to cell therapies for PAD. Therefore, the quality of the clinical studies 
requires thorough evaluation to exclude possibility of non-reproducible positive 
study results.  
Stem and progenitor cells are released from bone marrow in the circulation after 
stimulation with granulocyte colony-stimulating factor (Johnsen, 2001) and 
become a part of the PB-MNC together with lymphocytes and monocytes. 
Similarly to BM-MNC, some positive effects on ABI and amputation rates have 
been reported in clinical trials using  PB-MNC (Y. Liu et al., 2015), however, only 
limited conclusions can be drawn these studies due to limited patient numbers. 
There doesn’t seem to be a clear benefit of using PB-MNC over BM-MNC as 
studies comparing these two therapies have had conflicting results. Huang et al. 
(2007) reported an advantage of using PB-MNC in the largest comparative trial to 
date with 150 patients, while Tateishi-Yuyama et al. (2002), reported ABI, rest 
pain and pain free walking time improvements in BM-MNC treated patient 
population when comparing to PB-MNC, in a study with 47 patients. Yet, both of 
these studies failed to demonstrated improved amputation rates in any of the 
treatment groups. 
Furthermore, neither of these studies included comparisons to placebo and, 
thus, it is difficult to evaluate the efficacy of these treatments. It can be 
speculated that both BM-MNC and PB-MNC therapies suffer from similar 
shortcomings. For example, Li et al. (2010) has shown that bone marrow cell 
angiogenic potency (for example, implantation and VEGF production) was 
significantly reduced in aged patient populations, which represent the majority 
of CLI cases. In addition, both approaches use somewhat variable and undefined 
populations that might not represent the best approach for therapeutic 
angiogenesis.   
This has been attempted to address in studies using prominin-1 (CD133) 
expressing cells isolated from PB-MNC, which are thought to possess high 
regenerative capacity (Burt et al., 2010; Raval et al., 2014), however, the 
efficacy of the treatments was not demonstrated, perhaps due to the small 
number of patients enrolled in these studies. More recently, autologous 
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peripheral blood sorted CD133+ cell transplants were demonstrated to improve 
ulcer healing and ABI in a larger study enrolling 53 patients with diabetic critical 
PAD (Zhang et al., 2016). However, while reduced amputation rates were 
reported, these results were not statistically significant and, thus, the clinical 
efficacy for prevention of amputations cannot be claimed. 
Therefore, it can be proposed that therapies utilizing other cell types would be 
more suitable as treatment strategy for PAD. Cell types of interest include 
mesenchymal stem cells, due to their paracrine and immunomodulatory effects, 
and endothelial progenitor cells for taking part in angiogenesis directly, as 
discussed in the following sections.  
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1.5.2 MSCs 
Mesenchymal stem cells (MSCs), also known as marrow stromal cells, are 
multipotent adherent cells that possess capacity to self-regenerate and undergo 
osteogenic, chondrogenic and adipogenic differentiation (Conget and Minguell, 
1999; Jiang et al., 2002; Pittenger et al., 1999). Originally, MSCs were isolated 
from bone marrow, however, they can be found in most vascularised tissues 
(Crisan et al., 2008) and have been isolated from various sources, including 
adipose tissue (Eirin et al., 2012), peripheral blood (Tondreau et al., 2005) and 
skeletal muscle (Uezumi et al., 2010). 
MSCs are defined as cells expressing CD105, CD73, CD90, but not CD45, CD34, 
CD14, CD11b, CD79a, CD19 and HLA-DR (Dominici et al., 2006). Various stemness 
markers have been suggested to identify MSCs, for example CD146, SSEA-3, 
CD237, however, it is becoming increasingly clear that no single MSCs identifying 
marker exists (Álvarez-Viejo et al., 2015; Lv et al., 2014). Indeed, the 
phenotypes of MSCs differ depending on the cell source with both marker 
expression and functional differences reported as reviewed by Lv et al. (2014).  
While MSCs have also been reported to undergo endothelial differentiation and 
support neovascularisation (Oswald et al., 2004; Silva et al., 2005), the major 
effects of MSCs are mediated via paracrine immunomodulatory mechanisms 
(Liang et al., 2014; Murphy et al., 2013). Indeed, MSCs have a secretory 
phenotype and express various cytokines and growth factors, including ones that 
are highly relevant to angiogenesis – VEGF and bFGF (Tang et al., 2005). 
Furthermore, MSCs upregulate VEGF expression in response to hypoxia (Mayer et 
al., 2005), secrete factors that attract endothelial cells (L. Chen et al., 2008) 
and protect endothelial cells under hypoxic conditions (Bader et al., 2014).  
Another major advantage of using MSCs for cell therapies is presence of multiple 
potential MSCs sources, lack of associated ethical issues and their 
immunomodulatory properties which permits them to avoid immune clearance 
(Aggarwal and Pittenger, 2005). In addition, whereas growth rate and 
differentiation capacity of MSCs is affected by the age of the donor (Stolzing et 
al., 2008; L. W. Wu et al., 2014; Zaim et al., 2012), a report by Gremmels et al. 
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(2014) suggested that MSCs growth factor secretion and angiogenic capacity is 
not.  
Taken together, it can be speculated that the paracrine nature of MSCs is a 
crucial advantage over conventional BM-MNC and PB-MNC therapies, as it might 
provide a strong stimulus for angiogenesis in ischemic tissues and translate into 
superior clinical efficacy. Furthermore, the immunomodulatory properties and 
robustness of MSCs in older patients, support the rationale for clinical studies 
evaluating the efficiency of MSCs as a cell therapy for PAD.   
Various MSCs have been used in a clinical setting - Perin et al. (2011) sorted 
progenitor cells based on aldehyde dehydrogenise expression, Kirana et al. 
(2012) used CD90+ cells, while Gupta et al. (2013) selected population positive 
for CD90, CD73, CD166, CD106 markers.  In these studies, MSCs therapies were 
shown to be safe and of a better or comparable efficiency than BM-MNC 
therapies. However, amputation rates were similar between the treatment 
groups, and therefore the advantage of MSCs therapies is not clear. The small 
scale of these clinical studies further limits the conclusions that can be drawn. 
Additionally, it is essential to design large scale double blind studies comparing 
MSCs therapies to placebo to comprehensively evaluate the efficacy of MSC 
based PAD therapies. 
While therapies using MSCs are attracting significant interest due to their 
paracrine and immunomodulatory effects, there is lack of comprehensive clinical 
data supporting their efficacy. In addition, it can be argued that the need for a 
cell type that can directly contribute to therapeutic angiogenesis directly 
remains unmet. Thus, a range of other cells have been investigated, including 
circulating EPC which are obvious candidates for targeting angiogenesis. 
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1.5.3 EPC 
Circulating EPC were first reported by Asahara et al. (1997) who used CD34 and 
CD309 surface markers to isolate EPC from human peripheral blood. These cells 
acquired endothelial phenotype in vitro and contributed to angiogenesis in 
mouse and rabbit in vivo models of hind limb ischemia (Asahara et al., 1999). 
Another study using early EPC demonstrated that human EPC expanded ex vivo 
but not human microvascular endothelial cells (EC) restored blood flow in 
murine hindlimb ischemia model (Kalka et al., 2000), providing evidence for 
potential clinical benefit of early EPC cell therapies.  
The strong evidence presented by these publications led to extensive research 
into circulating EPC and it was proposed that circulating EPC originate from bone 
marrow and contribute to endothelialisation processes. This was further 
supported by evidence from Dacron graft endothelium studies by Shi et al. 
(1998) and later research using sex mismatched bone marrow donors by Li et al. 
(2000). 
However, the exact identity of EPC is still under a discussion, which is further 
complicated by various selection and culture methods described. Originally, two 
types of EPC were identified depending on their appearance in culture – early 
EPC (Asahara et al., 1997) and late EPC (Shi et al., 1998), and differences in 
their surface marker expression profiles, proliferative and angiogenic capacity 
have been demonstrated (Cheng et al., 2013; Hur et al., 2004; Medina et al., 
2010). 
While EPC endothelial marker expression has been reported (Asahara et al., 
1999; Kalka et al., 2000), their endothelial identity has been questioned. 
Indeed, cell selection by plating on fibronectin coated tissue culture plates 
carries a risk of contaminating cultures with platelets (Prokopi et al., 2009) and 
monocytes (Rehman et al., 2003; Schmeisser et al., 2003, 2001) which obtain 
similar phenotype as EPC and can express CD144, CD31 and eNOS. It has been 
proposed that EPC therapies benefit angiogenesis via paracrine secretion of 
various growth factors, for example VEGF, HGF, interleukin 6 and others 
(Gnecchi et al., 2005; Kinnaird et al., 2004; Kwon et al., 2014). 
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Other progenitor cell types have been described by Hill et al. (2003) who 
obtained adherent colony forming unit EC and showed that the in vitro 
characteristics correlated with endothelial function in vivo and cardiovascular 
event risk. However, the endothelial identity of these cells is in question as well 
and evidence has been presented demonstrating their myeloid properties (Yoder 
et al., 2007). Meanwhile, prolonged culture of adherent cells from umbilical 
cord blood also has been reported to give rise to cells with mature endothelial 
phenotypes (Ingram et al., 2004), while retaining some immature stem cell line 
characteristics (Guillevic et al., 2016). These cells can also be further specified 
into arterial or brain microvascular endothelial cells (Boyer-Di Ponio et al., 
2014). However, the therapeutic utility of these cells remains to be explored.  
Various culture methods do not guarantee creation of a pure EPC population, 
therefore selection using FACS can be used to obtain a more defined cell 
population. However, the marker profile of EPC is still debated. CD133 has been 
proposed in addition to CD34 and CD309 (Peichev et al., 2000; Povsic et al., 
2009). However, Case et al. (2007) demonstrated that CD34+ CD133+ CD309+ 
cells form hematopoietic progenitor but not endothelial cells. Aldehyde 
dehydrogenese expression has been proposed as another EPC marker (Povsic et 
al., 2007), while more recently Mund et al. (2012) has proposed using a CD34+ 
CD31+ CD146+ CD133- CD45- phenotype and provided evidence that these cells 
do not form hematopoietic colonies while retaining endothelial colony forming 
potential. 
Slight benefits in quality of life have been reported in clinical trials using CD34+ 
selected or a mix of CD34+/CD133+ cell therapies (Kawamoto et al., 2009; 
Losordo et al., 2012), however, clear placebo controlled data demonstrating 
reduction of amputation rates is lacking. In addition, the proliferative and 
angiogenic capacity can vary significantly between the different cell populations 
(Hur et al., 2004), thus, it can be proposed that well defined highly proliferative 
and secretory endothelial populations could offer superior efficacy for 
therapeutic angiogenesis. 
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1.5.4 Combination treatments 
With gene therapy or adult cell treatments alone having limited efficacy in PAD, 
it has been proposed that combining these approaches could enhance the 
efficacy of these therapies. Research in animal models has demonstrated higher 
efficiency of umbilical cord derived MSCs (Li et al., 2015) and EPC expanded 
ex vivo (Wang et al., 2015) in combination with a VEGF expressing plasmid.  
A trial reported by Skóra et al. (2015) randomised 32 patients to receive BM-MNC 
transfected with VEGF plasmid or pharmacological treatment with 
pentoxifylline. Statistically significant reduction of pain and increase of ABI was 
reported. A comparison with non-transfected cells was not made and, therefore, 
it’s hard to evaluate the contribution of transplanted cells and speculate about 
the benefits of combination therapy.  
Therefore, currently there is little research and a lack of evidence suggesting 
that combination therapies could overcome the lack of efficacy observed in 
adult cell therapies for PAD. It can be argued that additional complexity of 
combination treatments further complicates clinical testing of such therapies, 
and, given the limited efficiency of adult cell therapies alone, combination 
therapies are unlikely to resolve the issues observed with adult cell therapies. 
Therefore, other approaches focusing on other cell types need to be considered 
for clinical angiogenesis. 
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1.5.5 Summary - cell therapy for PAD  
In summary, while there is a strong rationale supported by preclinical studies for 
the use of cell therapies to target angiogenesis in PAD, clinical studies have 
failed to clearly demonstrate a robust improvement in critical clinical endpoints 
(prevention of major adverse effects of the limb) and currently none of the cell 
therapies for PAD have reached Phase III clinical trials. 
It is clear that alternative approaches are needed for targeting ischemia 
clinically. It can be speculated that adult cell therapies lack robustness for 
clinical angiogenesis, perhaps due to their mixed phenotypes, reduced secretory 
or proliferative activity with aging, or lack of capability to directly integrate in 
vascular networks. Thus, only novel approaches would deliver the significant 
increase in treatment efficacy needed for successful treatment of CLI and PAD. 
One such approach would be using human embryonic stem cells (hESC) to 
differentiate a large number or well defined endothelial cell populations. It can 
be proposed that the differentiation methods could be optimised to generate 
cells with high angiogenic capacity that can both contribute to angiogenesis 
directly, as well as aid angiogenesis via paracrine mechanisms. This would 
represent a significant shift in the mechanisms underlying the treatment and is 
likely to be more efficient than the use of pharmacological, surgical or adult cell 
treatment approaches alone.  
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1.6 Stem cells 
There are two characteristics that set stem cells apart from other cell types. 
The first is capacity to differentiate into mature functional cell types. The 
second is unlimited self-renewal via cell division. Interestingly, the first cells to 
fulfil these criteria and establish the field of stem cell research were derived 
from teratocarcinomas and teratomas. Kleinsmith and Pierce (1964) derived in 
vivo clonal cell lines from teratocarcinoma and showed that a single 
transplanted cell was able to differentiate in tissues representing all three main 
germ layers – endoderm, mesoderm and ectoderm.  
This led to attempts to isolate and grow these cells in in vitro and further 
refinements, most notably use of a feeder cell layer, led to large scale creation 
of pluripotent in vitro cell lines named embryonic teratocarcinoma cells (ECC) 
(Martin and Evans, 1974). The similarities between the behaviour of ECC and 
cells in developing embryos were quickly noted, and ECC were proposed as a 
tool to study early mammalian development (Martin, 1980, 1975). 
Shortly after, the observations and techniques developed with ECC, enabled the 
derivation of first murine embryonic stem cell (mESC) lines by two groups 
simultaneously (Evans and Kaufman, 1981; Martin, 1981). After deriving primate 
embryonic stem cells from rhesus monkey, Thomson et al. (1998, 1995) were the 
first group to report derivation of human embryonic stem cell (hESC) lines. 
Almost a decade later, generation of induced pluripotent stem cells (iPSC) was 
reported by Takahashi and Yamanaka (2006). The derivation of hESC and iPSC 
not only offered novel scientific models for human development, disease 
modelling and toxicology studies but also established the field of regenerative 
medicine. 
The ability to confirm the pluripotency of these cells is critical for stem cell 
work. Currently, there are multiple approaches to test stem cell pluripotency, 
both in vitro and in vivo. Firstly, a single transplanted undifferentiated stem cell 
into an immunodeficient mouse model should form teratoma consisting of all 
three germ layers. Alternatively, spontaneous differentiation to all germ layers 
can also be induced in vitro by culturing pluripotent stem cells in 3D spheroid 
embryoid body (EB) culture. Ideally, the ability of stem cells to form chimeras 
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and to contribute to germ lines should be tested, however, this testing is not 
performed with hESC due to ethical reasons.  
High placental type alkaline phosphatase activity was demonstrated in 
undifferentiated carcinoma cell lines (Bernstine et al., 1973) and is still 
commonly used for pluripotent stem cell identification (Singh et al., 2012). In 
addition, a range of markers for identifying pluripotency and differentiation 
using antibodies have been described. Stage specific embryonic antigens SSEA-1, 
SSEA-3 and SSEA-4, and human embryonic carcinoma antigens TRA-1-60, 
TRA-1-80 were the first ones described (Andrews et al., 1984; Kannagi et al., 
1983; Solter and Knowles, 1978) and are still used today.  
1.6.1 Human embryonic stem cells 
Human embryonic stem cells (hESC) are derived from the inner cell mass of a 
preimplantation blastocyst and fulfil the basic requirements that define 
pluripotency – hESC are able to self-renew and differentiate towards into other 
cell types from all three germ layers - ectoderm, mesoderm, endoderm as well 
as germline (Figure 3). The first hESC lines were derived by Thomson et al. 
(1998) from inner cell mass (ICM) of donated cleavage stage embryos produced 
for clinical purposes. Five hESC lines were established from five separate 
embryos – H1, H13 and H14 with a normal XY karyotype and H7 and H9 with a 
normal XX karyotype.  
They remained pluripotent after cryopreservation and prolonged culture, 
expressed pluripotency markers SSEA–3, SSEA-4, TRA-1-60, TRA-1-81, and had 
high telomerase and alkaline phosphatase activity. These cell lines formed 
teratomas and were able to differentiate in cell types from all three germ 
layers. The ability of these cells to form chimeras and contribute to germ lines 
was not tested due to ethical considerations. However, hESC ability to engraft 
into mouse blastocyst has been demonstrated (James et al., 2006). In addition, 
Amit et al. (2000) demonstrated pluripotency and stable karyotype in clonal cell 
lines derived from H9, demonstrating that H9 are highly stable and thus suitable 
for in vitro studies. The original hESC lines derived by Thomson et al. are still 
widely used and have become the ‘gold standard’ of hESC lines. 
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Figure 3: hESC derivation and differentiation. hESC are derived from the inner 
cell mass of a blastocyst and are able to self-renew indefinitely as well as 
differentiate towards adult cell types. Adapted from: Yabut and Bernstein (2011). 
Initially, hESC were derived using immunosurgical methods and cultured on 
irradiated mouse embryonic fibroblasts in media supplemented with 20% bovine 
serum (Thomson et al., 1998). Whereas this is acceptable for research purposes, 
a fully defined and preferably xeno free derivation and culture methods are 
needed for clinical applications.  
Early observations with mESC uncovered myeloid leukaemia inhibitory factor 
(LIF) as one of the main pluripotency factors produced by the feeder layer and 
further research showed that supplementing the media with bone morphogenic 
protein 4 (BMP4) in addition to LIF allows a serum free culture without a 
fibroblast feeder layer (Smith et al., 1988; Williams et al., 1988; Ying et al., 
2003). However, these factors were not sufficient to maintain undifferentiated 
hESC (Thomson et al., 1998), highlighting the differences between hESC and 
mESC pluripotency signalling networks. 
Initially, it was shown that bovine serum can be replaced with a knock out serum 
replacement (Amit et al., 2000). In addition, successful use of human fibroblasts 
was reported (Richards et al., 2002). Xu et al. (2001) reported successful feeder 
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free culture of hESC on mouse sarcoma cell derived matrigel or laminin in 
medium conditioned by MEF and later culture in non-conditioned media 
supplemented with bFGF and BMP signalling inhibitor noggin (Xu et al., 2005).  
First feeder and xeno free derivation and culture of hESC lines was reported by 
Ludwig et al. (2006) using mTeSR1 media, however, they did not maintain a 
stable karyotype. In addition, a comparison of various xeno free culture media 
(Rajala et al., 2007) showed that various xeno free media, including mTeSR1 had 
limited success in maintaining pluripotent hESC cultures. 
Soon after, generation of six clinical grade hESC lines was reported (Crook et al., 
2007). These cell lines were derived adhering to current good manufacturing 
practice (cGMP) standards, which define critical control points and procedures 
to ensure the quality, reliability and safety of medicinal products (Hewitt et al., 
2007). However, clinical grade human foreskin fibroblasts and cGMP bovine 
serum albumin serum replacement was used and, thus, these hESC lines were 
not derived and cultured in fully defined, xeno free systems.  
Nevertheless, it can be argued that xeno derived reagents are crucial for the 
reliability of hESC derived products and thus such reagents could be cGMP 
qualified after strict selection and testing criteria are met (Hewitt et al., 2007). 
Further refinements, most importantly the creation of cGMP compliant human 
fibroblast lines (Prathalingam et al., 2012), led to hESC lines derived in xeno 
free, cGMP conditions (Tannenbaum et al., 2012) which are highly suitable for 
future clinical applications.  However, the work towards completely feeder and 
serum free hESC derivation and maintenance procedures still is ongoing. 
In addition to H1 and H9 hESCs, here we also use clinical grade cell lines RC-9 
and RC-11 (Roslin Cells, UK) which are derived and cultured in compliance with 
laws set out by Human Fertilisation and Embryology Authority (“Human 
Fertilisation and Embryology Act 2008,” 2008) and cGMP guidelines as set out in 
Rules and Guidance for Pharmaceutical Manufacturers and Distributors (GOV.UK, 
2015).  
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1.6.2 Human induced pluripotent stem cells 
There are some concerns regarding the use of hESC – firstly, ethical 
considerations due to their embryonic origin, and secondly the requirement of 
patient matched hESC lines to avoid immune rejection. The generation of mouse 
and subsequently human induced pluripotent stem cells (iPSC) by Takahashi et 
al. (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) is arguably the most 
important development in the stem cell field in the last decade as it offers 
potentially unlimited, patient matched source of iPSC without a destruction of 
an embryo.  
These cells were generated from adult cells by transduction of OCT4, SOX2, KLF4 
and cMYC. They had similar morphology, surface marker expression profile and 
telomerase activity to hESC, expressed pluripotency factors, for example, 
OCT3/4, SOX2, NANOG, were able to differentiate to all three germ layers in 
vitro and form teratomas. Experiments with mouse iPSC have also demonstrated 
their capability to form chimeras and contribute to germ lines (Okita et al., 
2007).  
In addition, iPSC are a valuable tool for disease modelling as patient specific 
iPSC can be differentiated in somatic cell types for in vitro disease analysis. Park 
et al. (2008) reported generation of iPSC from patients with various genetic 
diseases, including Duchenne muscular dystrophy and Huntington syndrome, and 
confirmed the disease specific genotype. More complex disorders can also be 
successfully modelled using iPSC, for example, iPSC derived neuronal cells have 
been used to study molecular mechanisms underlying schizophrenia (Brennand et 
al., 2011), Alzheimer's disease (Israel et al., 2012) and bipolar disorder (Chen et 
al., 2014). 
There are still multiple concerns regarding the use of iPSC. Firstly, even though, 
these cells are not derived from embryos, their pluripotent nature still presents 
a range of ethical issues (de Miguel-Beriain, 2015). Secondly, the use of viral 
vectors for the generation of iPSC carries a risk of unwanted genetic mutations 
or oncogene activation, however, a wide range of non-viral iPSC generation 
strategies have been developed (Deng et al., 2015). In addition, concerns have 
been raised regarding primed state and “memory” of iPSC, yet, the discussion of 
48 
 
naïve vs primed pluripotency states also applies to hESC (De Los Angeles et al., 
2015; Hackett and Surani, 2014; Hu et al., 2016) and only recently naïve hESC 
have been directly derived from blastocyst (Ware et al., 2014). Finally, there’s 
still an ongoing discussion regarding the “aging signature” of human IPSC cells 
(L. Rohani et al., 2014) and very recently evidence has been presented showing 
accumulation of mutations in mitochondrial DNA in human iPSC derived from 
elderly adults (Kang et al., 2016). 
The ability to generate pluripotent stem cells from adult cells represents a 
significant advance for disease modelling and regenerative medicine. Yet, there 
are multiple obstacles that need to be overcome before we can utilise the full 
potential of hIPSC. 
1.6.3 Core pluripotency transcriptions factors 
Multiple pluripotency factors have been described and studied and three of 
these factors – OCT4, SOX2 and NANOG are seen as the core pluripotency 
regulators that work closely with other TF, for example cMYC, to form a 
pluripotency network (Boyer et al., 2005). They will be introduced in this 
section, while their interactions in pluripotency networks will be described in 
section 1.6.4 .  
Octamer-binding transcription factor 4 (OCT4) is encoded by POU5F1 gene and 
belongs to POU (Pit-Oct-Unc) transcription factor family. It is expressed in 
pluripotent and germ line cells and downregulated during differentiation (Rosner 
et al., 1990; Schöler et al., 1990). While mice heterozygous for POU5F1 are 
viable and fertile, Nichols et al. (1998) observed an absence of homozygous 
POU5F1 deficient pups and midgestation embryos, and subsequently showed that 
ICM did not develop in OCT4 deficient blastocysts in vitro and in vivo. 
Sex determining region Y box 2 (SOX2) gene has a similar phenotype to OCT4. It 
is expressed in ICM, mice heterozygous for SOX2 are viable and fertile, however, 
homozygous SOX2 deficient blastocysts have abnormal ICM development and fail 
to survive shortly after implantation (Avilion et al., 2003).  
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NANOG is a divergent homeodomain transcription protein that is expressed in 
mammalian ICM, epiblast and pluripotent cells (Chambers et al., 2003; Mitsui et 
al., 2003). As with the other core pluripotency TF, heterozygous NANOG 
deficient mice are viable and fertile, however, ICM of homozygous NANOG 
deficient blastocysts fails to proliferate and undergoes differentiation (Mitsui et 
al., 2003). Hyslop et al. (2005) demonstrated the expression of NANOG in human 
blastocyst ICM but not earlier stages, suggesting a role in the maintenance of 
hESC pluripotency, which is in contrast to observations in mESC where NANOG is 
not required for the maintenance pluripotency (Chambers et al., 2007). 
In addition, MYC family of basic helix-loop-helix leucine zipper transcription 
factors works closely with the core pluripotency factors. It has three members 
cMYC, nMYC and lMYC, which usually heterodimerize with MAX protein when 
binding DNA (Blackwood and Eisenman, 1991). Of these, cMYC, nMYC and MAX 
are required for late embryonic development (Charron et al., 1992; Davis et al., 
1993; Hatton et al., 1996). The role of cMYC in ESC pluripotency and renewal 
was first observed by Cartwright et al. (2005) and later research showed that 
cMYC and its targets formed a somewhat independent pluripotency regulating 
cluster from core pluripotency factors (X. Chen et al., 2008; Kim et al., 2008; 
Young, 2011). 
In summary, cMYC and the core pluripotency factors OCT4, SOX2 and NANOG are 
crucial for development of pluripotent cells and, therefore, embryonic 
development. The expression of these appears to be tightly regulated and 
interdependent, forming pluripotency networks as described in the following 
section.  
1.6.4 Regulation and maintenance of pluripotency 
The core pluripotency factors OCT4, SOX2 and NANOG are tightly regulated and 
interact with large number of other proteins and genes. Understanding these 
interactions not only gives us insight into mammalian development, but also 
provides a framework for understanding hESC characteristics and generating 
hIPSC (as introduced in section 1.6.2 ), this way advancing the field of cell 
therapies and regenerative medicine. 
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NANOG binds promoters of SOX2 and OCT4 (Boyer et al., 2005), while OCT4 and 
SOX2 function as a heterodimer, promoting expression of SOX2 (Avilion et al., 
2003; Catena et al., 2004; Chew et al., 2005; Tomioka et al., 2002), POU5F1 
(Chew et al., 2005; Okumura-Nakanishi et al., 2005) and NANOG (Rodda et al., 
2005). This way the core pluripotency factors form an auto-regulatory loop, as 
shown in Figure 4, which functions to establish and maintain pluripotent cell 
identity. 
 
 
Figure 4: Core pluripotency factor network. A. The core pluripotency factors 
(OCT4, SOX2 and NANOG) form an auto-regulatory loop responsible for 
establishing and maintaining pluripotency. B. Venn diagram illustrating genes 
regulated by the core pluripotency factors. Most of the target genes are regulated by 
multiple core pluripotency factors as shown by the overlapping areas. Adapted from: 
Boyer et al (2005). 
Analysis of core pluripotency factor transcription networks has revealed a wide 
range of genes regulated by OCT4, SOX2 and NANOG, including other 
pluripotency related TF, as well as protein complexes involved in histone 
modification, DNA methylation and chromatin remodelling (Huang and Wang, 
2014; Young, 2011). Most of the target genes are regulated by multiple core 
pluripotency factors as shown in Figure 4 (Babaie et al., 2007; Boyer et al., 
2005; Loh et al., 2006). In addition, most of the genes bound by core 
pluripotency factors are also bound other pluripotency related transcription 
factors, cMYC being the most frequent one, while only 2% of genes bound by 
core pluripotency factors not binding any of the closely associated pluripotency 
A B 
51 
 
factors (Young, 2011). This way, a gene switch is formed, where binding of few 
factors represses gene expression, while binding of multiple TF activates gene 
expression (Kim et al., 2008). 
The core pluripotency factors not only promote pluripotency gene expression but 
also suppress gene programs that initiate differentiation. An unifying lineage 
fate regulation model has been proposed by Wang et al. (2012), suggesting that 
NANOG represses neuroectoderm, SOX2 represses primitive streak formation, 
while OCT4 represses neuroectoderm, trophectoderm and primitive endoderm 
fates. 
In summary, the three core pluripotency factors OCT4, SOX2 and NANOG 
establish and maintain pluripotency via three complimentary processes – auto-
regulatory loop, activation of other TF and genes involved in pluripotency or 
differentiation, and suppression of genes responsible for differentiation. 
Together these processes not only maintain the pluripotent state, but also 
enable rapid differentiation towards any of the germ layers and later cell types, 
including endothelial cells which are the focus of this project. 
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1.7 Endothelial Development. 
Endothelial development has been studied both in vivo and in vitro, and more 
recently significant insights have been gained from studies using hESC 
differentiation models. During human embryonic development, ICM from 
blastocyst gives rise to epiblast cells. In the third week of development, 
gastrulation is initiated and primitive streak forms from the epiblast population 
followed by an appearance of mesodermal cells expressing brachyury (Wilkinson 
et al., 1990) as illustrated in Figure 5.  
Some of these cells start expressing kinase insert domain receptor (KDR, CD309) 
and later develop into endothelial cells expressing endothelial markers platelet 
endothelial cell adhesion molecule (PECAM, CD31) and vascular endothelial 
cadherin (CDH5, CD144). Similar differentiation patterns are observed during 
hESC differentiation towards endothelial lineages and have been used to 
evaluate and optimise hESC differentiation methods. 
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Figure 5: Overview of the development of endothelial cells (EC). Primitive 
streak (PS) forms in the epiblast population of the developing embryo, followed by 
appearance of mesodermal cells expressing brachyury. These cells then undergo 
further differentiation and form PECAM and CDH5 expressing cells via multipotent 
progenitor and hemangiogenic mesoderm intermediates. Adapted from: Coultas et 
al. (2005) and Park et al. (2013). 
1.7.1 Development of mesoderm. 
First step in the differentiation towards endothelial lineages is specification of 
mesoderm – one of the three primary germ layers, that gives rise to a range of 
tissues, including smooth muscle cells, blood cells and endothelium. 
Mesodermal cells are marked by expression of brachyury (Wilkinson et al., 1990) 
which is required for normal progression of gastrulation (Wilson et al., 1995). 
More recently, CD326− CD56+ surface marker expression profile has been 
proposed for identifying early mesoderm cells which have upregulated mesoderm 
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but not endoderm or ectoderm germ layer gene expression patterns (Evseenko et 
al., 2010). 
Various members of transforming growth factor beta (TGFB) family have been 
implicated in the development, maintenance and patterning of mesoderm.  
Nodal subfamily of TGFB factors is expressed during gastrulation in mouse 
embryos (Zhou et al., 1993) and induce mesoderm formation (Jones et al., 
1995), while nodal disruption abolishes primitive streak formation (Conlon et al., 
1994; Iannaccone et al., 1992). Other members of TGFB family described to be 
involved in mesoderm formation and demonstrated in mouse development 
models are activins (Matzuk et al., 1995; Song et al., 1999), BMP-4 (Winnier et 
al., 1995), and VG1 and its mammalian homologs (Andersson et al., 2007). 
WNT3A is expressed before gastrulation and is required for primitive streak 
formation and subsequent expression of nodal (Liu et al., 1999). Recent work by 
Yoon et al. (2015) using WNT3A visceral endoderm knockout models suggests 
that visceral endoderm derived WNT3A induces WNT3A gene and brachyury gene 
expression in the primitive streak. Taken together, this establishes WNT3A as 
one of the key players in mesodermal development. 
In addition, basic fibroblast growth factor (bFGF, also known as FGF-2) has been 
extensively described to have an important role in mesoderm formation. Indeed, 
Bursdal et al. (1998) demonstrated that in vitro treatment of mouse epiblast 
cells with bFGF induced expression of brachyury and vimentin. Expression of a 
dominant negative FGF receptor in Xenopus embryos results in abnormal 
gastrulation, however, mesoderm can still be detected (Amaya et al., 1991). In 
addition, subsequent research in zebrafish and Xenopus models has provided 
evidence that FGF signalling is required for mesoderm induction by TGFB family 
factors (Mathieu et al., 2004; Mitchell and Sheets, 2001). Thus, FGF signalling is 
regarded as synergetic and complimentary to TGFB signalling. 
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1.7.2 Development of endothelium. 
A subset of  mesoderm cells expressing brachyury, upregulate KDR (Fehling et 
al., 2003) and VEGF co-receptor neuropillin-1 (Cimato et al., 2009) expression, 
and these are regarded as the earliest angioblast precursors or multipotent 
cardiovascular precursor cells.   
KDR is a key receptor for normal endothelial and hematopoietic development 
and KDR deficient mice display embryonic lethality (Shalaby et al., 1995). 
Analysis of translational regulation of the KDR gene has revealed an enhancer 
that is activated by BMP, WNT and FGF (Ishitobi et al., 2011). In addition, it also 
contains various TF binding sites, including ETV2 which is expressed transiently 
before the expression of KDR and acts downstream of BMP, NOTCH, and WNT 
signalling (Lee et al., 2008). 
These KDR+ cells form vascular plexus which subsequently undergoes extensive 
remodelling and establishes closed circulatory loop. Vascular endothelial growth 
factor (VEGF) has been shown to drive endothelial specification of the KDR+ 
precursor cells (Giles et al., 2005; Kawasaki et al., 2008; Yamashita, 2004) and 
expression of endothelial markers, for example, CDH5 which initially can be 
detected in yolk sac during murine development, followed by an appearance in 
the more general embryonic vasculature (Alva et al., 2006). Downstream VEGF 
signalling through phospholipase Cγ1 is thought to mediate the endothelial 
differentiation and survival of the KDR+ cells (Sase et al., 2009), while 
phosphatidylinositol-3 kinase (PI3K) downstream signalling acts as a negative 
regulator (Merkely et al., 2015).  
Furthermore, KDR signalling is negatively regulated by TGFB (Ginsberg et al., 
2012; Mandriota et al., 1996), which also can interfere with endothelial 
specification by inducing endothelial-to-mesenchymal transition (Zeisberg et al., 
2007), or promoting alternative mesodermal, for example, smooth muscle cell 
fates (Kurpinski et al., 2010). 
Additionally, other signalling pathways contributing to endothelial 
differentiation are of interest for this project. Firstly, e-twenty six (ETS) family 
transcription factors, particularly ETS variant 2 (ETV2), play a key role in 
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endothelial specification (Oh et al., 2015) and can be regulated by intracellular 
cyclic adenosine monophosphate (cAMP) mediated activation of protein kinase a 
(PKA) (Yamamizu et al., 2012b). Secondly, the renin angiotensin system (RAS) 
has also been reported to contribute to endothelial differentiation and 
specification (Ishizuka et al., 2012; Zambidis et al., 2008). Yet, the role of cAMP 
and the RAS signalling in endothelial development requires further investigation. 
There is, however, some controversy regarding the development of endothelial 
and hematopoietic lineages and multiple models have been proposed as 
reviewed by Bautch et al. (2011) and illustrated in Figure 6. Initial observations 
in lineage tracing experiments suggested that KDR+ cells form hemangioblasts – a 
common precursor of endothelial and hematopoietic lineages (Choi et al., 1998; 
Nishikawa et al., 1998). In contrast, later in vivo studies demonstrated 
emergence of hematopoietic cells from endothelial cells expressing endothelial 
markers Cd31 and CD144 (Bertrand et al., 2010; Boisset et al., 2010; Kissa and 
Herbomel, 2010; Zovein et al., 2008) and additional supporting evidence has 
been provided using hESC differentiation models where a CD34+ CD31+ CD144+ 
population with hemogenic potential has been described (Bai et al., 2016).  
These observations can be merged into a developmental model where 
hemangioblast cells give rise to hemogenic endothelium in addition to 
hematopoietic stem cells (Lancrin et al., 2009) as shown in Figure 6c. Recently, 
Ditadi et al. (2015) proposed that CD73 and CD184 marker expression profile can 
be used to distinguish between vascular and hemogenic endothelium.  
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Figure 6: Three models proposed for the developmental relationships of 
endothelial and hematopoietic lineages. A. Hemangioblasts give rise to both 
endothelial and hematopoietic stem cells. B. Hemogenic endothelium gives rise to 
hematopoietic stem cells and subsequently hematopoietic cells. C.  Hemangioblasts 
give rise to hematopoietic stem cells and hemogenic endothelium, which is distinct 
from endothelium that arises from angioblasts. Adapted from: Bautch (2011). 
Taken together, the current evidence suggests that KDR+ cells give rise to 
various endothelial subpopulations, some of which commit to vascular 
endothelial fate, while others give rise to hematopoietic progenitors. 
1.7.3 Specification of arteries and veins. 
Primitive vascular plexus undergoes extensive remodelling, forming larger and 
smaller vessels and eventually establishing closed circulatory loop. Originally, it 
was believed that arterial and venous fates were induced in response to physical 
stimuli caused by blood circulation, however, soon after arterial (Ephrin B2, also 
known as EFNB2) and venous specific (Ephrin type-B receptor 4, EPHB4) markers 
were observed prior to establishment of blood flow (Wang et al., 1998), 
highlighting the genetic contribution of endothelial specification. 
NOTCH1 and NOTCH4 genes are specifically expressed in arteries, however, only 
NOTCH1 homozygous mutant mice embryos fail to reorganize vascular plexus and 
show embryonic lethality (Krebs et al., 2000; Swiatek et al., 1994). In addition, 
NOTCH delta like ligand 4 (DLL4) heterozygous embryos display similar 
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phenotype – failure to reorganize vascular plexus and embryonic lethality, and 
NOTCH signal transcriptional mediator recombination signal binding protein for 
immunoglobulin kappa J Region (RBPJ) null mutants do not express arterial 
markers (Krebs et al., 2004). The requirement for precise DLL4 expression, 
suggest that NOTCH-DLL4 signalling axis is the key player for arterial 
specification.  
Crosstalk between VEGF and NOTCH signalling pathways is at the core of current 
arterial specification model (Lawson et al., 2001) as illustrated in Figure 7, 
however, VEGF can induce both arterial and venous specification, depending on 
downstream signalling via PI3K or mitogen-activated protein kinases / 
extracellular signal regulated kinases (MAPK/ERK) respectively (Hong et al., 
2006; Ren et al., 2010). Interaction of these two pathways during VEGF signalling 
has been previously demonstrated in human umbilical vein endothelial cells, 
HUVECs (Blum et al., 2001; Deng et al., 2013), and observations in microvascular 
endothelial cells have led to a proposal that MAPK signalling is VEGF dose 
dependent, while PI3K activation is not enhanced by increasing VEGF 
concentrations (Akeson et al., 2010). This allows for differential signalling for 
endothelial specification and, indeed, VEGF signalling via MAPK, induces both 
DLL4, and NOTCH4 expression and NOTCH downstream target genes 
hairy/enhancer of split related with YRPW motif protein 1 and 2 (HEY1 and 
HEY2), hairy and enhancer of split 1 and 2 (HES1 and HES2) (Deng et al., 2013; 
Wythe et al., 2013; Yang et al., 2013). 
However, it is also important to note that PI3K signalling has been also shown to 
induce NOTCH1 and DLL4 expression (Liu et al., 2003), activate Fox transcription 
factors FOXC1 and FOXC2, and promote arterial specification in cultured 
endothelial cells (Hayashi and Kume, 2008). Therefore, it appears that complex 
interactions are formed between NOTCH and VEGF with downstream signalling 
pathways contributing to endothelial specification via various mechanisms. 
Other regulators that contribute to arterial specification via activating DLL4 are 
ETS factors (Wythe et al., 2013), catenin beta-1 (Yamamizu et al., 2010), and 
SOXF family (Corada et al., 2013; Sacilotto et al., 2013). With the onset of blood 
flow, arterial endothelium is exposed to various physical forces that are not 
present in the venous system. These can also contribute to arterial phenotype 
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via VEGF-NOTCH arterial induction axis, for example, shear stress induces VEGF 
expression and KDR upregulation (dela Paz et al., 2012), upregulates arterial 
EFNB2 gene expression (Masumura et al., 2009), and downregulates EPHB4 
expression levels in venous cells (Model et al., 2014). 
 
 
Figure 7: Specification of arterial and venous endothelium. A. Endothelium 
forms tunica intima in arteries and veins, and expresses arterial (red box) or venous 
(blue box) endothelial markers accordingly. B. VEGF induced NOTCH signalling at 
the core of current arterial specification model to establish venous or arterial 
endothelial cell identity. High VEGF signalling results in NOTCH1/4 activation 
leading to expression of arterial genes, for example HEY2 and HES, while low 
VEGF signalling induces COUP-TFII which prevents the arterial gene expression, 
leading to a development of venous phenotype. Adapted from: Corada et al. (2014) 
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In contrast, venous specification has been less researched and was thought to 
occur mostly in absence of NOTCH signalling. However, a venous specification TF 
factor, chicken ovalbumin upstream promoter transcription factor II (COUP-TFII), 
has been identified, is expressed in venous endothelial cells and acts via 
inhibiting NOTCH signalling (Chen et al., 2012; You et al., 2005). In addition 
EPHB4 has been described to mark venous endothelium (Wang et al., 1998) and 
is regulated by VEGF (Yang et al., 2013). These transcription factors highlight 
the genetic contribution of venous specification, directly contrasting actions of 
arterial transcription factors. 
Venous endothelium gives rise to lymphatic vasculature as recently reviewed by 
Semo et al. (2016). Venous COUP-TFII contributes to lymphatic differentiation by 
inducing Prospero Homeobox 1 expression (Srinivasan et al., 2010) which is the 
main determinant of lymphatic phenotype (Wigle et al., 2002; Wigle and Oliver, 
1999). VEGF-C and VEGF-D regulates proliferation and migration of the 
lymphatic endothelium via VEGFR3 receptor (Mäkinen et al., 2001), expression 
of which is progressively limited to lymphatic endothelium during development 
(Kaipainen et al., 1995). 
It also is important to appreciate that endothelial phenotypes also differ 
depending on the tissues and various highly specialised endothelial cell subtypes 
can be identified, for example, endothelium forming blood brain barrier, bone 
marrow endothelium and various endothelium types in kidneys (Garlanda and 
Dejana, 1997; Nolan et al., 2013). The specification of these endothelial 
subtypes is thought to be guided by interactions with neighbouring cells and 
various tissue specific signals, including soluble factors and extra-cellular matrix 
composition. Indeed, brain microvascular endothelium has been derived using 
neural cell coculture differentiation systems (Lippmann et al., 2012; Minami et 
al., 2015) and angiocrine VEGF-A has been shown to drive multipotent heart 
progenitor specification toward cardiac EC fates (Lui et al., 2013). 
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1.7.4 Angiogenesis 
After establishment of the major blood vessels during development and, to a 
lesser extent, in adults, new blood vessels form from the pre-existing 
vasculature through various processes – sprouting, intussuception, 
elongation/widening and through recruitment of circulating EPC (Carmeliet and 
Jain, 2011; Chung and Ferrara, 2011) as illustrated in Figure 8a. Together these 
processes are known as angiogenesis which is defined as new blood vessel 
development from the existing vasculature. Angiogenesis is of a great clinical 
interest both as a target during disease processes, for example cancer 
progression and ocular disease (Carmeliet and Jain, 2000; Gariano and Gardner, 
2004), as well as potential therapy for hypoxic disorders (Annex, 2013). 
VEGF is the key signalling molecule involved in angiogenesis, however, it is 
important to appreciate the contribution of other VEGF family members, VEGF 
subtypes and receptors. There are five members of the VEGF family – VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and placenta growth factor PLGF (Shibuya, 2013). 
Expression of VEGF-A requires precise regulation and mice lacking a single 
VEGF-A allele display abnormal blood vessel development and embryonic 
lethality (Carmeliet et al., 1996; Ferrara et al., 1996) demonstrating the 
importance of VEGF-A in the development of circulation system. 
Hypoxia induces the expression of VEGF (Liu et al., 1995; Namiki et al., 1995) 
and alternative splicing creates VEGF-A isoforms – VEGF121, VEGF165, VEGF189 and 
VEGF206, which differ in heparin binding affinities and signal transduction 
pathways (Fearnley et al., 2016, 2015; Houck et al., 1991; Tischer et al., 1991). 
Mice expressing only VEGF164 (murine VEGF proteins are single amino acid shorter 
than human ones) develop vasculature normally (Maes et al., 2004), while mice 
expressing only VEGF120 or VEGF188 display developmental abnormalities 
(Carmeliet et al., 1999b; Maes et al., 2004; Ruhrberg et al., 2002). VEGF206 does 
not have a mouse equivalent due to a frameshift resulting in frame stop codon 
(Shima et al., 1996) and is thought to be involved in inflammatory processes 
(Grützkau et al., 1998). 
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Figure 8: Overview of angiogenesis. A. New blood vessels can form from the pre-
existing vasculature through various processes – sprouting, intussuception, 
elongation, widening and through recruitment of circulating EPC. B. During 
sprouting, endothelial tip cell is selected through interaction of VEGF and NOTCH 
signalling pathways. These cells extend fillipodia which follow VEGF gradient, while 
a range of other signalling molecules contribute to angiogenesis indirectly – via 
altering pericyte and endothelial cell adhesion, stimulating breakdown of 
extracellular matrix and guiding tip cell migration. Adapted from: Carmeliet et al. 
(2003). 
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Novel anti-angiogenetic VEGF isoforms have also been reported (Eswarappa and 
Fox, 2015; Pritchard-Jones et al., 2007) and, interestingly, VEGF165b isoform has 
also been investigated in PAD and shown to be induced by WNT5A signalling and 
to supress angiogenesis in mouse hindlimb ischaemia models, explaining the 
paradox of increased VEGF165 levels, yet impaired angiogenesis, in general PAD 
patient population (Kikuchi et al., 2014). More recently, also a highly angiogenic 
VEGF isoform has been reported (Danastas et al., 2015), however, with 
somewhat limited role in physiological angiogenesis. 
VEGF-A can bind both FLT-1, also known as VEGFR1 (de Vries et al., 1992; 
Shibuya et al., 1990), and KDR, also known as VEGFR2, FLK-1 (Terman et al., 
1992), in addition to co-receptors neuropillin 1 and neuropillin 2 (NRP1 and 
NRP2) which potentiate the signalling of VEGF165 or VEGF165 and VEGF145 
accordingly (Gluzman-Poltorak et al., 2000; Soker et al., 1998). Binding of 
VEGF-A to KDR mediates endothelial cell migration and proliferation (Gerhardt 
et al., 2003; Hiratsuka et al., 2005). Signalling via FLT-1 appears not to be 
required during embryogenesis, as mice expressing FLT-1 without tyrosine kinase 
domain display normal development (Hiratsuka et al., 1998). However, FLT-1 
knockout mice display embryonic lethality due to abnormal endothelial cell 
growth and organisation (Fong et al., 1995). Given that FLT-1 has a higher 
affinity for VEGF-A and lower kinase activity, it is proposed to act as a regulator 
of VEGF signalling (Hiratsuka et al., 1998), with an important role in normal 
vessel sprouting (Kearney et al., 2004). 
However, it is important to appreciate the interplay between VEGF and TGFB 
during angiogenesis. TGFB induces angiogenesis in vivo (Roberts et al., 1986). 
And even though TGFB induces VEGF expression in EC (Ferrari et al., 2006) and 
VEGF signalling mediates EC proliferation and migration as described above, 
TGFB induces EC apoptosis in vitro (Pollman et al., 1999) which is VEGF 
dependent (Ferrari et al., 2009). With the arrival of small interfering RNA 
mediated downregulation of specific p38 MAPK isoforms, it was shown that this 
discrepancy is due to shift from pro-survival p38 MAPK kinase β to pro-apoptotic 
p38 MAPK kinase α VEGF signalling in the presence of TGFB (Ferrari et al., 2012). 
Crucially, this interplay with VEGF and TGFB provides a coordinated mechanism 
for capillary formation and angiogenetic sprouting. 
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Sprouting is led by a tip cell, which is selected by genetic determinants, namely 
FLT-1 and KDR expression in addition to NOTCH signalling (Jakobsson et al., 
2010). Metabolism also contributes to tip and stalk cell balance, for example, 
glycolysis regulator Phosphofructokinase-2/fructose-2,6-bisphosphatase enzyme 
deficiency impairs tip cell formation (De Bock et al., 2013) as well as cell 
proliferation and migration (Xu et al., 2014). More recently, presence of 
multiple tip cells in a developing sprout has been suggested (Pelton et al., 
2014), thus, it is possible that more complex interactions during angiogenic 
sprouting will be uncovered in the close future. 
Endothelial tip cells extend fillipodia which follow VEGF gradient (Gerhardt et 
al., 2003; Ruhrberg et al., 2002) as illustrated in Figure 8b. In tip cells, VEGF 
binding to KDR activates via PI3K/AKT signalling pathway to upregulate 
expression of DLL4, this in turn activates NOTCH signalling in nearby stalk cells, 
inhibiting formation of additional tip cells, downregulating KDR expression (Liu 
et al., 2003; Lobov et al., 2007; Suchting et al., 2007) and upregulating 
phosphatase and tensin homolog  protein which limits stalk cell proliferation 
(Serra et al., 2015). In contrast, stalk cells express jagged1 which limits NOTCH 
signalling, counterbalancing the effect of DLL4 (Benedito et al., 2009). In 
addition, stalk cells also produce non membrane bound FLT-1 which sequesters 
VEGF-A, further refining angiogenic response (Chappell et al., 2009; Kappas et 
al., 2008; Kearney et al., 2004). 
Stalk cells proliferate and multiple mechanisms have been proposed to underlie 
lumen formation in the newly developed sprout, while the exact mechanisms are 
still being uncovered, changes in cell polarisation, CDH5 expression patterns, 
cell shape and vacuole formation are all likely to contribute to lumen formation 
(Charpentier and Conlon, 2014). 
Angiogenesis is an important process both in health and disease and can be 
upregulated or downregulated in pathologic processes, for example in diabetic 
retinopathy, ocular disease and cancer biology. Understanding the processes and 
mechanisms underlying angiogenesis not only increases our understanding of 
human development but also can potentially provide multiple therapeutic 
targets. Given the essential role of endothelial cells during angiogenesis, cell 
therapies are an attractive approach for therapeutic angiogenesis for various 
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vascular diseases, including PAD. Given the large number of cells required for 
such therapies, hESC differentiation towards endothelial lineages has been 
proposed as a highly perspective approach for therapeutic angiogenesis. 
  
66 
 
1.8 Endothelial differentiations from hESC and iPSC. 
Endothelial differentiations from hESC and iPSC can be used to generate large 
numbers of EPC and EC populations and, thus, attract significant attention as 
potential approaches for clinical cell therapy angiogenesis. Numerous 
publications have described various approaches to endothelial cell 
differentiation as summarised in an extensive review by Descamps and Emanueli 
(2012). There are three main differentiation strategies, as illustrated in  
Figure 9 – differentiations in three dimensional stem cell aggregates (embryoid 
bodies, EBs), differentiations using co-cultures with adult cell types, and 
monolayer based differentiations. More recently, the focus has been on 
developing protocols that can generate large numbers of endothelial cells in a 
relatively short period of time using, if possible, chemically defined, clinical 
grade reagents. In addition, transdifferentiation of adult cell types can also be 
used to generate endothelial cells. All these approaches will be discussed in the 
following subsections. 
1.8.1 Endothelial differentiation of hESC and iPSC – main 
approaches. 
Initially, spontaneous appearance of cells expressing endothelial markers was 
observed in mESC derived EBs (Vittet et al., 1996). Later, these observations 
were confirmed in spontaneously differentiating hESC derived EBs by Levenberg 
et al. (2002) who sorted and cultured CD31 expressing cells from day 13 EBs. 
These cells expressed endothelial markers CD31, CD144 and vWF, were capable 
of taking up Dil-Ac-LDL, formed tubules in matrigel and integrated with host 
vasculature when transplanted in immunodeficient mice. Similarly, Wang et al. 
(2004) observed CD144+ CD31+ CD45- cells as early as Day 7 during spontaneous 
EB differentiation, and showed that they had both endothelial and 
hematopoietic potential. 
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Figure 9: Endothelial differentiation approaches. Three main approaches have 
been described for endothelial differentiations of hESC. Initially, hESC were 
differentiated in embryoid body based systems, while later methods using co-culture 
with other cell types or monolayer culture were described. These differentiation 
approached yield mixed cell populations with 2-80% of cells expressing endothelial 
markers (for example, CD31 or CD144). These cells then can be sorted and 
cultured further to obtain near pure endothelial populations. Adapted from: 
Mummery et al. (2012). 
While co-culture differentiation methods have been mostly focused on 
differentiation of hematopoietic cells, differentiation of endothelial cells has 
also been reported. For example, Kaufman et al. (2001) demonstrated 
differentiation of hematopoietic precursor cells after hESC co-culture with 
murine bone marrow cell line S17 or the yolk sac endothelial cell line C166. In 
these experiments, CD34+ CD31+ cells were also observed and suggested to 
identify endothelial progenitor population. Similarly, CD34+ KDR+ population was 
observed in a co-culture system with OP9 stromal cells by Vodyanik et al. (2005). 
However, co-culture differentiation methods have not gained popularity for 
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endothelial differentiations, perhaps due to low efficiencies and presence of 
other cell types in the differentiation system. 
Later, first feeder and serum free endothelial monolayer differentiation system 
was reported by Kane et al. (2012, 2010) which was further optimised to use 
cGMP compliant reagents (Kaupisch et al., 2012). Extensive testing of these cells 
showed downregulation of pluripotency marker expression as well as 
upregulation of mesodermal and endothelial marker expression. Over 80% CD31+ 
CD144+ yield was reported after 21 day of differentiation and the differentiated 
cells produced NO, formed tubules in vitro and contributed to blood flow 
recovery in hindlimb ischemia model. Interestingly, downregulation of 
anti-angiogenic and upregulation of angiogenic micro-RNAs was observed (Kane 
et al., 2010) and, in addition, novel micro-RNAs regulating endothelial 
differentiation were identified (Kane et al., 2012). 
1.8.2 Endothelial differentiation of hESC and iPSC – recent 
developments. 
Interest in developing efficient methods for hESC endothelial differentiation has 
remained high and recently there have been numerous publications describing 
novel approaches to endothelial differentiation and providing further evidence 
for the utility of these cells for therapeutic angiogenesis.  
Sahara et al. (2014) employed a CDH5 GFP reporter hESC line to develop and 
optimise a novel, two step endothelial differentiation protocol.  Firstly, 
mesoderm was induced using BMP4 and GSK3B inhibitor; followed by treatment 
with VEGF, γ-secretase inhibitor DAPT, PLGF and HGF for vascular specification. 
This combination is reported to generate over 40% of CD144+ CD31+ cells, 
yielding 2.5 x 106 CD144+ CD31+ from 106 of hESCs. Further selection and 
expansion of CD144+ CD31+ cells increased their number to 20 million by day 14. 
The ability of these cells to form blood vessels in vivo was also confirmed, 
however, it was noted that cells isolated before expansion demonstrated more 
than three times higher efficacy of vascular tube formation in in vivo Matrigel 
plugs, when compared to HUVECs and differentiated cells expanded up to day 
14. This suggests that early differentiated endothelial cells might be superior for 
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therapeutic angiogenesis, and thus methods for expanding these cells, while 
retaining their angiogenic capacity, are needed for future cell therapies. 
A potential solution to this problem could be the approach taken by Prasain et 
al. (2014) who optimised differentiation for increased yield of cells expressing 
VEGF co-receptor NRP1, speculating that NRP1+ CD31+ population would 
represent a highly proliferative EPC population with a stable phenotype. 
Treatment of 104 hESC cells with Activin a, bFGF, VEGF and BMP4 yielded 3 x 104 
NRP1+ CD31+ cells on day 12 of the differentiation. These cells were highly 
proliferative, maintained stable phenotype over prolonged culture and could be 
expanded to over 1012 cells by day 61 of culture. The ability of these cells to 
contribute to vascular repair in vivo of both ischemic retina and limb was 
demonstrated, however, comparison of angiogenic activity between early and 
expanded endothelial cells was not performed. 
More recently, a significant advance was reported by Patsch et al. (2015) who 
screened various GSK3B inhibitors for mesodermal specification and optimised 
vascular specification phase to establish a high yield endothelial differentiation 
protocol. GSK3B inhibitor screen showed that CP21R7 induced the highest levels 
of mesoderm gene expression when used together with BMP4 for three days. 
Subsequently, both Forskolin and VEGF were shown to be required for highly 
efficient vascular specification and generation of CD144+ cells. Over 60% 
differentiation efficacy was reported, generating over 25 x 106 CD144+ cells from 
106 hESC in six days.  
In addition to demonstrating formation of vascular structures using commonly 
used in vitro tubule formation assay and in vivo matrigel plug assay, a range of 
other assays were performed providing a unique insight into the characteristics 
of derived endothelial cells (Patsch et al., 2015). Transcriptional signature of 
the derived cells was compared to primary cells and showed that after day 4 of 
the differentiation the differentiated cells lost their pluripotent stem cell 
signature and upregulated genes related to endothelial cell differentiation, 
angiogenesis, endothelium and blood vessel development, becoming highly 
similar to the respective primary cells. Transcriptome and metabolomic profile 
analysis was performed and showed signatures similar to primary endothelial 
cells. Additionally, the day 6 differentiated cells formed a tight monolayer and 
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this barrier function was responsive to thrombin, as well as various cytokines, for 
example VEGF, tumour necrosis factor alpha, interleukin 1B. Taken together, 
these cells closely resembled primary ECs both phenotypically, functionally and 
on a metabolic level, providing strong evidence for the suitability of such cells 
for clinical purposes.  
Meanwhile, a low yield but high efficiency method has been reported by Wu et 
al. (2015). They showed that anti-adsorptive agents can be used to selectively 
plate out cells that give rise to almost pure (>90%) CD144+ CD31+ cultures within 
5 days. Impressively, this was achieved using a minimal set of growth factors, 
namely, ACT-A and WNT agonist for mesoderm specification, and VEGF for 
endothelial specification, which on their own yielded less than 4% of CD144+ 
CD31+ cells. It can be speculated that this selection method could be applied to 
the more efficient differentiation protocols described above to obtain near-pure 
endothelial cell cultures without the need of cell sorting. 
Currently, there is a vast amount of data demonstrating that endothelial cells 
derived from hESC acquire endothelial phenotype and are capable of 
contributing to angiogenesis, as demonstrated by a range of in vitro and in vivo 
assays. It can be speculated, that it would be possible to obtain clinically 
relevant numbers of almost pure differentiated endothelial cells with a high 
proliferative and angiogenic capacity by combining approaches described above.  
This would represent a significant advance for future CLI and PAD cell therapies, 
and the field of regenerative medicine. 
1.8.3 Endothelial differentiation using other cell sources. 
To avoid ethical and clinical issues associated with the use of hESC and iPSC, 
endothelial differentiations using other cell courses have been explored. These 
methods aim to induce or exploit plasticity of various adult cell types to 
generate endothelial cells without pluripotent intermediates. 
Initial reports used viral vectors to partially dedifferentiate fibroblasts followed 
by endothelial differentiation (J. Li et al., 2013; Margariti et al., 2012). An 
alternative approach was employed by Kurian et al. (2013) who demonstrated 
that episomally delivered pluripotency factors, increase fibroblast plasticity 
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without inducing pluripotency and allow for differentiation of multipotent CD34+ 
cells.  The obtained CD34+ cells were sorted and differentiated towards 
endothelial lineages where endothelial, arterial and venous marker expression 
was observed. In addition, generated endothelial cells formed tubules in vitro 
and integrated in host vasculature in vivo. While fibroblasts exposed to 
pluripotency factors did not form teratomas, the use of pluripotency factors 
remains an important limitation. 
A direct transdifferentiation approach was reported by Veldmann et al. (2013) 
who demonstrated skeletal muscle transdifferentiation to endothelial lineages in 
vivo in zebrafish and in vitro mouse myofibroblast cultures. This established 
ETV2 as the main orchestrator of endothelial transdifferentiation and recently 
there have been multiple publications using multiple TF in addition to ETV2 for 
direct endothelial transdifferentiation of fibroblasts (Han et al., 2014; Van Pham 
et al., 2016; Wong and Cooke, 2016).  
In contrast, Morita et al. (2015) screened a panel of TF factors for direct 
conversion of human fibroblasts into ECs and demonstrated that transient ETV2 
expression alone was able to efficiently induce endothelial phenotypes. The 
generated cells which formed vascular in vitro and in vivo, as well as 
contributed to blood flow recovery in hindlimb ischemia model. However, this 
method generated 30-40% of cells expressing CD309, while CD144 expression 
levels were not reported. Thus, it’s not clear whether this approach generated 
stable cells expressing CD144 or just a more immature endothelial progenitor 
cells. 
Ginsberg et al. (2015, 2012) speculated that lineage-committed amniotic 
fluid-derived cells might be a cell type allowing for more efficient 
transdifferentiation to endothelial lineages due to higher plasticity and more 
similar phenotype to early endothelial cells than fibroblasts. They were able to 
generate >80% cells expressing CD144+ by Day 21 of the differentiation by using 
vectors expressing ETS factors ETS related gene 1 (ERG1) and friend leukaemia 
integration 1 transcription factor (FLI1) constitutively in addition to transient 
ETV2 expression and TGFB signalling inhibition. Transcriptome analysis revealed 
a full induction of endothelial gene expression, and the generated endothelial 
cells formed tubules in Matrigel in vitro and in vivo assays, as well as integrated 
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in the host vasculature. They also demonstrated that the cells were genetically 
stable, however the use of lentiviral vectors as well as the long differentiation 
protocol limits the suitability of this method for clinical setting. 
The use of viral vectors should be avoided when generating cells for therapeutic 
angiogenesis. A novel method was reported by Sayed et al. (2015) who 
hypothesised that innate immunity takes part in nuclear reprogramming by 
increasing cell plasticity. Indeed, they were able to transdifferentiate human 
and murine fibroblasts to endothelial lineages, by using a toll-like receptor 3 
(TLR3) agonist and endothelial differentiation media. Further evidence of the 
role of TLR3 was provided showing that TLR3 knockout cells resisted 
transdifferentiation. Expression of pluripotency genes NANOG and OCT4 was not 
detected. Endothelial identity and functionality was confirmed in a range of 
tests, including transcriptome analysis, NO production and in vivo hindlimb 
perfusion assays. This represents a significant advance for therapeutic 
angiogenesis as endothelial cells were generated from adult cells without the 
use of viral or other gene vectors, or pluripotent intermediates. However, the 
reported yields endothelial cell yields were low (2-4%) so currently this is only a 
proof of principle study and further optimisation is required to take advantage 
innate immunity mechanisms for therapeutic reprogramming of adult cell types. 
The described methods generate endothelial cells without the use of hESC or 
iPSC potentially circumventing the ethical and clinical issues associated with 
pluripotent cells. However, most of these methods use viral vectors or suffer 
from limited efficacy which limits their suitability for therapeutic uses. In 
addition, while some adult cell sources are widely available the scale up 
required for angiogenetic therapies would still pose a significant challenge. 
Thus, endothelial differentiations of hESC or iPSC remain the most attractive 
approach for future clinical therapies. 
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1.9 Summary 
In summary, CVD represents a significant clinical and socioeconomic burden. 
Atherosclerosis, one of the fundamental processes in CVD, can lead to PAD which 
has high amputation and mortality rates. Currently, there are no effective 
pharmacological treatments for preventing CLI and aiding angiogenesis. While 
the current surgical revascularisation strategies for PAD and CLI offer increased 
limb salvage rates, these procedures are invasive and there is a large patient 
population, who are not suitable for these treatments. Recent trials with gene 
therapy or adult cell therapies for PAD have yielded mixed results, highlighting 
the need for novel approaches for clinical angiogenesis therapies. 
One of such approaches is the use of human embryonic or induced pluripotent 
stem cells. These cells are capable of differentiating towards endothelial 
phenotypes and, theoretically, it is possible to obtain unlimited number of pure 
endothelial populations that are highly suitable for clinical use. Endothelial 
development has been widely researched in vivo, providing insight into the key 
mechanisms driving endothelial specification. Similarly, research of angiogenesis 
has demonstrated the role of endothelial cells and suggests that endothelial cell 
based therapies could vastly benefit PAD. 
Whereas, multiple endothelial differentiation approaches have been published, 
there’s scope for further research and optimisation differentiation protocols, 
particularly focusing on endothelial cell yields and purity and well as clinical 
compatibility. Research of hESC differentiation towards endothelium in vitro 
also offers an opportunity to investigate other signalling pathways contributing 
to endothelial development and specification. 
Development of clinically relevant endothelial differentiation protocols is crucial 
for progression of differentiated endothelial cell progression towards clinical 
therapies and offers hope to meet a significant clinical need. 
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1.10 Project aims. 
The aims of this project were: 
 To develop and optimise a clinically relevant, serum-free endothelial 
differentiation (hESC-EC) protocol.  
 To characterise hESC-EC differentiation during the differentiation. 
 To generate hESC cell lines reporting markers of interest for optimisation 
of hESC-EC differentiation. 
 To investigate potential signalling pathways that could be exploited to 
increase the efficacy or yield of hESC-EC differentiations. 
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Chapter 2: Materials and Methods 
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2.1 General laboratory practice 
All chemicals were supplied by Sigma-Aldrich, UK, unless otherwise stated. 
Control of Substances Hazardous to Health (COSHH) guidelines were followed 
when handling hazardous substances. Powder free nitrile gloves and laboratory 
coat was worn during work at the laboratory. Laboratory spectacles, facemask 
and fume hood was used, if appropriate. 
2.2 Tissue culture 
All tissue culture was performed in standard biological safety class II vertical 
laminar flow cabinets under sterile conditions. Cells were cultured at 37°C in a 
humidified incubator atmosphere maintained at 5% CO2. 
2.2.1 hESC culture 
Human embryonic stem cell (hESC) lines H1 and H9 (Thomson et al., 1998) 
supplied by WiCell, USA and cGMP clinical grade lines RC-11 and RC-9 (Roslin 
Cells Ltd, Edinburgh) used with approval of the UK Stem Cell Bank steering 
committee, were cultured in StemPro media (Thermo Fisher Scientific, UK) 
(Table 2) in 6 well format tissue culture plates coated with CellStart matrix 
(Thermo Fisher Scientific, UK) and later Vitronectin (Thermo Fisher Scientific, 
UK) as shown in Table 3. Cultures received daily media exchange six times a 
week. Cultures were allowed to reach 90% confluence before passaging to avoid 
spontaneous differentiation. For passage, cultures were washed with Phosphate 
Buffered Saline (PBS) (Thermo Fisher Scientific, UK), supplemented with fresh 
StemPro media, cut to small colonies using StemPro EZ-Passage tool (Thermo 
Fisher Scientific, UK) and seeded in a 1:2 to 1:6 ratio in new culture plates. Cells 
were obtained from cell stocks tested for normal karyotype prior to freezing. As 
the risk of genetic changes increases with prolonged culture (Lund et al., 2012), 
hESCs were not cultured above passage 50. 
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Component Concentration 
DMEM F12 + GlutaMAX  
StemPro hESC supplement 1x 
BSA 1.8% 
Mercaptoethanol 0.1mM 
bFGF 20ng/ml 
Table 2: Components of StemPro media. 
ECM Supplier Volume and 
concentration 
per well 
Incubation 
Cellstart Thermo 
Fisher 
Scientific, UK 
750µL 2h at 37°C 
Vitronectin Thermo 
Fisher 
Scientific, UK 
500µL, 
25µg/mL 
1h at RT 
Gelatin Sigma-
Aldrich, UK 
1mL 0.1% 1h at RT 
Table 3: Extracellular matrices used for hESC culture and differentiation. 
2.2.2 hESC cryopreservation and recovery 
For cryopreservation, hESC cultures were allowed to reach 90% confluency, 
washed with PBS, supplemented with 0.9mL fresh StemPro media and cut to 
small colonies using StemPro EZ-Passage tool. 0.9mL of freezing solution (60% 
KOSR, 20% DMSO, and 20% DMEM F12 + GlutaMAX) was added. The suspension was 
transferred to a cryovial, placed in a Mr. Frosty Freezing Container with 
isopropanol (Thermo Fisher Scientific, UK) and stored at -80°C. This ensures 
controlled rate freezing of approximately 1°C/min, which is optimal for cell 
preservation. The following day, cryovials were transferred to liquid nitrogen for 
prolonged storage. 
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To recover frozen hESC cultures, cryovials were placed in a 37°C waterbath. 
Before complete thawing, prewarmed StemPro media was added dropwise and 
cells were transferred to a 15mL Falcon, centrifuged at 300 x g for 3 minutes 
and resuspended in StemPro supplemented with 10µM Y-27632 (Tocris, UK) to 
reduce apoptosis after thawing (Watanabe et al., 2007). 
2.2.3 NCI60 cancer cell line culture 
NCI60 cancer cell lines (IGROV-1, K562, OVCAR3) were cultured in RPMI1640 
media (Thermo-Fischer, UK) supplemented with 10% foetal bovine serum (FBS, 
Thermo Fischer, UK), 100U/mL penicillin, 100µg/mL streptomycin, 10µg/mL 
gentamicin (Thermo Fisher Scientific, UK) and 1µg/mL Amphotencin B (Thermo 
Fisher Scientific, UK). Cells were cultured in tissue culture treated T75 or T150 
flasks and received 100% feeds every 2-3 days. Cultures were allowed to reach 
near confluence, dissociated using 0.05 % Trypsin, 0.53mM EDTA and split in a 
1:8 ratio. 
2.2.4 Human embryonic kidney 293T cell line culture 
Human embryonic kidney 293T cells (HEK293T, ATCC, UK) were cultured in MEM 
media (Thermo Fisher Scientific, UK) supplemented with 100µg/mL penicillin, 
100µg/mL streptomycin, 2mM L-Glutamate and 1mM sodium pyruvate (Thermo 
Fisher Scientific, UK). HEK293T were passaged 1:6 using 1x citric saline 
(10mg/ml potassium chloride, 4.4mg/ml sodium citrate) after reaching 70% 
confluence. 
2.2.5 Human saphenous vein endothelial cell (HSVEC) and human 
umbilical vein endothelial cell (HUVEC) culture 
Human saphenous veins were obtained from patients undergoing coronary bypass 
graft at the Golden Jubilee National Hospital, or patients undergoing elective 
varicose vein stripping at the Glasgow Gartnavel General. The procedure was 
approved by Glasgow West Ethics committee. Written informed consent was 
required from the patients prior to participation. 
HSVECs and HUVECs were cultured in Cascade Biologics Medium 200 (Thermo-
Fischer, UK) supplemented with Low Serum Growth Supplement Kit (Thermo-
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Fischer, UK), 20% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 2mM 
L-Glutamine. Cells were cultured in tissue culture treated T25 or T75 flasks and 
received 100% feeds every 2-3 days. Cultures were allowed to reach near 
confluence, dissociated using 0.05 % Trypsin, 0.53mM EDTA and seeded at 
2,500-5,000 cells per cm2.  
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2.3 hESC-EC differentiation 
For hESC differentiation towards endothelial cell lineages (hESC-EC 
differentiation), hESCs were grown to full confluence, cultures were dissociated 
with TrypLE select (Thermo Fisher Scientific, UK) and controlled size embryoid 
bodies (10 000 cells per EB) were formed using round bottom tissue culture 
96 well plates (Corning, UK) coated with 5% Pluronic F-127, following the Spin-EB 
protocol as described by Ungrin et al. (2008) in 100µl Stemline media (Sigma-
Aldrich, UK) with 10ng/ml BMP4, 10ng/ml VEGF, 5ng/ml Activin A, (all 
Peprotech, US), 10ng/ml Wnt3a (R&D Biosystems, UK) and 10µM Y-27632 (Tocris, 
UK) as described by Olivier et al. (2016). This is Day 0 of the differentiation.  
The cultures were further supplemented with 20ng/ml BMP4, 30ng/ml VEGF, 
10ng/ml WNT3a and 5ng/ml Activin A on Day 2 of the differentiation. On Day 3, 
the formed embryoid bodies were plated out on wells coated with 0.1% Gelatin 
solution (Table 3) and cultured in Day 3 media, consisting of EBM-2 media 
(Lonza, UK) supplemented with EGM-2 SingleQuots (Lonza, UK). FBS and VEGF 
from the kit were excluded and the media was supplemented with 50ng/ml VEGF 
(Peprotech, US). Cultures were given 100% media exchange on Day 5. Day 7 is 
the end of the differentiation. 
2.3.1 Intracellular cAMP level quantification during hESC-EC 
differentiation 
To determine optimal Forskolin concentrations for increasing intracellular cAMP 
levels during hESC-EC differentiation, Promega cAMP Glo Max kit (Promega, UK) 
was used as per manufacturer’s instructions. Briefly, Day 3 embryoid bodies 
were incubated in Day 3 media supplemented with 100µM IBMX and Forskolin at 
concentrations ranging from 0.1µM - 50 µM (induction buffer). DMSO was used as 
a negative control.  
After 1 hour stimulation, each EB was plated in a well of a 96 well plate in 
37.5µL of the induction buffer. 2.5 µl of 1M MgCl2 and 10µl of cAMP Detection 
Solution with PKA were added to each well and the plate was mixed by shaking 
for 1 minute. During the incubation, cAMP stimulates PKA activity, depleting 
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ATP. After 20 minute incubation, 50 µl of Kinase-Glo® Reagent was added to 
each well and plate was mixed by shaking for 1 minute.  
Kinase-Glo® Reagent contains Luciferase which requires ATP for production of 
oxyluciferin and subsequently light. In this coupled PKA-Luciferase reaction, 
increase of cAMP levels, decreases bioluminescent signal. Luminiscence was 
measured after 10 minute incubation with Victor X3 plate reader (PerkinElmer, 
UK). 
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2.4 Generation of reporter construct plasmid vectors 
Eukaryotic expression plasmids were used to generate reporter constructs where 
promoter of a gene of interest drives expression of either eGFP or RFP reporter 
protein. 
2.4.1 Transformation of chemically competent bacteria 
DH5α Max (Thermo Fisher Scientific, UK) or JM109 (Promega, UK) chemically 
competent E.Coli bacterial strain was used to produce plasmids. For each 
transformation 5ng for DH5α or 25ng for JM109 of plasmid of interest or ligation 
product was added to thawed 50µL of cells kept on ice and carefully mixed. 
After 30 minute incubation on ice, heat shock was used to induce uptake of the 
plasmid by placing tubes in a 42oC water bath for a 40 seconds, after which, 
tubes were returned on ice for further two minutes. 900µL for DH5α or 450µL for 
JM109 of Super Optimal broth with Catabolite repression (SOC) medium (Thermo 
Fisher Scientific, UK), consisting of 2% tryptone, 0.5% yeast extract, 10mM 
sodium chloride, 2.5mM potassium chloride, 10mM magnesium chloride, 10mM 
magnesium sulphate and 20mM glucose, was added to the tubes, followed by 
incubation at 37°C for 1 hour in a shaking incubator set to 180 oscillations per 
minute. 20-50µL of the resulting mixture was plated on to Luria-Bertani agar 
plates containing 100µg/mL ampicillin or 50µg/mL Kanamycin, as required. After 
5 minutes, plates were inverted, incubated and checked for colony growth the 
next day. 
2.4.2 Low volume plasmid DNA purification 
Purification of plasmid DNA from low volume E.Coli bacterial cell culture was 
performed using Wizard® Plus SV Minipreps DNA Purification System (Promega, 
UK). A single well isolated colony was picked to inoculate 12mL of Luria broth 
media with added 100µg/mL ampicillin or 50µg/mL Kanamycin, as required. 
After 6 - 8 hour incubation at 37°C in a shaking incubator set to 180 oscillations 
per minute, 2mL of the solution was stored at 4oC and bacterial cells were 
harvested by spinning the remaining solution at 6000 × g for 15 minutes. The 
pellet was resuspended in 250µl of Cell Resuspension Solution with RNAse A by 
pipetting up and down thoroughly and transferred to an eppendorf tube. 250µl 
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of Cell Lysis Solution, containing SDS to solubilize cell membrane and denature 
proteins and NaOH to denature DNA, was added, the tube was inverted few 
times to mix and incubated in room temperature until the solution cleared. 10µl 
of Alkaline Protease Solution was added to the solution, tube was inverted to 
mix and incubated for 5 minutes. Alkaline protease lyses various proteins, 
including endonucleases. 350µl of Neutralization Solution containing guanidine 
hydrochloride and glacial acetic acid was added to the solution, making the 
solution acidic, rendering alkaline proteases inactive and renaturing plasmid 
DNA. Renatured plasmid DNA dissolves in the solution while genomic DNA and 
proteins form precipitate. Tube was inverted few times and centrifuged at 
16 000 x g for 10 minutes. 
The cleared lysate was carefully transferred to the spin column, followed by 
centrifugation at 16 000 x g for 1 minute. Plasmid DNA from the cleared lysate is 
bound to the spin column membrane. This was followed by two washes with 
column wash solution of 750µl and 250µl, 1 and 2 minute centrifugation 
respectively at 16 000 x g. Any remaining contaminants, including RNA, are 
washed away during this step. To prevent any carryover of the column wash 
solution and to remove any residual ethanol, the spin column was placed in a 
fresh eppendorf tube and another spin was performed. Plasmid DNA was eluted 
by adding 100µl of Nuclease-Free Water to the Spin Column and centrifuging at 
16 000 g for 1 minute. Restriction digests were performed to confirm identity of 
the plasmid and the presence of an insert as per 2.4.6 . If required, the plasmid 
DNA solution was stored at -20oC. 
2.4.3 High volume plasmid DNA purification 
High volume plasmid DNA purification was performed using PureLink® HiPure 
Plasmid Filter Purification Maxi Kit (Thermo Fisher Scientific, UK). Bacterial 
solution from the low volume plasmid DNA purification (2.4.2 ) was used to 
inoculate up to 500mL of LB broth followed by overnight incubation at 37oC in a 
shaking incubator set to 180 oscillations per minute. Bacterial cells were 
harvested by centrifugation at 6000 × g for 15 minutes. The pellet was 
resuspended in 10mL Resuspension Buffer containing RNase A. 10 mL of Lysis 
Buffer was added, the solution was mixed by inverting and incubated at room 
temperature for 5 minutes. 10 mL of Precipitation Buffer, containing potassium 
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acetate to renature plasmid DNA, was added. The solution was inverted to mix 
and centrifuged at 12 000 × g for 10 minutes.  
The supernatant was transferred to an anion exchange column that was 
previously equilibrated with 30 mL Equilibration Buffer, and allowed to drain by 
gravity flow. The negatively charged phosphates on the backbone of the DNA 
bind the positively charged surface of the resin. 60mL of Wash Buffer (W8) was 
added to the column and allowed to drain by gravity flow. This buffer has 
moderate NaCl content and washes away RNA, proteins and carbohydrates, while 
DNA remains bound to the column resin. 15mL of high NaCl content Elution 
buffer (E4) was added to the column and allowed to drain by gravity flow. This 
elutes DNA from the resin. 
DNA was precipitated from the elution buffer by adding 10.5mL of isopropanol, 
mixed and centrifuged at 12 000 × g for 30 minutes at 4°C. Supernatant was 
discarded and the pellet was washed in 5mL of 70% ethanol. The tube was 
centrifuged at 12 000 × g for 5 minutes at 4°C, the supernatant was discarded, 
tube was inverted and pellet was allowed to air dry for 10 minutes at room 
temperature. DNA was resuspended in 200µL of nuclease free water. If required, 
the plasmid DNA solution was stored at -20oC. 
2.4.4 PCR 
Phusion High-Fidelity PCR Kit (NEB, UK) was used for amplification of fragments 
of interest from plasmid or genomic DNA as per manufacturer’s instructions, 
using PCR reaction components as shown in Table 4 and cycling conditions as 
shown in Table 5.  Primers were designed to include endonuclease restriction 
digestion sites, if required. Annealing temperature was based on average 
calculated annealing temperature (Tm) of both primers and was tested prior to 
PCR.  
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Component Concentration 
5X Phusion HF Buffer 1X 
10mM dNTPs 200µM 
10µM Forward Primer 0.5µM 
10µM Reverse Primer 0.5µM 
Template DNA < 250ng 
DMSO (optional) 3% 
Phusion DNA Polymerase 
1 unit/50µl 
PCR 
Table 4: PCR reaction components. 
 
Cycle Step Cycles Temperature Time 
Initial denaturation 1 98°C 30 seconds 
Denaturation 
34 
98°C 10 seconds 
Annealing 45-72°C 30 seconds 
Extension 72°C 30 seconds 
Final extension 1 72°C 10 minutes 
Hold 1 4°C ∞ 
Table 5: Cycling conditions for a routine PCR. 
2.4.5 PCR purification 
PCR clean-up was performed using QIAquick PCR Purification Kit (Qiagen, UK). 
Briefly, 5 volumes of Buffer PB were added to 1 volume of PCR product, the 
solution was applied to QIAquick spin column and it was centrifuged at 
16 000 x g for 1 minute. The flow through was discarded, 750µL of Buffer PE 
containing ethanol was added to the spin column followed by another spin at 
16 000 x g for 1 minute. The flow through was discarded, the column was placed 
in the empty collection tube and centrifuged at 16 000 x g for 2 minutes to 
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remove any residual ethanol. The spin column was placed in a new eppendorf 
tube, 30µL of nuclease free water was applied to the membrane followed by a 1 
minute incubation and centrifugation at 16 000 x g for 1 minute. 
2.4.6 Restriction digestion 
Double restriction digestions were performed as per manufacturer’s instructions 
using endonucleases manufactured by NEB, UK, unless otherwise stated. When 
small amounts of DNA were required, 20μL reactions were used, containing 100-
200ng of DNA, 0.5μL of restriction endonucleases and 2μL of 10x buffer. The 
reactions were incubated for 1-2 h at 37°C. For larger amounts of DNA, 50μL 
reactions were used, containing up to 10μg of DNA, 5μL of restriction 
endonucleases and 5μL of 10x buffer. The reactions were incubated overnight at 
37°C. 
2.4.7 Agarose gel electrophoresis 
Agarose gel eletrophoresis was used to confirm DNA fragment sizes after PCR or 
endonuclease digestion, as well as to separate successfully cut plasmids. Current 
is applied to an the gel immersed in 1x Tris/Borate/EDTA (TBE) solution (10mM 
Tris, 10mM boric acid, 10mM EDTA, pH 8.3) and negatively charged DNA migrates 
through the gel towards the positive electrode. Varying the percentage of the 
agarose gel changes the pore size with higher percentages resulting in smaller 
pores, limiting migration of larger DNA fragments, this way separating the 
fragments by size.  
0.8 - 1.5% w/v agarose gels were used (Thermo Fisher Scientific, UK) with 0.2-
0.5μg/mL ethidium bromide for DNA band visualisation using ChemiDoc XRS+ 
Imaging System (Bio-Rad Laboratories, UK). 6x blue/orange loading dye 
(Promega, UK) was added to the DNA solution at the time of loading the DNA and 
constant voltage of 30V - 100V was applied. 1Kbp and 100bp ladders (both 
Promega, UK) were used to estimate DNA fragment size. 
2.4.8 DNA gel extraction 
To separate plasmids after endonuclease restriction digestion, the digestion 
product was run on agarose gel as described in 2.4.7 and bands were visualized 
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under trans UV illumination using a DNA ladder (100bp and 1Kbp, both Promega, 
UK) as a reference. The band of interest was cut with a clean scalpel blade and 
gel extraction was performed using Wizard® SV Gel and PCR Clean-up System 
(Promega, UK) as per manufacturer’s instructions. 10µL of Membrane Binding 
Solution (4.5M guanidine isothiocyanate, 0.5M potassium acetate, pH 5.0) was 
added per every 10µg of gel, followed by incubation in a 65oC waterbath until 
the gel was fully dissolved. The solution was incubated on the provided silica gel 
column for 1 minute, followed by centrifugation 16 000 x g for 1 minute. Two 
washes, 700µL followed by 500µL, with membrane wash solution (10mM 
potassium acetate pH 5, 80% ethanol, 16.7μM EDTA pH 8.0) were performed. 
This was followed by centrifugation at 16 000 x g for 5 minutes to remove any 
remaining ethanol. The spin column was placed in a new eppendorf tube, 50µL 
of nuclease free water was applied to the membrane followed by a 
centrifugation at 16 000 x g for 1 minute. 
2.4.9 Dephosphorylation of plasmid DNA 
To prevent spontaneous recirculation of plasmid DNA after restriction digestion, 
the plasmid DNA was treated with Antarctic Phosphatase (NEB, UK). Briefly, 
appropriate volume of 10X Antarctic Phosphatase Reaction Buffer was added to 
up to 5µg plasmid DNA in nuclease free water. 1 µl of Antarctic Phosphatase was 
added, the solution was gently mixed, followed by 15 minute incubation at 37°C. 
Antarctic Phosphatase was inactivated by incubation at 70°C for 5 minutes. 
2.4.10 Ligation of insert into plasmid backbone 
Inserts were ligated into plasmid backbone using Quick Ligation Kit (Promega, 
UK). Molar ligation ratios were calculated using formula below and 1:3, 1:1 and 
3:1 molar ratios were used: 
𝐼𝑛𝑠𝑒𝑟𝑡 𝑛𝑔 = 𝑉𝑒𝑐𝑡𝑜𝑟 𝑛𝑔 ×  
𝐼𝑛𝑠𝑒𝑟𝑡 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡 𝑠𝑖𝑧𝑒 𝐾𝑏𝑝
𝑉𝑒𝑐𝑡𝑜𝑟 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡 𝑠𝑖𝑧𝑒 𝐾𝑏𝑝
×  𝑟𝑎𝑡𝑖𝑜 
𝐼𝑛𝑠𝑒𝑟𝑡
𝑉𝑒𝑐𝑡𝑜𝑟
  
For each ligation reaction, 50ng of Vector plasmid was put in an eppendorf tube 
and volume was adjusted to 9µL with nuclease free water. 10µL of 2x Quick 
Ligase buffer and 1µL of quick T4 ligase was added to the tube and mixed. The 
88 
 
solution was incubated at room temperature for 5 minutes, followed by 
refrigeration at 4oC or storage at -20oC. 
2.4.11 DNA sequence analysis 
DNA sequences were analysed by dideoxy sequencing using BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, UK). Sequencing PCR 
reaction was set up with reagents as shown in Table 6 and made up to the final 
volume with nuclease free water. PCR reaction consisted of 20 cycles of 96°C for 
50 seconds, 50°C for 20 seconds, 60°C for 2 minutes. 
Reagent per reaction 
DNA 200 – 500ng 
BigDye Sequencing 
buffer 5x 
4µL 
Ready Reaction Mix 1µL 
Sequencing Primer 
(2µM) 
2µL 
Final volume 20µL 
Table 6: Reagents used in sequencing PCR reactions. 
Sequencing PCR reactions were purified using Agencourt CleanSeq (Beckman 
Coulter Ltd, UK). Briefly, 10µL of CleanSeq reagent and 62µL of 85% ethanol was 
added to each well followed by brief vortexing and centrifugation. The reagent 
contains paramagnetic beads coated with carboxyl molecules which bind DNA in 
the presence of polyethylene glycol and salt. The plate was put on a magnetic 
block for two minutes, and put upside down to remove ethanol while beads with 
bound DNA remain in plate. This was followed by 150µL of 85% ethanol wash, 
excess ethanol was removed by brief upside-down centrifugation while keeping 
plate on the magnet block, after which the plate was allowed to air dry. Plate 
was removed from the magnet block, 40µL of nuclease free water was added to 
each well and the DNA was resuspended by pipetting up and down. Plate was 
returned to magnet block for two minutes, 20µL of the cleaned up sequencing 
product was loaded into optically clear 96 well plates and DNA sequencing was 
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performed using Applied Biosystems 3730 Genetic Analyser (Applied Biosystems, 
UK). 
2.4.12 Plasmid transfections 
Generated reporter plasmids were transfected in HUVEC and HSVEC using 
cationic lipid Lipofectamine LTX (Thermo Fisher Scientific, UK) following 
manufacturer’s instructions. Briefly, 4 x 104 cells were seeded per well in a 24 
well format. For each well, 0.5µg of plasmid DNA were diluted in 100µL of 
Optimem reduced serum media, 0.5µL of Plus reagent was added and the 
solution was incubated for 10 minutes. 1.5µL of Lipofectamine LTX was added 
and the solution was incubated for 25 minutes. Cultures were supplemented 
with fresh 0.5mL of media as per 2.2.5 and the solution containing DNA-
Lipofectamine complexes was added. 
For transfections of NCI60 cell lines, Lipofectamine 2000 (Thermo Fisher 
Scientific, UK) was used following manufacturer’s instructions. Briefly, 2 x 105 
cells were seeded per well in a 24 well format in 0.5mL of OptiMem reduced 
serum media. For each well, 0.5µg of plasmid DNA were diluted in 25µL of 
Optimem, and 1.5µL of Lipofectamine 2000 were diluted in separate 25µL of 
Optimem. These two solutions were combined, incubated for 5 minutes and 
added to cells. After 6 hour incubation, media was replaced to fresh NCI60 
culture media as per 2.2.3 .  
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2.5 Generation of reporter construct lentiviral vectors 
2.5.1 Production of lentivirus 
Second generation, self-inactivating lentiviral vectors were used. HEK293T cells 
were cultured in T150 flasks and passaged in a 1:2 ratio the day before 
transfection. The following day, triple transient transfection was performed 
using polyethylenimine (PEI). PEI is a cationic polymer that forms dense particles 
with DNA that accumulate next to negatively charged cell membranes and are 
subsequently endocytosed. PEI containing endosomes are susceptible to lysis, 
releasing  the DNA in cell cytoplasm (Boussif et al., 1995; Sonawane et al., 
2003). 
Briefly, per each T150 flask, 32.5µg of packaging plasmid Int, 17.5µg of plasmid 
encoding the vesicular stomatitis virus envelope (pMDG) (Plasmid Factory, 
Bielefeld, Germany) and 50µg of the generated reporter plasmid were added to 
5mL Optimem reduced serum media with Glutamax (Thermo Fisher Scientific, 
UK ) and combined with 5mL of the same media with 2µM PEI. The combined 
reagents were incubated for 20 minutes at room temperature in dark to allow 
formation of PEI-DNA polyplexes.  
Each flask of HEK293T cells was washed with 10 mL of Optimem media and 10mL 
of polyplex Optimem solution was added per flask. The cells were incubated for 
4 hours at 37°C in 5% CO2. After the incubation, the solution was replaced with 
20mL of HEK293T medium. Transfected cultures were incubated at 37°C in 5% 
CO2 and media containing lentiviral particles was removed after 48 hours. 
Another 10mL of HEK293T medium was added and cultures were incubated for 
further 24 hours after which media was removed. The collected media was 
sterile filtered through a 0.22µM filter and stored at 4°C in dark prior to 
concentration. 
2.5.2 Concentration of lentivirus 
Ultra-clear centrifuge tubes (Beckman Coulter Ltd, Buckinghamshire, UK) were 
washed with 70% ethanol and sterile PBS. Collected media with lentiviral 
particles was put in tubes and centrifuged in Optima L-80 XP Ultracentrifuge 
(Beckman Coulter) at 23 000rpm at 4oC for 1 hour. The media was poured off 
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carefully, and tubes were topped up with the remaining collected media. Spins 
were repeated, until all the collected media with lentiviral particles was 
processed. After the final spin, media was poured off and the tubes were 
drained by placing them upside down on a layer of tissue paper. After 1-2 
minutes, 100µl of Optimem media was added to each tube and the tubes were 
placed on ice for 20 minutes. The media was mixed by pipetting up and down 
several times and aliquoted in individual single use aliquots that were stored 
at -80oC.  
 
2.5.3 Determination of functional lentivirus titre 
Functional lentivirus titre was determined using qPCR based assay as described 
by Butler et al. (2001). Viral genomic RNAs are reverse transcribed to yield 
linear viral cDNA. This method uses a pair of primers and probes to detect late 
reverse transcription products. The primer and probe sequences are as follows: 
forward: 5’-TGTGTGCCCGTCTGTTGTGT-3';  
reverse: 5'- 75 GAGTCCTGCGTCGAGAGAGC-3';  
probe: 5'-(FAM)-CAGTGGCGCCCGAACAGGGA- (TAMRA)-3’).  
HEK293T cells were seeded at the density of 5 x 104 per well in a 12 well format. 
After 24 hours, the media was replaced with 1mL fresh media and serial 
dilutions from 10-2 to 10-6 were made from a thawed concentrated lentivirus 
aliquot and added to the wells. 72 hours later, cells were washed with PBS and 
200µL of PBS was added to each well. Cells were snap frozen followed by DNA 
extraction as per 2.6.1  and DNA was eluted in 50µL of nuclease free water. The 
DNA concentration was estimated using Nanodrop (ND-1000 spectrophotometer, 
Labtech International, UK) and values were kept for later calculations. All the 
samples were diluted to a DNA concentration of 250ng/µL. A standard curve was 
generated using diluted expression plasmid corresponding to 1013 to 104 plasmid 
copies.  
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The amount of plasmid required for 1013 copies was determined as follows: 
1. Molecular weight of a single expression plasmid was calculated: 
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 (𝑏𝑝)  × 660 𝑑𝑎𝑙𝑡𝑜𝑛𝑠
6.023 × 1023
 = 𝑔 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 
2. Plasmid copy number in 1mL was calculated: 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 (𝑔/𝑚𝐿)
𝑔 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
 = 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 
3. Volume of plasmid stock for 1x1013 copies for top standard: 
1013
𝑝𝑙𝑎𝑠𝑚𝑖𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟
 × 1000 = 𝜇𝐿 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 𝑠𝑡𝑜𝑐𝑘 
The qRT-PCR reaction was run as per Table 7 with reactions set up as shown in 
Table 7.  
 
Reagent per reaction 
DNA samples  or 
standard curve 
1µL 
Taqman universal 
master mix 2x 
6.25µL 
Primer/probe mix 3.125µL 
H20 2.125µL 
Table 7: qRT-PCR reaction for determination of lentivirus titre. 
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Lentivirus titre was calculated as follows: 
1. Standard curve was obtained by plotting obtained cycle threshold (Ct) 
values vs logarithmic plasmid copy number per sample in Excel and the 
best fit formula was used calculate total number copies of viral DNA per 
each of the infected culture wells. 
2. Total amount of DNA in ng collected from each well was calculated by 
multiplying individual DNA concentration readings by elution volume of 
50µL. 
3. Percentage of total DNA used per reaction was calculated: 
250𝑛𝑔 𝐷𝑁𝐴 𝑢𝑠𝑒𝑑 𝑝𝑒𝑟 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛
𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 𝑛𝑔
 = % 𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑢𝑠𝑒𝑑 
4. Percentage of total DNA used was multiplied by cells seeded per well 
(5 x 104) to estimate the number of cells used for 250ng of DNA. 
5. Values obtained in step 1 and 4 were used to calculate number of viral 
copies per cell: 
𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑝𝑖𝑒𝑠 𝑜𝑓 𝑣𝑖𝑟𝑎𝑙 𝐷𝑁𝐴
𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
 = 𝑣𝑖𝑟𝑎𝑙 𝐷𝑁𝐴 𝑐𝑜𝑝𝑖𝑒𝑠 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙 
6. And finally PIU/mL was calculated: 
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑣𝑜𝑙𝑢𝑚𝑒 𝑎𝑑𝑑𝑒𝑑 
 × 1000 × 𝑣𝑖𝑟𝑎𝑙 𝐷𝑁𝐴 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙 = 𝑃𝐼𝑈/𝑚𝐿 
This calculation was performed for every infected HEK293T well and the 
average PIU/mL between all the wells was used to calculate volume of 
concentrated viral solution required in experiments to achieve desired 
multiplicity of infection (MOI) which is a ratio between virus and cells.  
94 
 
2.5.4 Lentiviral Transductions 
For lentiviral transductions of pluripotent hESC, cells were dispersed using 
Accutase (Thermo Fisher Scientific, UK) and 1 x 104 to 3 x 104 cells were seeded 
onto tissue culture treated 24 wells coated with vitronectin as per 2.2.1 . The 
following day, media was exchanged and supplemented with 4µg/mL of 
polybrene (hexadimethrine bromide). Polybrene is a cationic polymer that 
enhances lentiviral transduction efficiency by increasing receptor independent 
uptake of the virus via cell membranes (Davis et al., 2002). Lentivirus was added 
at the appropriate MOI and cultures were incubated for 24 hours, followed by 
two PBS washes and addition of fresh media to the wells. 
For lentiviral transductions of HSVEC and HUVEC or NCI60 cancer cell line cells, 
2 x 104 cells were seeded per well in a 48 well format. The following day, media 
was exchanged and supplemented with 8µg/mL of polybrene. Lentivirus was 
added at the appropriate MOI and cultures were incubated for 24 hours, 
followed by two PBS washes and addition of fresh media to the wells. 
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2.6 Molecular Biology 
2.6.1 Extraction of DNA from cells 
Extraction of total DNA from cell cultures was performed using QIAamp DNA mini 
and blood mini kit (Qiagen, UK) following manufacturer’s instructions. Cultures 
were washed in PBS and 200µl of PBS was added to each well. Cell scraper or 
vigorous pipetting was used to detach the cells and the resulting suspension was 
transferred to a microcentrifuge tube containing 20 µl of Qiagen Proteniase K. 
200µL of buffer AL, containing guanidine hydrochloride that disrupts DNA and 
RNA, was added and the sample was thoroughly mixed by pulse vortexing. The 
suspension was incubated at 56oC for 10 minutes for efficient lysis. Then, 200µL 
of ethanol was added, the samples was further mixed by pulse-vortexing and 
applied to the spin column. QIAamp spin column silica membrane selectively 
binds DNA and RNA, while protein and other contaminants are washed away in 
the two following washes, 500µl each. First wash buffer AW1 contains guanidine 
hydrochloride and ethanol, while the second was buffer contains only ethanol to 
wash away any residual salts. This was followed by DNA elution in 50µL room 
temperature sterile nuclease-free water. The DNA solution was stored at -20oC. 
2.6.2 Extraction of total RNA from cells 
Extraction of total RNA from cell cultures was performed using miRNeasy kit 
(Qiagen, UK) following manufacturer’s instructions.  Cell monolayer was washed 
with PBS and 700µL QIAzol Lysis Reagent was added, followed by vigorous 
pipetting to dislocate the cells. The solution was transferred to a 
microcentrifuge tube and mixed by pulse vortexing for 1 minute followed by 5 
minute incubation. QIAzol Lysis Reagent is a phenol / guanidine based solution 
that effectively lyses tissues and preserves RNA by inhibiting RNases. 140 µL of 
chloroform was added followed by mixing of the sample and further 2 minute 
incubation at room temperature. After 15 minute centrifugation at 12 000 x g at 
4oC, the sample separates in three phases. In low pH conditions, the upper 
aqueous phase contains RNA and is separated by a white, DNA containing 
interphase from lower red organic phenol-chloroform phase with proteins and 
lipids (Chomczynski and Sacchi, 2006; Rio et al., 2010). The upper phase was 
transferred to a new microcentrifuge tube and mixed with 1.5x volumes 100% 
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ethanol. This enhances the binding of larger RNA molecules (>18 nucleotides) to 
the silica membrane of the RNeasy mini spin column. The solution was loaded 
onto the column and centrifuged at 8000 x g for 30 seconds, followed by a 700µL 
wash with guanidine hydrochloride and ethanol containing Buffer RWT. DNAse I 
treatment was performed to remove any residual DNA. This was followed by 
another wash with RWT buffer and two 500 µL washes with ethanol based Buffer 
RPE. Second wash was followed by a prolonged centrifugation to remove any 
residual ethanol from the column membrane. The RNA was eluted in 30 - 50 µL 
of nuclease free water added directly to the membrane and passed through 
twice to increase the RNA concentration. The concentration of RNA was 
estimated by Nanodrop (ND-1000 spectrophotometer, Labtech International, 
UK). The RNA was stored at -80°C, if required. 
2.6.3 cDNA synthesis 
To synthesise cDNA from the extracted RNA, Taqman reverse transcription kit 
(Thermo Fisher Scientific, UK) was used as per manufacturer’s instructions in 
20µL reactions as described in Table 8 and Table 9. 
 
Reagent per reaction 
10x buffer 1x 
MgCl2  5.5mM 
dNTP mix 2mM 
Random hexamers 2.5µM 
RNAse inhibitor 0.4U/µL 
Multiscribe 1.25U/µL 
RNA 200 – 500ng 
Table 8: cDNA synthesis reaction. 
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Cycle Step Cycles Temperature Time 
Primer annealing 1 25°C 10 minutes 
Reverse transcription 1 48°C 30 minutes 
Inactivate multiscribe 1 95°C 5 minutes 
Hold 1 4°C ∞ 
Table 9: cDNA synthesis cycling conditions. 
 
2.6.4 qRT-PCR analysis 
Gene expression analysis was performed using Taqman gene expression assays 
(Thermo Fisher Scientific, UK) as shown in Table 10 in 10µL reactions in 384-well 
format with each reaction containing 1 x Taqman Master Mix, 1 x TaqMan gene 
expression probe, 10-20ng cDNA and nuclease free H2O as required. ABI Prism 
Applied Biosystems 7900HT or QuantStudio™ 7 Flex System real time PCR system 
was used with cycling conditions as shown in Table 11. 
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Gene name Probe ID  Gene name Probe ID 
Housekeeper genes  Pluripotency genes 
UBC Hs01871556_s1  NANOG Hs04399610_g1 
GAPDH Hs02758991_g1  POU5F1 (OCT4) Hs00999632 
Endothelial genes  SOX2 Hs01053049_s1 
PECAM-1 (CD31) Hs00169777_m1  Other genes 
CDH5 (VE-
Cadherin, CD144) 
Hs00901465_m1 
 
ETV2 Hs01012850_g1 
KDR Hs00911700_m1  T (Brachyury) Hs00610080_m1 
PDGFB Hs00966522_m1  APLN Hs00936329_m1 
ROBO4 Hs00219408_m1  APLNR Hs00270873_s1 
Arterial genes  NFATC1 Hs00542678_m1 
HEY2 Hs00232622_m1  SEMA3D Hs00380877_m1 
EFNB2 Hs00970627_m1  DACH1 Hs00362088_m1 
DLL4 Hs00184092_m1  TAL1 Hs01097987_m1 
Venous genes    
EPHB4 Hs00174752_m1    
NRP2 Hs00187290_m1    
Table 10: List of Taqman gene expression assays used. 
 
Cycle Step Cycles Temperature Time 
Initial denaturation 1 95°C 10 minutes 
Denaturation 
40 
95°C 10 seconds 
Annealing and 
Extension 
60°C 
60 seconds 
Table 11: qRT-PCR cycling conditions. 
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Data was analysed by using the comparative Ct (cycle threshold) method 
(Schmittgen and Livak, 2008). Ct is the PCR cycle at which the fluorescent signal 
reaches a threshold level set in the exponential phase of the PCR amplification. 
For each sample, an internal gene expression control is analysed in addition to 
genes of interest. The obtained internal control Ct value was subtracted from Ct 
value for gene of interest: 
𝐶𝑡 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 − 𝐶𝑡 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 =  𝛿𝐶𝑡 
To compare difference in gene expression between two samples, the obtained 
δCt values were subtracted:  
𝛿𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 1 − 𝛿𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 2 =  𝛿𝛿𝐶𝑡 
And the fold change (relative quantification, RQ) was calculated: 
𝑅𝑄 =  2−𝛿𝛿𝐶𝑡 
RQmin and RQmax values were used to plot error bars, showing the range of 
possible RQ values with a confidence interval set at 95%. SEM of δδCT values was 
calculated and preRQ max and min values were obtained: 
𝑝𝑟𝑒𝑅𝑄 = 2−(𝑅𝑄 ±𝑆𝐸𝑀 𝑜𝑓 δδ𝐶𝑇)  
Then RQmax and RQmin values were calculated as follows: 
𝑅𝑄𝑚𝑎𝑥 =  𝑝𝑟𝑒𝑅𝑄𝑚𝑎𝑥 − 𝑅𝑄 
𝑅𝑄𝑚𝑖𝑛 =  𝑅𝑄 −  𝑝𝑟𝑒𝑅𝑄𝑚𝑖𝑛 
 
  
100 
 
2.7 Immunocytochemistry (ICC) 
For Immunocytochemistry, cells in a 12 well format were washed with PBS and 
fixed with either cold 4% paraformaldehyde or 1:1 acetone and methanol mix 
cooled to -20oC. Cells were washed with PBS three times and permeabilised, if 
required, with 0.5% Tween (Tween 20 diluted in PBS) for 30 minutes. Cells were 
washed with 0.1% Tween and incubated with 20% Normal Goat Serum (NGS) for 1 
hour. This was followed by another wash with 0.1% Tween and cells were 
incubated overnight at 4oC with primary antibodies diluted in 2% NGS. After the 
incubation, cells were washed three times with 0.1% Tween, 5 minutes per 
wash. Diluted secondary antibodies were added as appropriate and cells were 
incubated in dark for 1 hour at room temperature. This was followed by 2 
washes with 0.1% Tween and two washes with PBS, 5 minutes each. Finally, 15µl 
of ProLong Gold Antifade Mountant with 4',6-diamidino-2-phenylindole (DAPI) 
(Thermo Fischer Scientific, UK) was added per well and coverslip was applied, 
avoiding formation of bubbles. Imaging was performed with Axiovert 200M 
microscope (Carl Zeiss Microscopy, Germany) using Axiovision software 
(AxioVs40). 
Antigen Species 
Raised in 
Conjugate Dilution Supplier 
CD31 Mouse - 1:40 Dako 
ETV2 Rabbit - 1:500 Abcam 
GFP Mouse - 1:500 Abcam 
Anti-Rabbit Goat Alexa Fluor® 546 1:500 ThermoFisher 
Anti-Mouse Goat Alexa Fluor® 488 1:500 ThermoFisher 
Table 12: Antibodies used for ICC. 
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2.8 Flow Cytometry 
For flow cytometry (FC) analysis, cultures were dissociated using TrypLE Select 
(Thermo Fisher Scientific, UK), resuspended in FC buffer consisting of PBS with 
1% knock out serum replacement (Thermo Fisher Scientific, UK) and 2nM EDTA 
(Thermo Fisher Scientific, UK). For each test, 1x105 cells were used in 100µl FC 
buffer with antibodies, as required, as shown in Table 13. Cells were incubated 
for 20 minutes – 1 hour, washed twice using PBS and pelleted using 300 x g 
centrifugation for 3 minutes and analysed using FACSCanto II flow cytometer or 
LSR II cytometer (both BD, UK) with BD FACSDiva Software v.6.1.3 (BD, UK). 
Forward and side scatter gating was used to exclude dead cells, forward scatter 
height and width gating was used to exclude cell doublets as illustrated in Figure 
10. Subsequent analysis was performed using FlowJo 10 software (Treestar, US). 
 
Figure 10: Example of gating strategy for FACS analysis. Forward and side 
scatter gating was used to exclude dead cells (left), forward scatter height and width 
gating was used to exclude cell doublets (right). 
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Antigen Species 
Raised in 
Conjugate Dilution Supplier 
SSEA3 Rat Alexa fluor® 647 1:100 BD Bioscience 
SSEA3 Mouse PE 1:50 BD Bioscience 
Tra-1-60 Mouse PE 1:50 BD Bioscience 
CD56 Mouse PE 1:50 BD Bioscience 
CD326 Mouse APC 1:100 BD Bioscience 
CD326 Mouse FITC 1:25 BD Bioscience 
CD309 Mouse PE 1:50 BD Bioscience 
CD34 Mouse APC 1:100 BD Bioscience 
CD31 Mouse APC 1:100 R&D Systems 
CD31 Mouse PE 1:50 BD Bioscience 
CD31 Mouse FITC 1:25 BD Bioscience 
CD144 Mouse APC 1:100 eBioscience 
CD144 Mouse PE 1:50 BD Bioscience 
CD144 Mouse FITC 1:25 BD Bioscience 
CD43 Mouse PE 1:50 BD Bioscience 
Table 13: Antibodies used for FC analysis. 
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2.9 Statistical analyses 
Statistical analysis was performed on non-normalised values using GraphPad 
Prism software suite 5 (GraphPad Software, US). Data values were presented as 
mean ± standard error of the mean (SEM) to demonstrate the accuracy of the 
estimated population mean (Altman and Bland, 2005). Data values were 
presented as averages, if only two data points were available.  
Student t-test was used for analysis of two treatment groups. For two or more 
treatment groups, analysis of variance (ANOVA) was performed. If required, two 
way ANOVA analysis was used to account for variability between independent 
experiments as described by Lew (2007). ANOVA p-value is displayed above the 
figures. If ANOVA p-value was below 0.05, indicating statistically significant 
differences between the means, statistical significance of the differences 
between the individual groups was determined by Tukey post-hoc test. 
Differences were considered significant at p<0.05. 
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Chapter 3: Development and characterisation of 
hESC-EC differentiation protocol. 
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3.1 Introduction 
To date, there have been a large number of publications describing hESC 
differentiation towards endothelial lineages and, more recently, there has been 
an increased focus in developing high efficiency methods that yield a high 
number of endothelial like cells. However, while significant advances have been 
made in increasing the yield of these differentiation protocols, often the 
reagents used limit their suitability for clinical purposes due to being poorly 
defined, as is the case with various serum derived products or not being xeno 
free, for example, Matrigel. Indeed, the recent methods reported by Sahara et 
al. (2014), Prasain et al. (2014) and Patsch et al. (2015) all use Matrigel in their 
differentiation protocols.  
These poorly defined reagents raise multiple concerns in relation to clinical use. 
Firstly, they carry a risk of contaminant or pathogen transmission and, whereas 
screening can be undertaken to minimise this risk, it is impossible to screen for 
novel or currently unknown pathogens. Secondly, as these reagents are not 
chemically defined, it cannot be excluded that they contribute to cell signalling 
during the differentiation and therefore batch to batch variability of these 
reagents can consequently alter the differentiation process. 
Other groups have reported differentiation protocols that have been developed 
keeping clinical relevance in mind. Kaupisch et al. (2012) reported optimisation 
of a serum-free derivation of endothelial cells under cGMP compatible conditions 
that yielded approximately 30% of CD144+ cells. The endothelial progenitor 
(CD133+ CD56+) differentiation was demonstrated in multiple hESC lines, 
however, the generation of CD144+ cells was only performed with RC-13 hESC. 
The efficacy of this protocol in other cell lines remains to be demonstrated.  
Wu et al. (2015) used a minimal set of growth factors to induce endothelial 
differentiation in a clinically relevant manner as neither Matrigel or serum was 
used. However, the reported differentiation efficacy before selection using anti-
absorptive agents was below 4% and thus a relatively low amount of endothelial 
like cells was generated which limits the clinical usefulness of this approach. 
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In contrast, Sriram et al. (2015) reports a promising, clinically relevant xeno and 
serum free five day endothelial differentiation protocol that yields over 90% of 
EPC expressing CD31 and CD34. However, CD144 expression was not reported 
after the five day differentiation, only after cell sorting and further culture. 
Even though the differentiation is performed both using hESC H9 and H1, no data 
is provided on repeats and reproducibility. In addition, the pluripotent hESC cells 
were cultured on Matrigel which contains various unspecified growth factors that 
may alter the cell behaviour (Hughes et al., 2010; Ojala et al., 2012). Overall, 
this protocol represents a significant advance towards clinically relevant 
hESC-EC differentiation. However, more refinement and data is needed to 
validate the findings and make this method truly clinically relevant. 
Initially, the endothelial differentiations performed in this chapter followed a 
protocol, where hESC are mechanically cut with a StemPro® EZ-tool and 
cultured in a low adherence plate to form EBs for mesodermal induction. The 
method, however, was not robust and displayed high variation between 
experiments and cell lines. This can be explained by the variability in the EB size 
and morphology. Cell to cell and extracellular matrix interactions play an 
important role in stem cell differentiation (Chen et al., 2007) and while 3D 
culture can aid mesodermal hESC fate during spontaneous differentiation 
(Bauwens et al., 2008; Hsiao et al., 2014), the differences in size and 
morphology can also introduce additional variation. EB size has been shown to 
influence the efficiency of cardiac (Mohr et al., 2010) and hematopoietic (Ng et 
al., 2005) differentiation. Size can also affect EB growth profiles (Mohr et al., 
2010), as well as oxygen and cytokine concentrations at the core of the EBs (Van 
Winkle et al., 2012). Therefore, it was hypothesised that controlled size EB 
generation could be used to minimise the variability and increase the robustness 
of endothelial lineage differentiation. 
Conventional methods for EB generation are liquid suspension culture, 
methylcellulose culture and hanging drop formation (Dang et al., 2002; 
Kurosawa, 2007). Only hanging drop formation allows for control of EB size, 
however, this technique is technically challenging and does not allow for media 
exchange and thus an alternative methods need to be considered. More recently, 
various other approaches have been established for controlled size EB 
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generation, for example, using agarose coated micro-wells (Pettinato et al., 
2015) or commercially available Aggrewell™ dishes (Stover and Schwartz, 2011). 
Alternatively, low attachment, round bottom 96 well plates can be used for 
controlled size EB formation (Ng et al., 2005), and this approach has been 
further refined to use v-shaped 96 wells coated with Pluronic (Ungrin et al., 
2008). Initially, hESC-EC differentiation was optimised in our lab using low 
attachment, round bottom 96 well plates. However, the cost of these plates was 
a serious limitation of this method. In contrast, Pluronic coating of tissue culture 
96 wells plates is a low cost alternative and presents a simple, high throughput 
way for generating controlled size EBs. Therefore, it was evaluated if hESC-EC 
differentiations can be undertaken in Pluronic coated instead of low adherence 
96 well tissue culture plates. 
Further optimisation of the endothelial differentiation protocol also requires 
evaluation of potential signalling pathways that enhance or interfere with 
endothelial specification, survival and proliferation. As described in section 
1.7.4, TGFB plays a role in angiogenesis and modulates VEGF signalling, and thus 
is a prime candidate for optimisation. TGFB signals via type I and type II 
receptor complexes with activin receptor-like kinase 1 (ALK1) and ALK5 type I 
receptors expressed in EC as illustrated in Figure 11 (Cunha and Pietras, 2011; 
Oh et al., 2000). ALK1 and ALK5 receptor complexes signal via SMAD1/5/8 or 
SMAD2/3 TF accordingly, often having opposing effects on cell apoptosis, 
proliferation and migration (Goumans et al., 2002). In addition, endoglin, a type 
III receptor expressed on EC (Jonker and Arthur, 2002), promotes TGFB signalling 
via ALK1 (Lebrin et al., 2004) and TGFB also has a range of SMAD independent 
effects via direct modulation of various signalling mediators forming complex 
signalling networks (Moustakas and Heldin, 2005).  
Observations during endothelial hESC differentiations have shown that inhibition 
of TGFB signalling can increase endothelial yield (James et al., 2010; Sahara et 
al., 2014), as well as preserve endothelial phenotype and proliferation (James et 
al., 2010). This is in line with previous reports demonstrating that TGFB 
signalling inhibits endothelial cell proliferation (Castañares et al., 2007) and 
destabilises Fli1 (Asano and Trojanowska, 2009), which is one of the ETS factors 
which contributes to the maintenance of EC phenotype (Ginsberg et al., 2012; 
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Israely et al., 2013).  This led to hypothesis that TGFB inhibition could further 
enhance hESC-EC differentiation yield via increasing differentiation efficacy 
during the differentiation, maintaining endothelial cell phenotype and aiding EC 
expansion during prolonged culture. 
This was followed by preliminary analysis of marker expression during the 
optimised hESC-EC protocol and more detailed gene expression analysis to 
confirm the expected progression of hESC-EC differentiation – loss of 
pluripotency markers, induction of mesoderm, followed by endothelial 
progenitor and endothelial gene expression. This supporting data is essential for 
understanding and designing future experiments using hESC-EC differentiation 
protocol.
 
Figure 11: Overview of TGFB signalling. TGFB signalling is mediated via TGFB 
type II receptor complexes with type I receptors ALK1 or ALK5 and downstream 
SMAD 1/5/8 or 2/3 TF accordingly. Receptor activated SMADs form a complex with 
SMAD4 and activate a range of genes. Type II receptor Endoglin which is expressed 
on endothelial cells enhances signalling via ALK1. Adapted from Cunha and Pietras 
(2011). 
109 
 
3.2 Aims 
The aims of this chapter were: 
 To develop a hESC-EC differentiation protocol:  
o To test whether controlled size EB generation in 96 well plates is a 
suitable low cost alternative to low adherence 96 well plates for 
hESC-EC differentiation. 
o To evaluate if inhibition of TGFB signalling is beneficial for 
endothelial specification and expansion during hESC-EC 
differentiation. 
 To characterise hESC differentiation during differentiation using hESC-ECs 
differentiation protocol. 
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3.3 Results 
3.3.1 hESC differentiation towards endothelial lineages via 6-well 
embryoid body culture intermediate. 
Initially, multiple hESC lines (H1, H9, and clinical RC-9 and RC-13) were 
differentiated in a monolayer differentiation system towards endothelial 
lineages (Kane et al., 2010; Kaupisch et al., 2012). Differentiations with RC-13 
yielded 1.1% cells expressing CD144 and CD31 at the end of the differentiation, 
while no expression of CD144 and CD31 was detected with H1, H9 and RC-9 
differentiations (all n=1, data not shown). As the monolayer differentiation 
system did not differentiate hESCs towards endothelial lineages, further repeats 
were not performed and work was undertaken in order to develop an alternative 
differentiation method via 6-well embryoid body culture intermediate. 
Two hESC lines – H9 and RC-11 were differentiated towards endothelial lineages 
following differentiation protocol using 6-well embryoid body culture for 
mesoderm induction. As presented in Figure 12, initial differentiations with H9 
yielded 32.1 ±2.3 % cells expressing both endothelial markers CD31 and CD144, 
and over 33.8 ±1.4 % cells expressing endothelial progenitor marker CD309. 
However, negligible % of cells expressed CD144 and CD31 (0.6 ±0.6 %), or CD309 
(1.3 ±0.8 %) after differentiations using hESC line RC-11. Additionally, repeated 
H9 differentiation attempts also failed to generate cells expressing CD31 and 
CD144 (personal communication, Dr Peter Burton, University of Glasgow). 
Therefore, a novel protocol was developed using controlled size EBs generated in 
low adherence 96 well plates for mesodermal induction. 
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Figure 12: Endothelial marker expression at the end of differentiation towards 
endothelial lineages via 6-well embryoid body culture intermediate. A. H9 and 
RC-9 were differentiated towards endothelial lineages (n=3, independent 
experiments) following differentiation protocol using embryoid body culture for 
mesoderm induction and marker expression was assessed using FC at the end of 
the differentiation. Data shown as mean ± SEM. B. Generation of variable size EBs. 
C. Generation of controlled size EBs. Scale bars 100µm. Adapted from: 
ThermoFisher (2007).   
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3.3.2 Optimisation of a novel hESC-EC differentiation protocol: 
Pluronic F-127 well treatments. 
Seeding a set number of cells in low adherence 96 well plates allows for 
controlled size EB generation for hESC-EC differentiation. However, the high 
cost of such plates is a serious limitation for routine use and, thus, Pluronic 
F-127 (Pluronic) treatments were evaluated as a low cost alternative for 
controlled size EB generation (Ungrin et al., 2008). It was proposed that hESC-EC 
differentiations using Pluronic coated 96 well plates would display comparable 
efficacy to differentiations performed in low adherence plates. Two hESC cell 
lines – H9 and RC-9 were differentiated towards endothelial lineages using 
hESC-EC differentiation protocol. The pluripotent hESC cultures were 
enzymatically dissociated and 10 000 cells were seeded per well in either low 
adherence 96 well plates with round wells (control) or 96 well plates with round 
or v-shaped wells coated with Pluronic F-127 for the generation of EBs. EC and 
pluripotency marker expression was evaluated on day 7 of the differentiation by 
FC. 
The data presented in Figure 13 shows that differentiations with RC-9 
successfully generated cells expressing EC markers, with 27.9 ±3.6 % cells 
expressing CD144 and over 43.5 ±5.5 % cells expressing CD31 in control. Pluronic 
well treatments did not significantly change CD144 marker expression with 28.4 
±6.3 % and 28.2 ±3.0 % positive cells in Pluronic coated round and v-shaped wells 
respectively. Similarly, CD31 expression remained comparable with 44.6 ±5.3 % 
and 37.9 ±2.6 % CD31+ cells in differentiations using Pluronic treated round or 
v-shaped wells respectively. There were no statistically significant changes in 
pluripotency marker TRA-1-60, or SSEA3 expression.  
Differentiations with H9, as shown in Figure 14, also successfully generated cells 
expressing EC markers, with 21.3 ±3.7 % cells expressing CD144 and over 
44.6 ±7.9 % cells expressing CD31. Pluronic well treatments did not significantly 
change EC marker expression with 21.3 ±3.7 %, 25.7 ±7.7 %, 28.1 ±5.4 % cells 
expressing CD144 when comparing low adherence round wells with Pluronic 
coated round and v-shaped wells respectively. There were no statistically 
significant changes in EC marker CD31 and pluripotency marker TRA-1-60, SSEA3 
expression. 
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To sum up, hESC enzymatic dissociation and generation of controlled size EBs of 
10 000 cells per EB in Pluronic coated 96 well plates for hESC-EC differentiation 
was comparable to differentiations set up in low adherence 96 well plates. Given 
the significantly lower cost of Pluronic coated 96 well plates, the future 
differentiations were performed using Pluronic coated u-shaped 96 well plates. 
 
 
Figure 13: Effect of Pluronic well treatments on EC and pluripotency marker 
expression during hESC-EC differentiation in RC-9. Pluronic coated round and 
v-shaped wells were compared to low adherence round wells (control) during RC-9 
hESC-EC differentiation (n=3, independent experiments). Data shown as mean ± 
SEM, statistical significance determined using one-way ANOVA. All non-significant, 
ANOVA p>0.05. 
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Figure 14: Effect of Pluronic well treatments on EC and pluripotency marker 
expression during hESC-EC differentiation in H9. Pluronic coated round and 
v-shaped wells were compared to low adherence round wells (control) during H9 
hESC-EC differentiation (n=3, independent experiments). Data shown as mean ± 
SEM, statistical significance determined using one-way ANOVA. All non-significant, 
ANOVA p>0.05. 
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3.3.3 Optimisation of a novel hESC-EC differentiation protocol: 
TGFB signalling inhibition. 
To evaluate, whether TGFB signalling inhibition would increase the percentage 
of cells expressing EC markers or total cell numbers at the end of hESC-EC 
differentiation, 10μM SB431542 was added after mesodermal and vascular 
specification as described by James et al. (2010), from day 5 of hESC-EC 
differentiation. Expression of EC markers CD31 and CD144 as well as 
pluripotency markers TRA-1-60 and SSEA3 was evaluated on day 7, and, in 
addition, the differentiation culture was continued for additional analysis on day 
10 and day 14 of the differentiation.  
The marker expression remained comparable (data not shown, n=1 each cell 
line) between the SB431542 and control dimethyl sulfoxide (DMSO) treated H9 
cultures on day 7, while a reduction in CD144 (34.5% vs 21.2%) and CD31 (52.0% 
vs 41.8%) expression was observed in RC-11 SB431542 treated cultures. The EC 
marker expression remained lower in SB431542 treated cultures on day 14 both 
in H9 and RC-11. Pluripotency marker SSEA3 expression remained comparable in 
treated and control cultures both in H9 and RC-11. There was a trend of higher 
total cell counts in SB431542 treated differentiations on day 7 and day 10 of the 
differentiation, with larger differences observed on day 14 (3.7 x 106  vs 1.9 x 
106 cells in H9 and 3.0 x 106  vs 1.9 x 106 cells in RC-11). 
The data described above suggests that there was no added benefit of TGFB 
inhibition on EC differentiation and expansion during hESC-EC differentiation. 
Therefore, this experiment was not repeated and characterisation of hESC-EC 
differentiation was performed.   
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3.3.4 hESC-EC differentiation protocol. 
The final differentiation protocol, as illustrated in Figure 15, takes eight days, 
during which EBs are formed from hESC on day 0 and cultured in mesodermal 
induction media as described by Olivier et al. (2016). The EBs are then plated 
out on in six well plates on day 3 for endothelial induction, with an appearance 
of spindle shaped cells between day 3 – 5 and elongated cell islands on day 7 
(Figure 16). Analysis of H9 hESC-EC differentiation demonstrated that 
pluripotency marker expression is gradually lost during the differentiation 
(Figure 17), however, residual SSEA3+ expression could still be observed in 
4.4 ±1.5 % of the cells on day 7. Mesodermal population of CD326low CD56+ cells 
(Boulberdaa et al., 2016; Evseenko et al., 2010) was detected on day 3 
(43.0 ±10.7 %), followed by the appearance of CD309+ CD34+ cells (27.4 ±5.0 %) 
and CD31+ CD144+ cells (22.6 ±3.0 %) as shown in Figure 18. Differentiations 
yielded 22.3 ±1.9 % cells co-expressing CD31 and CD144 on day 7. 
 
 
Figure 15: Schematic representing hESC-EC differentiation. Embryoid bodies 
(EBS) are made from monolayer culture of hESC for mesoderm induction and on 
day 3 of the differentiation, the EB are plated in 6-well plates for further monolayer 
culture in vascular induction phase. Differentiation finishes on day 7. 
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Figure 16: Morphology changes during hESC-EC differentiation. Monolayer 
hESC cultures are used to make EB, which remain in EB culture till day 3. Then 
these are plated out in 6-well plates, where they attach and cells start migrating and 
proliferating on the well surface, forming spindle shaped cells as seen on day 5 and 
elongated cells on day 7, as shown in the inlay. Scale bars 100µm. 
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Figure 17: Analysis of pluripotency and mesodermal marker expression 
during hESC-EC differentiation. Pluripotency marker SSEA3 expression and 
mesodermal population (Cd326low CD56+) was measured using FC on day 0, 5, 3 
and 7 of H9 hESC-EC differentiation (n=3, independent experiments, representative 
shown). Isotype control – blue; Markers of interest – red. Percentages of expression 
displayed: marker staining %. 
119 
 
 
Figure 18: Appearance of endothelial progenitor and endothelial marker 
expressing populations during hESC-EC differentiation. Endothelial progenitor 
marker (CD34 and CD309) and EC marker (CD31 and CD144) expression was 
measured using FC on day 0, 5, 3 and 7 of H9 hESC-EC differentiation (n=3, 
independent experiments, representative shown). Isotype control – blue; Markers of 
interest – red. Percentages of expression displayed: marker staining %. 
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3.3.5 Gene expression changes during hESC-EC differentiation. 
For gene expression analysis during hESC-EC differentiation, H1 hESC and RC-11 
hESC were differentiated as described in Methods section 2.3, and RNA was 
collected on day 0, and Days 2 - 7 of the differentiation. All differentiations 
yielded >20% CD31+ CD144+ cells on day 7 of the differentiation. Statistical 
significance was evaluated using δCT values. 
In H1 cells, a two fold increase in NANOG gene expression was unexpectedly 
observed on day 3 (p<0.05 vs day 0). This was followed by a trend of 
downregulation, yet, on day 7 the expression of NANOG remained comparable to 
expression levels observed on day 0 with a Ct value of 23.1 ±0.2 (p>0.05). In 
contrast, SOX2 was rapidly downregulated 50-fold by day 2 (p<0.001 vs day 0) 
and was further downregulated during the differentiation reaching a Ct value of 
34.2 ±0.3 on Day 7 (p<0.001 vs day 0).  
Brachyury was significantly upregulated more than 300-fold on day 2 (p<0.001 vs 
day 0), followed by downregulation on day 3 (p<0.001 vs day 2) and day 4 
(p<0.01 vs day 3) matching the expected pattern of mesodermal induction.  
KDR expression was upregulated 3-fold on day 2 (p<0.01 vs day 0) and further 
upregulated on day 3 (p<0.001 vs day 2) to 15-fold increase, compared to day 0 
(p<0.001) reaching Ct of 26.1 ±0.2. CDH5 was slightly upregulated as early as day 
2 (p<0.001 vs day 0) and highly upregulated from day 4 onwards (p<0.001 vs day 
3) reaching Ct of 25.8 ±0.3 on Day 7 of hESC-EC differentiation, in line with the 
expected endothelial specification.  
In RC-11, NANOG expression was downregulated by day 6 (p<0.05 vs day 0) and 
reached 30-fold decrease on day 7 (p<0.001 vs day 0) with Ct of 29.6 ±0.6, which 
is a smaller decrease than expected. SOX2 gene expression was rapidly 
downregulated 12-fold on day 2 (p<0.001 vs day 0), with expression levels 
decreasing further during the differentiation and reaching Ct of 35.1 ±0.3 on Day 
7. Brachyury expression was highly upregulated on day 2 (p<0.001 vs day 0), and 
this was followed by downregulation on day 4 (p<0.05 vs day 3), following a 
similar trend as seen in hESC-EC differentiations with H1. KDR was upregulated 
8-fold on day 2 (p<0.001 vs day 0) and further upregulated by day 5 (p<0.001 vs 
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day 3), reaching Ct of Ct 21.1 ±0.2. CDH5 was slightly upregulated on day 3 
(p<0.001 vs day 0) and highly upregulated during endothelial specification phase 
as expected from day 4 onwards (p<0.001 vs day 3) reaching Ct value of 
25.6 ±1.0 on Day 7 of hESC-EC differentiation. 
In summary, in both hESC lines a higher than expected pluripotency gene NANOG 
expression was observed, while SOX2 expression was rapidly downregulated as 
expected. Brachyury gene expression peaked on Day 2, indicating mesodermal 
induction, followed by upregulation of KDR and CDH5 expression indicating EC 
specification during day 3 -7 of hESC-EC differentiation as expected.  
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Figure 19: Gene expression changes during hESC-EC differentiation in H1. 
RNA was collected on day 0, and Days 2 - 7 of hESC-EC differentiation (n=3, 
independent experiments). Expression of pluripotency genes NANOG and SOX2, 
mesoderm associated gene Brachyury, multipotent progenitor gene KDR, and 
endothelial gene CDH5 was quantified using qRT-PCR. Statistical significance was 
evaluated using repeated measures ANOVA with Tukey’s post hoc comparisons, * 
p<0.05, ** p<0.01, *** p<0.001 when compared to d0 hESC control, unless indicated 
otherwise. Data shown is RQ ± RQ max and min. Ct values displayed above bars. 
All differentiations yielded >20% cells expressing CD144 and CD31 on day 7, 
representative FC plot shown. 
ANOVA p<0.001 ANOVA p<0.001 
ANOVA p<0.001 
ANOVA p<0.001 
ANOVA p<0.001 
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Figure 20: Gene expression changes during hESC-EC differentiation in RC-11. 
RNA was collected on day 0, and Days 2 - 7 of hESC-EC differentiation (n=3, 
independent experiments). Expression of pluripotency genes NANOG and SOX2, 
mesoderm associated gene Brachyury, multipotent progenitor gene KDR, and 
endothelial gene CDH5 was quantified using qRT-PCR. Statistical significance was 
evaluated using repeated measures ANOVA with Tukey’s post hoc comparisons, * 
p<0.05, ** p<0.01, *** p<0.001 when compared to d0 hESC control, unless indicated 
otherwise. Data shown is RQ ± RQ max and min. Ct values displayed above bars. 
All differentiations yielded >20% cells expressing CD144 and CD31 on day 7, 
representative FC plot shown. 
ANOVA p<0.001 ANOVA p<0.001 
ANOVA p<0.001 ANOVA p<0.001 
ANOVA p<0.001 
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3.4 Discussion 
In summary, the data presented in this chapter demonstrated a novel protocol 
for differentiation of hESC towards endothelial lineages, using controlled size EB 
culture for mesodermal induction and monolayer culture for endothelial 
specification. This method was more robust for endothelial lineage 
differentiation than the previous 6-well based protocol and could be reproduced 
in H1, H9, RC-9 and RC-11. Further steps were taken to optimise hESC-EC 
differentiation, showing that Pluronic coated wells could be used as a low cost 
alternative for hESC-EC differentiation and suggesting that TGFB signalling 
inhibition did not confer additional benefit for this differentiation method. 
Finally, expression of pluripotency, mesoderm, endothelial progenitor and 
endothelial genes during hESC-EC differentiation was profiled. 
The initial monolayer endothelial differentiation protocol did not generate cells 
expressing endothelial markers CD144 and CD31, in contrast to the observations 
previously reported by Kaupisch et al. (2012). Given that multiple cell lines were 
tested, it appears that the monolayer differentiation protocol does not 
sufficiently activate cell signalling pathways directing endothelial 
differentiation. In addition, cell to cell interactions contribute to the 
differentiation processes (Bratt-Leal et al., 2009; Itskovitz-Eldor et al., 2000) 
and might be lacking in a monolayer culture, therefore, an EB based endothelial 
differentiation protocol was developed and initially appeared promising with 
efficient endothelial differentiations with H9.  
However, further testing revealed that it lacked robustness and it was 
speculated that this is due to the heterogeneous nature of the EBs generated 
using EZ-Passage Tool. Therefore, it was proposed that generation of controlled 
size EB using one of the previously described 96-well EB generation methods (Ng 
et al., 2005; Ungrin et al., 2008) could increase the reliability of the protocol. 
Here data are presented showing that generation of controlled size EBs for 
mesoderm induction during hESC-EC differentiation increases the reliability of 
the protocol with efficient differentiation in two cell lines - H9 generating >25% 
CD31+ CD144+ cells, and RC-11 generating >20% CD31+ CD144+ cells.  
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In addition, the use of Pluronic well coating was evaluated to create a low cost 
alternative to commercially available low adherence 96-well plates (Ungrin et 
al., 2008). No significant differences could be seen in CD31, CD144, TRA-1-60 
and SSEA3 marker expression on day 7 of the differentiation. However, it cannot 
be excluded that Pluronic could alter signalling either directly or indirectly. 
Indeed, Pluronic has been reported to induce expression of VEGF and TGFB in 
wound healing assays (Kant et al., 2013) and possibly alter gene expression 
profiles during early hESC-EC differentiation (personal communication, 
Dr Elizabeth Scott, University of Glasgow). However, in vitro evaluation reports 
are lacking, and in depth marker comparison was not performed in the 
experiments described in this chapter, therefore conclusions cannot be drawn. 
One of the reported disadvantages of using round bottom wells is the formation 
less compact cell pellet and multiple separate aggregates (Ungrin et al., 2008), 
however, this was not observed during hESC-EC differentiation. ROCK inhibitor 
Y-27632 is used on day 0 during hESC-EC differentiation to reduce cell apoptosis 
due to dissociation to single cells. However, it is also reported to aid formation 
of hESC agglomerates (Horiguchi et al., 2014; Watanabe et al., 2007) and this 
could explain the observed robust EB formation in round bottom wells.  
Taken together, the observations suggest that both low adherence round shape 
and Pluronic coated round or v-shaped wells can be used for the differentiations, 
with no significant differences observed in pluripotency and endothelial marker 
expression at the end of hESC-EC differentiations. Pluronic coated round wells 
were used for the following experiments. 
To investigate whether TGFB signalling inhibition would benefit EC 
differentiations and increase EC yield during hESC-EC differentiation, SB431542 
was applied to differentiation cultures from day 5 onwards. The preliminary 
observations presented here show comparable EC marker expression between 
the SB431542 treated and control H9 differentiations, and reduced CD31 and 
CD144 expression in RC-11. As this suggested that TGFB inhibition did not 
enhance hESC-EC differentiation, additional repeats were not performed.  
The lack of beneficial effect of TGFB inhibition on EC differentiation can be 
explained by multiple differences between previous reports and the 
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experimental approach reported in this chapter. TGFB signalling has been 
reported to have a detrimental effect on KDR signalling and ETS factors (Asano 
and Trojanowska, 2009; Ginsberg et al., 2012). Here, however, TGFB inhibitor 
was applied from day 5 during hESC-EC differentiation, while KDR expression is 
significantly upregulated as early as day 2. Thus, earlier inhibition of TGFB 
signalling might be required to limit the negative effects of TGFB earlier during 
hESC-EC differentiation.  
Another possible explanation for the observed discrepancies is the differences in 
EC differentiation efficacies. Both reports showing the beneficial effect of TGFB 
inhibition for vascular specification, used low efficiency differentiations with 
James et al. (2010) reporting 1.8% CD31+ CD144+ yield and Sahara et al. (2014) 
reporting up to 8.7% efficacy. HESC-EC differentiations reported in this chapter 
were more efficient and generated over 30% CD144+ cells. The higher efficacy of 
hESC-EC differentiation protocol might limit the additional benefit of TGFB 
inhibition as any detrimental effects of TGFB might be overcome by other 
cytokines and growth factors present in hESC-EC differentiation mix. 
In addition, the expression of TGFB was not evaluated during hESC-EC 
differentiation. It cannot be excluded that the levels of paracrine TGFB 
secretion during hESC-EC differentiation method were too low to have a 
significant detrimental effects by day 7 of the differentiation.  Measuring the 
concentrations of TGFB in the media during hESC-EC differentiations would be 
necessary to clarify this. Furthermore, inhibition of TGFB signalling by SB431542 
should be evaluated to confirm the efficacy of the used compound. 
A trend of increased cell numbers in SB431542 treated differentiations was seen 
with the largest differences observed after prolonged culture on day 14. Indeed, 
TGFB signalling is known to suppress growth and proliferation of many cell types, 
including endothelial and hematopoietic cells, while it can also stimulate some 
mesenchymal cell types (Huang and Huang, 2005). This is also consistent with 
observations by James et al. (2010) who reported that TGFB inhibition stabilises 
endothelial phenotype and increases endothelial proliferation. 
Here, however, a reduction in CD31 and CD144 marker expression in SB431542 
treated differentiations was observed on day 14. Given the large increase in cell 
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numbers, it appears that SB431542 non-specifically increased proliferation in 
multiple cell types which remained in culture after day 7. Similarly, some loss of 
endothelial phenotype and increase in CD31- cell numbers was observed in the 
original paper after culturing CDH5 sorted cells in the presence of SB431542 
(James et al., 2010). Therefore, it can be suggested that TGFB inhibition can be 
used to expand carefully selected cultures, while there’s little benefit in mixed 
differentiation systems. 
Taken together, it can be speculated that TGFB inhibition is beneficial only with 
the first appearance of KDR+ cells but not during later endothelial specification. 
It could also be beneficial to prevent the anti-proliferative and pro-apoptotic 
effects of TGFB signalling after sorting the cells of interest, however, there 
appears to be no added benefit in using TGFB inhibitor in differentiations with 
mixed cell populations. Therefore, TGFB inhibition was not used in the following 
hESC-EC differentiation experiments. However, as additional repeats were not 
performed, no conclusions can be drawn from these observation. 
The final protocol uses controlled size EB culture in media supplemented with 
BMP4, WNT3A, activin A and VEGF to induce mesoderm lineages as described by 
Olivier et al. (2016). Of these, BMP4, WNT3A and activin A are the core 
signalling molecule required for mesodermal induction (Nostro et al., 2008) and 
later for inducing gene expression patterns required for endothelial 
specification, for example, via inducing Etv2 (Lee et al., 2008) and KDR 
expression (Ishitobi et al., 2011). VEGF not required for mesodermal induction, 
however, it plays a supporting role by contributing to activation of Etv2 
(Rasmussen et al., 2012) and increasing angioblast and early endothelial cell 
proliferation (Gentile et al., 2013).  
ROCK inhibitor is used on day 0 to aid hESC survival after dissociation to single 
cells (Watanabe et al., 2007) and the media is not changed until day 3, thus 
residual effects Y-27632 may persist during mesoderm induction. Interestingly, 
Yung et al. (2011) has observed a detrimental effect of Y-27632 on 
differentiation of single or dual positive cells for CD34, CD31 or CD309 in a hESC 
hematopoietic differentiation system, while in contrast Joo et al. (2012) has 
reported increased KDR+ cell expansion in Y-27632 treated mESC endothelial 
differentiation cultures. Therefore, a more detailed evaluation of the use of 
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ROCKi in this hESC-EC differentiation system should be undertaken to evaluate 
any possible detrimental or beneficial effects on differentiation. 
After mesoderm induction, EBs are plated out and grown in endothelial growth 
medium containing multiple growth factors and cytokines, including bFGF, IGF, 
EGF and VEGF. Of these, VEGF is the key growth factor for endothelial 
specification and expansion (Kawasaki et al., 2008; Yamashita, 2004) and was 
optimised for use with this protocol (personal communication, Dr Peter Burton, 
University of Glasgow). The concentrations of the other growth factors were not 
optimised and were used as supplied with the endothelial media kit (Lonza EBM-
2 + EGM-2 as described in 1.3), using the proprietary concentrations. It can be 
suggested, that further optimisation could be undertaken to pinpoint the best 
growth factor concentrations for vascular specification and to minimise any 
differentiation and growth signals for other lineage precursor cells present in the 
heterogeneous differentiation culture.  
Once plated, cells migrate and proliferate on the gelatin coated surfaces, 
forming a monolayer where spindle shaped cells can be observed, consistent 
with endothelial morphology. However, gelatin can support attachment and 
growth of a range of cell lineages and therefore other surface treatments might 
be beneficial for maximising endothelial cell yield. Indeed, treatments reducing 
well surface adherence can be used to select endothelial progenitor like cells, 
obtaining nearly pure endothelial cultures, as reported by Wu et al. (2015).  
However, given that EBs remain in suspension during mesodermal differentiation 
in Pluronic treated wells, it is not clear whether low adherence wells could be 
used for plating out the EBs during hESC-EC differentiation. It can be speculated 
that the mesodermal population observed during preliminary surface marker 
expression analysis on day 3 needs further maturation towards endothelial 
lineages, if low adherence treatments are to be used with the hESC-EC protocol. 
Further research is needed to evaluate if alternative well treatments could be 
used with hESC-EC differentiation method to select and support cell populations 
of interest. 
Gene expression and marker expression was profiled during the optimised hESC-
EC differentiation. As expected, most pluripotency markers were progressively 
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downregulated during the differentiation both on gene and marker expression 
level. Interestingly however, NANOG expression was upregulated during hESC-EC 
differentiations with H1. NANOG is part of the core pluripotency network and is 
downregulated during hESC differentiation (Bhattacharya et al., 2005), however, 
expression in adult tissues, for example heart and muscle, has also been 
reported (Hart et al., 2004). While expression of NANOG in mature endothelial 
cells is not reported, it has been shown to be induced during EC 
dedifferentiation during angiogenesis and possibly represents more immature 
cells with higher proliferative potential (Kohler et al., 2013, 2011). 
It has also been proposed that NANOG supresses differentiation to endoderm but 
not mesoderm lineages (Wang et al., 2012). Furthermore, AKT/NANOG axis has 
been implied in mesodermal differentiation (Bertero et al., 2015) and 
WNT/NANOG axis has been shown to upregulate KDR expression in EC (Kohler et 
al., 2011). As both AKT and WNT3A is used from day 0 – day 3 of hESC-EC 
differentiation, it is tempting to speculate that during the initial differentiation 
NANOG expression is sustained by AKT and WNT3A signalling and contributes to 
hESC differentiation to endothelial lineages. This is in line with the observed 
trend of reduced NANOG expression during days 4 – 7 when KDR expression stops 
increasing and remains steady.  
While less pronounced, NANOG expression also remained high in RC-11, and a 
trend of reduced NANOG expression was observed on day 4 and became 
significant on day 6. KDR expression remained steady between Days 4 – 7 and 
this therefore mimics the pattern seen in H1 and suggests that NANOG marks 
immature cell population and possibly takes part in inducing the expression of 
KDR. It can also be speculated that further downregulation would be observed in 
both in RC-11 and H1 as the cells acquire more mature phenotype after day 7. 
However, further research on gene expression in prolonged culture is required to 
confirm this. 
Given that strong downregulation could be observed in gene expression of SOX2 
both in H1 and RC-11 the expression of NANOG appears to be due to immature 
phenotype of the cells, not maintained pluripotency. The link between the 
expression of NANOG and KDR needs further validation, possibly by using RNA 
interference or other knockdown models. Additionally, in order to ascertain the 
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suitability of hESC-EC differentiation products for use in clinical practice, 
residual pluripotency has to be evaluated, using in vitro and in vivo pluripotency 
assays, for example teratoma formation. 
Expression of Brachyury showing mesodermal specification peaked at day 2 both 
in RC-11 and H9, followed by a rapid downregulation and upregulation of KDR, 
indicating appearance of multipotent cardiovascular progenitor cells. Surface 
marker expression analysis in H9, showed appearance of Cd326low CD56+ 
mesodermal population (Evseenko et al., 2010) on day 3 which is in line with 
upregulation of Brachyury observed a day earlier. CDH5 was strongly upregulated 
after the appearance of KDR+ cells on day 3 both in H1 and RC-11.  This follows 
the expected gene expression patterns for differentiations towards endothelial 
lineages. 
While the surface marker and gene expression profiles confirm the commitment 
towards endothelial phenotypes, it would also be also necessary to confirm the 
endothelial lineage of the cells using a range of function tests, for example, 
using in vitro tubule formation assays, AcLDL uptake assays and NO production. 
While preliminary functional testing was done (personal communication, Dr 
Peter Burton and Dr Elizabeth Scott, University of Glasgow), a full range of tests 
is required as these would indicate the clinical potential of the differentiated 
cells and, thus, are crucial part of evaluation of hESC-EC differentiation. 
Further testing, both on gene level and on surface marker expression level, is 
required to identify and characterise the cell population that does not express 
EC or EPC markers at the day 7 of the differentiation. While it can be speculated 
that this cell population represents a mixture of other differentiated and 
progenitor cell types of mesodermal lineage, this was not evaluated. Staining for 
other mature cell markers, for example alpha smooth muscle actin for 
identifying smooth muscle cell phenotypes, would give additional insight into 
this. Additionally, western blot protein expression analysis should be performed 
to confirm the expression of proteins of interest, and as a control for the 
antibodies used as expected protein molecular weight could be confirmed. 
Finally, here multiple hESC cell lines (H1, H9, RC-9 and RC-11) were used for the 
experiments. While this confirms that the developed hESC-EC differentiation 
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generates cells expressing EC markers CD31 and CD144 robustly in a range of cell 
lines, it also complicates the evaluation of the experimental results, due to the 
heterogeneity of hESC cell lines (Abeyta et al., 2004; Cahan and Daley, 2013; 
Osafune et al., 2008). Here, it was attempted to use one of the gold standard 
hESC lines (H1 and H9) for initial experiments, followed by validation of the 
findings in at least one of the Roslin Cells (RC-9, RC-11 or RC-13) hESC lines. For 
consistency, it would have been beneficial to use the same set of cell lines for 
all experiments, however, here it was not always possible due to varying hESC 
cell line availability over the course of the experimental work for this thesis. 
In summary, optimisation of a novel, serum free hESC-EC differentiation protocol 
was undertaken and it was demonstrated that the use controlled size EB 
increases the reliability of the protocol and that TGFB inhibition does not further 
increase EC % at the end of the differentiation. The final hESC-EC differentiation 
protocol was then validated in RC-11 and H1 and gene expression analysis was 
undertaken, showing stepwise activation of mesodermal, endothelial progenitor 
and endothelial genes, and reduction of pluripotency marker expression. This 
protocol represents an advance over current methods as it achieves high EC yield 
using only defined reagents suitable for clinical applications. 
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Chapter 4: Generation of reporter cell lines for 
monitoring of hESC-EC differentiation. 
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4.1 Introduction 
The previous chapter described the work undertaken to develop and optimise a 
novel, serum free, two step differentiation protocol that generated up to 30% 
CD31+ CD144+ cells. While this represents a significant advance when compared 
to the differentiation methods published previously (Descamps and Emanueli, 
2012), there is still scope for further optimisation with focus on the use of small 
molecule drugs to increase the differentiation efficiency and generate large 
numbers of CD31+ CD144+ cells. In particular, high throughput live cell 
monitoring could provide the needed insight in the effects of various compounds 
on cell differentiation during hESC-EC differentiation. 
There are multiple approaches that can be employed for high throughput 
screening of endothelial differentiation. Use of antibody based approaches for 
labelling proteins of interest has been widely used in stem cell research and long 
term monitoring of various cell surface marker expression changes has been 
reported in a range of cell lines (Eilken et al., 2011). More importantly, 
successful live cell immunofluorescence staining has also been reported in 
human pluripotent cells (Manos et al., 2011). However, there are multiple 
limitations of immunofluorescence based screening approaches – highly specific 
and stable antibodies are required, the detection is limited to the proteins 
expressed on cell surface, and antigens can be masked when tight cell junctions 
are established (Manos et al., 2011). And, while methods for delivering 
antibodies intracellularly have been described (Canton et al., 2013; Raz-Prag et 
al., 2010), their suitability for monitoring of hESC differentiation remains 
unclear with concerns regarding potential toxicity and effects on the 
differentiation processes. 
Another approach is the use reporter cell lines, where reporter protein sequence 
is inserted after the endogenous gene sequence in the genome, allowing for a 
simultaneous expression of the gene of interest and the reporter (Rojas-
Fernandez et al., 2015). Alternatively, a reporter construct can be created 
where an extrinsic cognate promoter drives expression of a reporter gene, such 
as green or red fluorescent protein (GFP or RFP accordingly) and the construct 
can be delivered into the cells using electroporation or, for example, lentiviral 
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vectors can be used to for the delivery and random integration of the reporter 
construct.  
Indeed, NANOG (Fischer et al., 2010) and OCT4 (Huangfu et al., 2008) extrinsic 
reporter construct cell lines have been used to monitor stem cell pluripotency 
and reprogramming, while reporters of endothelial specific genes, for example 
CDH5 (Sahara et al., 2014) and PECAM (Zeng et al., 2007), have been used to 
investigate endothelial biology and differentiation. Such cell lines allow for 
efficient real time monitoring of gene regulation and have been widely used in 
stem cell research and, therefore, this approach was selected for the purposes 
of the hESC-EC optimisation. 
As discussed in the previous chapter, hESC-EC differentiation protocol can be 
divided in two phases – the mesodermal induction phase and the endothelial 
specification phase. Thus, it is clear that a cell line with a single reporter gene 
would not be sufficient to monitor the efficacy of both differentiation phases 
and the use of multiple reporter constructs has to be considered. Additionally, it 
can be proposed that cell lines with multiple reporter constructs linked to non-
overlapping fluorescent proteins (for example, GFP and RFP) could be an 
invaluable tool for the optimisation of the endothelial differentiation process. 
The mesoderm induction phase of hESC-EC differentiation ends on day 3 of the 
differentiation, after the expression of mesodermal gene Brachyury peaks on 
day 2 as demonstrated in 3.1.6. To optimise this phase of the differentiation, a 
reporter for a gene expressed after mesodermal induction but prior to induction 
of the full endothelial program would be required. There are multiple candidate 
genes which match this requirement. For example, friend leukaemia integration 
1 TF (FLI1) has been demonstrated to be a key TF for endothelial development 
(Liu et al., 2008) and transdifferentiation (Ginsberg et al., 2012), and to 
regulate CDH5 expression (Asano et al., 2010). However, FLI1 is expressed early 
during differentiation and is also expressed in cloche zebrafish mutant lacking 
endothelial cell development (Brown et al., 2000) and, thus, an alternative gene 
reporting endothelial specification would be preferable. 
The zinc finger TF GATA2 is another key player in endothelial and hematopoietic 
development (Lugus et al., 2007; Shi et al., 2014). However, in later 
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development it becomes restricted to hematopoietic lineages (Brown et al., 
2000) and hESC can be differentiated towards endothelial lineages in the 
absence of GATA2 (Huang et al., 2015), limiting the usefulness of GATA2 
reporters for the optimisation of the endothelial differentiation. 
In contrast, ETV2, a member of the E-twenty six TF factor family, plays a central 
role in endothelial development. Indeed, ETV2 induces vascular mesoderm 
(Kataoka et al., 2011) and is required for endothelial and hematopoietic 
development (Ferdous et al., 2009; Shi et al., 2014). Overexpression of ETV2 
induces endothelial gene expression in hESC (Elcheva et al., 2014), increases 
efficiency of endothelial differentiation (Lindgren et al., 2015) and can be 
exploited for endothelial transdifferentiation of fibroblasts (Morita et al., 2015), 
skeletal muscle (Veldman et al., 2013) and amniotic cells (Ginsberg et al., 2015, 
2012). Given the overwhelming evidence for the role of ETV2 in early endothelial 
development, it was selected as the best candidate gene for the early 
differentiation reporter construct. 
It is also necessary to select a gene indicating endothelial commitment. Here, 
CDH5 was used, as it has been widely used for monitoring of endothelial 
differentiation before (James et al., 2010; Sahara et al., 2014; Schmeckpeper et 
al., 2009). Additionally, ROBO4, a member of the roundabout family, was chosen 
as a complimentary, endothelium specific gene (Huminiecki et al., 2002; 
Huminiecki and Bicknell, 2000) for more robust monitoring of endothelial 
differentiation. 
This chapter describes the work undertaken for the generation and validation of 
hESC reporter cell lines for hESC-EC differentiation optimisation. Firstly, ETV2 
and ROBO4 expression was profiled during hESC-EC differentiation, this was 
followed by generation of CDH5, ROBO4 and ETV2 reporter constructs. The 
functionality of the constructs was tested in NCI60 cancer cell lines, followed by 
generation of lentiviruses carrying the reporter constructs and further validation 
attempts in primary cell lines and during hESC-EC differentiation. Finally, 
alternative CDH5 and ETV2 reporter constructs were outsourced and tested 
during hESC-EC differentiation. 
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4.2 Aims 
The aims of this chapter were: 
 To assess the expression of ETV2 and ROBO4 during hESC-EC 
differentiation 
 To generate ETV2, CDH5 and ROBO4 virally delivered reporter constructs 
and test them during hESC-EC differentiation. 
 To validate the outsourced ETV2 and CDH5 reporter constructs. 
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4.3 Results 
4.3.1 ETV2 and ROBO4 expression during hESC-EC 
differentiation. 
To assess ETV2 expression during hESC-EC differentiation, H1 and RC-11 were 
differentiated as described in Methods section 2.3, and RNA was collected on 
day 0, and days 2 - 7 for RT-PCR analysis. For ROBO4 expression analysis, RNA 
was collected on day 0, 3, 5 and 7 of hESC-EC differentiations with H9. 
As shown in Figure 21, ETV2 was expressed both in pluripotent RC-11 and H1 
with Ct values of 30.6 ±1.2 and 31.3 ±0.2 accordingly. In RC-11, the expression 
of ETV2 was upregulated 8-fold on day 3 (p<0.001 vs day 2) and further 
upregulated on day 4 (p<0.001 vs day 3) reaching Ct values of 26.4 ±1.0. This 
was followed by rapid downregulation on day 5 (p<0.001 vs day 4) and return to 
baseline levels by day 7.  
In contrast, ETV2 expression was rapidly upregulated and peaked on day 3 during 
H1 hESC-EC differentiation (p<0.001 vs day 0 and day 2, Ct of 26.3 ±0.2). This 
was followed by downregulation on day 5 (p<0.001 vs day 3, p<0.01 vs day 4). By 
day 7, ETV2 remained expressed at a slightly higher level than on day 0 with Ct 
values of 30.7 ±0.1.  
In addition to the gene expression analysis, ETV2 expression was also assessed at 
protein level between days 4 - 7 of hESC-EC differentiation with RC-11 (Figure 
23). Staining was not performed before day 4 due to cells being differentiated in 
EBs which are not suitable for ICC. As shown in Figure 23, staining for ETV2 could 
be observed with the first appearance of CD31+ cells on day 4 and co-localised 
with cell nuclei, as expected. ETV2 expression was not observed after day 5 of 
hESC-EC differentiation. 
ROBO4 was expressed at a low level in pluripotent H9 hESC (Figure 22) with an 
average Ct value of 33.8 ±0.2. As expected, the expression of ROBO4 was 
upregulated 19-fold on day 5 of hESC-EC differentiation (p<0.05 vs day 0) and 
further upregulated over 120-fold on day 7 (p<0.01, vs day 0) reaching Ct values 
of 25.8 ±0.1. 
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Figure 21: Expression of ETV2 during hESC-EC differentiation. RNA was 
collected on day 0 (D0), and days 2 – 7 (D2-D7) of hESC-EC differentiation with RC-
11 (n=3, independent experiments) and H1 (n=3, independent experiments). 
Expression of ETV2 was quantified using qRT-PCR. Statistical significance was 
evaluated using repeated measures ANOVA with Tukey’s post hoc comparisons, 
* p<0.05, ** p<0.01, *** p<0.001 when compared to d0 hESC control, unless 
indicated otherwise. Data shown is RQ ± RQ max and min. 
 
Figure 22: Expression of ROBO4 during hESC-EC differentiation. RNA was 
collected on days 0, 3, 5 and 7 (D0, D3, D5 and D7) of hESC-EC differentiation with 
H9 (n=3, independent experiments). Expression of ROBO4 was quantified using 
qRT-PCR. Statistical significance was evaluated using repeated measures ANOVA 
with Tukey’s post hoc comparisons, * p<0.05, ** p<0.01, *** p<0.001 when 
compared to d0 hESC control, unless indicated otherwise. Data shown is RQ ± RQ 
max and min. 
ANOVA p<0.001 ANOVA p<0.001 
ANOVA p<0.001 
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Figure 23: Immunocytochemistry showing the expression of ETV2 during 
hESC-EC differentiation. RC-11 were differentiated towards endothelial lineages 
(n=3, independent experiments, representative images shown) and fixed between 
days 4 and 7 of hESC-EC differentiation. ETV2 staining shown in yellow, CD31 in 
green, DAPI in blue. Red arrows show overlap of ETV2 and DAPI staining. Scale 
bar 20µm. Continued on page 140, 141 and 142. 
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Figure 23 (cont.): Immunocytochemistry showing the expression of ETV2 
during hESC-EC differentiation with RC-11. RC-11 were differentiated towards 
endothelial lineages (n=3, independent experiments, representative images shown) 
and fixed between days 4 and 7 of hESC-EC differentiation. ETV2 staining shown in 
yellow, CD31 in green, DAPI in blue. Red arrows show overlap of ETV2 and DAPI 
staining. Scale bar 20µm. Continued on pages 141 and 142. 
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Figure 23 (cont.): Immunocytochemistry showing the expression of ETV2 
during hESC-EC differentiation with RC-11. RC-11 were differentiated towards 
endothelial lineages (n=3, independent experiments, representative images shown) 
and fixed between days 4 and 7 of hESC-EC differentiation. ETV2 staining shown in 
yellow, CD31 in green, DAPI in blue. Red arrows show overlap of ETV2 and DAPI 
staining. Scale bar 20µm. Continued on page 142. 
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Figure 23 (cont.): Immunocytochemistry showing the expression of ETV2 
during hESC-EC differentiation with RC-11. RC-11 were differentiated towards 
endothelial lineages (n=3, independent experiments, representative images shown) 
and fixed between days 4 and 7 of hESC-EC differentiation. ETV2 staining shown in 
yellow, CD31 in green, DAPI in blue. Red arrows show overlap of ETV2 and DAPI 
staining. Scale bar 20µm. 
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4.3.2 Generation and preliminary validation of reporter constructs 
for hESC-EC differentiation. 
Two lentiviral plasmid backbones were outsourced (ABMgood, US) for generation 
of the hESC-EC reporter constructs - pLenti promotorless (pLenti) and pLenti 
promotorless GFP (pLenti-GFP). The plasmid maps, including multiple cloning 
sites are shown in Figure 24. 
Primers with added restriction sites of interest as shown in Table 14, were used 
to amplify the promoters of interest from purified H9 hESC DNA, and to clone 
the fragments of interest using the respective restriction sites in plasmids, as 
shown in Table 15 and described in section 1.4. In addition, monomeric RFP 
(mRFP) sequence was amplified from pMXs-mRFP1 plasmid (Addgene, US) and 
ligated in the pLenti backbone. Overview of the steps taken for generation of 
CDH5 and ETV2 RFP reporter constructs can be seen in Figure 25, and a similar 
overview is given for the generation of CDH5 and ROBO4 GFP reporter constructs 
in Figure 26. 
 
 
Figure 24: Schematic of the two outsourced plasmid backbones used for 
generation of hESC-EC differentiation reporter constructs. Adapted from: 
Promoterless GFP Lentiviral Vector, and Promoterless Lentiviral Vector product 
manuals (ABMgood, US).   
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Fragment  Restriction 
sites 
Primer sequence 
mRFP FW ApaI ATTAGGGCCCGCCACCATGGCCTCCT 
 RV XhoI GCGCCTCGAGTTCTCAGTTATGTATTTTTCCATGC 
Promoters 
CDH5 FW NotI ATTAGCGGCCGCTCTCTCCTGGTCAGCAG 
 RV SacII ATTACCGCGGCTGTGGGCTGAGGGATG 
CDH5 FW SpeI GCGCACTAGTTTCTCAGGGTCTCTGCT 
 RV NotI ATTATGCGGCCGCATCTTGGGCGCAGGG 
ROBO4 FW SalI CGCGGTCGACGCTGACATTGTAGGCTC 
 RV ApaI ATTAGGGCCCGGAGGCTGTCTCCTCC 
ETV2 FW NotI CCGCGGCCGCACAGGCTGATCTAGAACTCC 
 RV SacII CGCCGCGGCTGGGAGAAGTTTACGG   
                                                                                                                                                                                                                                                                             
Table 14: Primers used for polymerase chain reaction.  FW – Forward primer, 
RV - Reverse primer. Sequences in bold indicate restriction sites. 
 
 Restriction Sites Insert 
pLenti 
 ApaI / XhoI mRFP 
 NotI / SacII CDH5 
 NotI / SacII ETV2 
pLenti-GFP 
 SalI / ApaI ROBO4 
 SpeI / NotI CDH5 
Table 15: Restriction sites used to insert the amplified inserts into pLenti and 
pLenti-GFP plasmids. 
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Figure 25: Schematic of steps taken to generate pLR-CDH5 and pLR-ETV2 
reporter constructs. The generated constructs contain an RFP sequence driven by 
CDH5 or ETV2 promoter respectively. 
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Figure 26: Schematic of steps taken to generate pLG-ROBO4 and pLG-CDH5 
reporter constructs. The generated construct contains an enhanced GFP (eGFP) 
sequence driven by ROBO4 or CDH5 promoter respectively. 
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Control digests of the generated reporter plasmids were performed to confirm 
the presence of the promoter inserts. As shown in Figure 27a, control restriction 
digestion generated fragments of the expected sizes. The digest of 
pLG-ROBO4 (column A) with SalI and ApaI generated 9.2 kbp and 1 kbp 
fragments; pLG-CDH5 (column B) SpeI and NotI digest generated 9.2 kbp and 
1.2 kbp fragments; pLR-ETV2 (column C) XhoI and NotI digest resulted in 7.4 kbp 
and 1.6 kbp fragments; while pLR-CDH5 (column D) XhoI and NotI digest 
generated 7.4 kbp and 1.9 kbp fragments, as expected. In addition, the 
generated plasmids were sequenced and the presence of the promoter 
constructs was confirmed. 
 
Figure 27: Control digests of generated reporter. Control restriction enzyme 
digests of the generated plasmids confirm presence of the inserts. Column A: pLG-
ROBO4 SalI and ApaI digest. Column B: pLG-CDH5 SpeI and NotI digest. Column 
C: pLR-ETV2 XhoI and NotI digest. Column D: pLR-CDH5 XhoI and NotI digest. 
1Kb. Promega 1Kb DNA ladder, fragments of interest indicated on the left hand 
side. 
Initially, it was attempted to validate the generated plasmids using transfections 
in NCI60 cell lines expressing the markers of interest. While there was visible 
GFP expression in cell lines transfected with a plasmid expressing enhanced GFP 
(eGFP) under constitutively active cytomegalovirus (CMV) promoter (a kind gift 
from Dr Laura Denby, University of Glasgow), GFP reporter expression was not 
observed in the cell lines transfected with the reporter constructs (n=1, data not 
shown). Therefore, it was decided to attempt validation using lentiviral vectors 
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carrying the constructs as this would allow for validation using primary cell lines 
or during hESC-EC differentiation.  
Lentiviral vectors were generated using pLR-ETV2, pLR-CDH5, pLG-CDH5 and 
pLG-ROBO4 plasmids as described in Methods section 1.5. The concentrated 
lentivirus solution was titred in HEK293T cells and, in addition, particle counts 
and sizes were estimated using Nanosight (Malvern, UK) with the results shown 
in Table 16. 
To validate the reporter constructs, HUVEC, HSVEC and IGROV cell lines were 
transduced using the generated lentiviruses carrying the CDH5 and ROBO4 
reporter constructs. Furthermore, H9 and RC-11 hESC were transduced with 
lentiviral vectors carrying pLR-ETV2 or pLG-CDH5 construct accordingly, followed 
by hESC-EC differentiation. Reporter expression was observed visually and 
evaluated using FC on day 5 and day 7, as appropriate. While control cell lines 
transduced with lentiviral vectors carrying constitutively active spleen focus-
forming virus (SFFV) eGFP (a kind gift from Prof. Adrian Thrasher, Institute of 
Child Health, University College London, UK) induced the expression of eGFP in 
the majority of cells across the cell lines, expression of GFP in the cell lines 
transduced with reporter constructs was not observed (all n=1, data not shown). 
Due to the lack of any reporter expression in these experiments, additional 
repeats were not performed and alternative reporter constructs were 
outsourced. 
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Vector Titre, 
PIU/mL 
Particle count, 
P/mL 
Particle size, 
nm 
pLR-CDH5 4 x 109 3 x 1011 123 
pLG-ROBO4 9 x 109  1.3 x 1012 134 
pLR-ETV2 8 x 107 1.5 x 1012 120 
pLG-CDH5 2.5 x 1010 * * 
ETV2-GFP (Genecopoeia) 4.5 x 108 * * 
CDH5-GFP (Published) 9 x 108 * * 
 
Table 16: Titres of the generated lentiviruses. Infectious particle counts were 
obtained by titring in HEK293T cells. In addition, total viral titre and particle sizes 
were measured using Nanosight, unless indicated by *. 
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4.3.3 Preliminary validation of an outsourced CDH5 reporter 
CDH5 reporter construct is crucial for the optimisation of the endothelial 
differentiation as it indicates mature endothelial commitment. As the CDH5 
reporter constructs described in the previous section could not be validated, a 
construct where a 2.5kb CDH5 promoter fragment drives eGFP expression 
(SM-CDH5-GFP reporter) was obtained (a kind gift from Sahara et al. (2014)). 
Control restriction digests were performed and yielded expected fragment sizes, 
as shown in Figure 28. The generated lentiviral vectors were titrated using 
HEK293T cells and a titre of 9 x 108 PIU/mL was obtained as shown in Table 16. 
To validate the SM-CDH5-GFP reporter, RC-11 and H9 hESC were infected on 
day 0 of hESC-EC differentiation (both n=1, separate experiments, data not 
shown). In both of these cell lines, large percentage of cells expressing GFP but 
not staining positive for CD144 was observed. Furthermore, reporter GFP 
expression was observed in CD144- pluripotent H9 hESC. While additional repeats 
are required to draw conclusions, these observations suggested that this 
construct does not function correctly in this differentiation system and more 
work is require to generate reliable CDH5 reporter hESC lines. Therefore, further 
repeats and validation experiments were not performed and it was decided to 
focus on alternative reporter constructs for optimisation of the hESC-EC 
differentiation. 
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Figure 28: Control digests of the outsourced SM-CDH5-GFP reporter 
construct.  A single restriction site for NdeI and ApaI present in the plasmid. Double 
digest generated 5kb and 8kb fragments as expected. 1Kb shows Promega 1Kb 
DNA ladder, fragments of interest indicated on the left hand side.  
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4.3.4 Validation of an outsourced ETV2 reporter. 
The analysis of ETV2 expression, as described in section 4.3.1 suggests that 
expression of ETV2 indicates early endothelial commitment. Therefore, the use 
of an ETV2 reporter construct represents a novel approach for the optimisation 
of the early endothelial differentiation. As the generated ETV2 reporter 
constructs did not validate, a construct where 1.5 kbp ETV2 promoter fragment 
drives eGFP expression (GC-ETV2-GFP) was acquired from Genecopoeia (US). 
Control restriction digests were performed and yielded expected fragment sizes 
of 5.7kb, 2.2kb and 1.6kb as shown in Figure 29. The generated lentiviral vectors 
were titrated using HEK293T cells and a titre of 4.5 x 108 PIU/mL was obtained 
as shown in the previous table (Table 16). 
To validate the GC-ETV2-GFP reporter construct, RC-11 hESC were transduced 
with the GC-ETV2-GFP lentivirus at a MOI of 10, grown to confluence and 
differentiated towards EC lineages (n=1, data not shown). When evaluating the 
GC-ETV2-GFP transduced hESC-EC differentiations, GFP expression was observed 
on day 4 and to a higher level on day 7 of hESC-EC differentiation, not matching 
the expected expression pattern of ETV2 from the gene expression data reported 
in 4.3.1 .  
To ensure that all the cells carry the reporter gene construct, polyclonal 
reporter cell lines were generated by transducing RC-11 with lentiviral vectors 
carrying ETV2-GFP reporter construct, followed by culture in a selection media 
containing 2 µg/ml puromycin, and hESC-EC differentiation (n=3). Reporter 
expression was analysed by FC on days 0, 4 and 7 of the differentiation and by IC 
on day 4. CD144+ expression was evaluated on day 7 using FC.  
Unexpectedly, the majority of cells (73.2% ±8.6) expressed GFP on day 0 of 
hESC-EC differentiation and the expression levels decreased over time with, on 
average, 24.3% (±7.7) expressing GFP on day 7, as shown in Figure 30. On 
average, 22.5% (±5.9) of cells expressed CD144 at the end of the differentiation 
suggesting successful hESC-EC differentiation. IC on day 4 of the differentiation 
(Figure 31) further confirmed the observation of high GFP expression that was 
not confined to cells expressing ETV2. 
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This suggests that the GC-ETV2-GFP reporter construct does not specifically 
report ETV2 expression in hESC-EC differentiation system. Therefore, the work 
with this reporter construct was not continued. 
 
 
Figure 29: Control digests of the outsourced GC-ETV2-GFP reporter construct. 
SalI digest generated 5.7kb, 2.2kb and 1.6kb fragments observed as expected. 1Kb 
shows Promega 1Kb DNA ladder, fragments of interest indicated on the left hand 
side. 
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Figure 30: Validation of the outsourced GC-ETV2-GFP reporter construct. 
RC-11 (n=3, independent experiments, representative data shown) were transduced 
with lentiviral vectors carrying GC-ETV2-GFP reporter construct, grown in a 
selection media containing puromycin, followed by hESC-EC differentiation. 
Reporter expression was analysed by FC on days 0, 4 and 7 of the differentiation, 
and CD144+ expression was evaluated on day 7 using antibody staining and FC. 
Uninfected hESC control differentiation or isotype controls, as appropriate, shown in 
blue.  
155 
 
 
Figure 31: Immunocytochemistry showing the expression of ETV2 and GFP on 
day 4 of hESC-EC differentiation with RC-11 carrying the GC-ETV2-GFP 
construct. RC-11 (n=3, representative images shown) were differentiated towards 
endothelial lineages, fixed and stained on day 4 of the differentiation. ETV2 staining 
shown in yellow, GFP in green, DAPI in blue. Red arrows indicate cells expressing 
GFP but not ETV2.  A. Non-infected control. B. RC-11 infected with a lentiviral 
vector carrying the outsourced GC-ETV2-GFP reporter construct, followed by 
culture in selection media. C. Isotype control. Continued on page 156. 
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Figure 31 (cont.): Immunocytochemistry showing the expression of ETV2 and 
GFP on day 4 of hESC-EC differentiation with RC-11 carrying the GC-ETV2-
GFP construct. RC-11 (n=3, representative images shown) were differentiated 
towards endothelial lineages, fixed and stained on day 4 of the differentiation. ETV2 
staining shown in yellow, GFP in green, DAPI in blue. Red arrows indicate cells 
expressing GFP but not ETV2.  A. Non-infected control. B. RC-11 infected with a 
lentiviral vector carrying the outsourced GC-ETV2-GFP reporter construct, followed 
by culture in selection media. C. Isotype control. 
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In summary, the data presented in this chapter showed that ETV2 is transiently 
upregulated at the end of the mesodermal induction phase of hESC-EC 
differentiation and, therefore, is a suitable gene for the monitoring of the early 
differentiation. CDH5, ROBO4 and ETV2 reporter constructs were generated 
using pLenti and pLenti-GFP plasmid backbones. Preliminary validation of the 
constructs in NCI60, HSVEC and HUVEC cell lines, as well as during hESC 
differentiation, suggested lack of reporter functionality and, thus, the work with 
these constructs was discontinued to focus on other reporter constructs. This 
was followed by preliminary validation of outsourced CDH5 and ETV2 reporter 
constructs. Here, the preliminary analysis showed non-specific reporter gene 
expression when either of these constructs were transduced in hESC. While 
further repeats are required to confirm these observations, it was decided to 
discontinue to work with these constructs and other approaches for optimisation 
of the hESC-EC differentiation were employed. 
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4.4 Discussion 
The described hESC-EC differentiation protocol efficiently generates cells 
expressing EC markers CD31 and CD144, without the use of cell sorting during 
the differentiation process. However, there is scope for further optimisation to 
both increase the percentage of cells expressing EC markers at the end of the 
differentiation and to aid EPC survival and proliferation during the 
differentiation. The use of reporter cell lines allows monitoring gene expression 
changes in real time during the differentiation and, thus, is highly suitable for 
the purposes of screening small molecule drugs during hESC-EC differentiation. 
Firstly, multiple reporter constructs for monitoring hESC-EC differentiation were 
generated and validation was attempted. This was followed by validation of 
outsourced CDH5 and ETV2 reporter constructs, as described in the following 
discussion. 
 
Optimisation of the hESC-EC differentiation protocol – choice of genes for 
monitoring of the EPC and EC commitment. 
HESC-EC differentiation consists of two phases – mesoderm induction and 
vascular specification phase. It is clear that monitoring expression of a single 
gene would not be sufficient for the optimisation of both differentiation phases 
and, thus, a gene indicating early endothelial progenitor commitment is required 
in addition to endothelial specification reporters. Here, ETV2, a member of the 
E-twenty six TF factor family, expression was used for monitoring early 
endothelial commitment. ETV2 is crucial for blood and vascular development 
and ETV2 knock-out mice display embryonic lethality with vascular defects and 
significantly reduced KDR+ mesoderm formation (Ferdous et al., 2009; Lee et 
al., 2008; Wareing et al., 2012). ETV2 is expressed transiently during 
development (Ferdous et al., 2009), initiates the specification of vascular 
mesoderm (Kataoka et al., 2011) and facilitates endothelial and hematopoietic 
differentiation (Shi et al., 2014). Indeed, ETV2 binds and activates multiple key 
endothelial genes, including KDR, TAL1, CDH5 and PECAM (De Val et al., 2008; 
Ferdous et al., 2009; Prandini et al., 2005). 
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Furthermore, a range of experimental approaches have confirmed the role of 
ETV2 in the induction of endothelial phenotype. A key paper by Ginsberg et al. 
(2012) demonstrated that transient ETV2 expression transdifferentiated amniotic 
c-kit+ cells to endothelial cells. These cells were highly proliferative and showed 
similar transcriptome profiles to HUVECs and human adult liver sinusoidal ECs. 
Later, Veldman et al. (2013) reported that ETV2 induced endothelial 
transdifferentiation of zebrafish fast muscle cells to endothelial cells in vivo and 
showed that it was not dependent on VEGF signalling. The ability of ETV2 to 
induce EC phenotypes has also been confirmed in murine (Koyano-Nakagawa et 
al., 2012) and human stem cell differentiation models (Elcheva et al., 2014; 
Lindgren et al., 2015). Therefore, ETV2 is a highly suitable gene for monitoring 
of early endothelial differentiation and it can be proposed that the hESC-EC 
protocol can be optimised for increased ETV2+ cell generation during the first 
phase of the differentiation.  
Firstly, the expression of ETV2 was quantified during hESC-EC differentiation 
with RC-11 and H1. ETV2 expression was upregulated after the downregulation 
of brachyury expression (see gene expression data in 3.3.6), and peaked on day 
3 in H1 and day 4 in RC-11, followed by downregulation. This is in line with the 
expected expression patterns as well as with observations by Lindgren et al. 
(2015) where ETV2 expression was also upregulated at the end of mesodermal 
specification phase, after the peak of brachyury expression. Similarly, ETV2 
expression was upregulated by day 3 and downregulated after day 5 of hESC-EC 
differentiation with H9 (Boulberdaa et al., 2016). 
When protein expression levels were compared, ETV2 expression was localised to 
cell nuclei, as expected, and transiently visible on days 4 and 5 of the 
differentiation, in line with the RNA expression data. However, here no 
relationship between ETV2 expression levels and the differentiation efficiency 
was established. While ETV2 overexpression has been reported to induce 
endothelial phenotypes (Elcheva et al., 2014; Lindgren et al., 2015), evidence 
from fibroblast endothelial transdifferentiation suggests that ETV2 expression 
has to be precisely regulated for optimal endothelial differentiation (Morita et 
al., 2015). Thus, currently it is not clear whether increased ETV2 expression in 
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hESC-EC differentiation system would result in higher CD31+ CD144+ cell 
percentage at the end of the differentiation. 
In addition, ETV2 protein expression levels were not analysed prior to day 4 of 
hESC-EC differentiation due to EB culture system being unsuitable for ICC 
staining. However, western blotting could be used instead to validate the ETV2 
antibody, quantify ETV2 protein levels during mesodermal induction phase and 
to gain further insight into ETV2 expression patterns during hESC-EC 
differentiation. This would further confirm the suitability of ETV2 for monitoring 
of early endothelial differentiation. 
For monitoring of the vascular specification phase, reporter constructs for CDH5 
and ROBO4 expression were generated. CDH5 is the major protein forming 
endothelial adherens junctions (Dejana et al., 1999), has been widely used in 
endothelial reporter constructs (James et al., 2010; Sahara et al., 2014; 
Schmeckpeper et al., 2009) and is progressively upregulated during hESC-EC 
differentiation as described in section 3.3.6. ROBO4 has gained attention as 
another gene specifically expressed in mature endothelium (Huminiecki et al., 
2002; Huminiecki and Bicknell, 2000) and, as expected, ROBO4 mRNA expression 
was upregulated from day 5 of hESC-EC differentiation with the appearance of 
CD31+ CD144+ cells. Therefore, the use of these two reporter constructs should 
allow for robust monitoring of endothelial phenotype induction during hESC-EC 
differentiation. 
 
Preliminary validation of the generated CDH5, ETV2 and ROBO4 reporter 
construct plasmids. 
Four reporter constructs were generated (pLR-CDH5, pLR-ETV2, pLG-ROBO4 and 
pLG-CDH5) by cloning promoters of interest upstream from reporter protein GFP 
or RFP sequences. Control digests and plasmid sequencing were performed and 
confirmed the presence of the promoter inserts in the generated plasmids. 
Preliminary validation used NCI60 cell lines, selected for their expression of 
genes of interest using BioGPS NCI60 cell line gene expression database (Wu et 
al., 2009) and transfected with the generated constructs. The plasmids were 
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successfully transfected in the NCI60 cell lines, as suggested by the observed 
expression of eGFP in the control cultures transfected with the CMV-eGFP 
plasmid. However, the expression of reporter genes was not observed in any of 
the cell lines transfected with the reporter constructs.  
While more repeats are needed to draw reliable conclusions, this suggests that 
either the reporter constructs were not functional. Generally, GFP transcript 
and fluorescence levels display a good correlation, and as little as <100 GFP 
transcripts are sufficient for GFP detection by FC allowing for monitoring of 
genes with weak expression (Bloom et al., 2014). Therefore, FC analysis or the 
more sensitive Proximity Ligation Assay qPCR (Ståhlberg et al., 2012) should be 
performed to confirm the lack of reporter gene expression. However, this 
experiment was not repeated and validation was attempted using lentiviral 
vectors which would allow for reporter gene validation in a range of cell lines 
and also during hESC-EC differentiation, when strong gene of interest induction 
is observed. 
 
Preliminary validation of lentiviral vectors carrying the generated CDH5, 
ETV2 and ROBO4 reporter constructs. 
Lentiviral vectors carrying pLR-CDH5, pLR-ETV2, pLG-ROBO4 and pLG-CDH5 
constructs were generated and titred in HEK293T cells. In addition, pLR-CDH5, 
pLR-ETV2 and pLG-ROBO4 lentiviral vector particle size was estimated and 
matched the expected lentiviral size of approximately 120nm (Perletti et al., 
2004).  
To validate the CDH5 or ROBO4 reporter constructs, HSVEC, HUVEC and IGROV 
cell lines, and hESC lines subjected to hESC-EC differentiation were transduced 
with the generated viruses and reporter gene expression was observed visually 
and evaluated by FC. Lentiviral vector carrying SFFV-GFP construct was used as a 
control and demonstrated high transduction levels. However, reporter 
expression was not observed in any of these validation experiments. While this 
data suggests lack of the reporter construct functionality, only single repeats 
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were performed of these experiments and, thus, this data should be regarded as 
preliminary and more repeats are needed to confirm these observations. 
 
Promoter fragments used in the CDH5, ETV2 and ROBO4 reporter constructs. 
Another possible explanation for the lack of the reporter functionality is the use 
of an incomplete promoter fragment. Indeed, previously described CDH5 
promoter constructs (Alva et al., 2006; Sahara et al., 2014) have used longer 
promoter sequences, while here the promoter fragment size was limited to 
approximately 1 kbp for optimal virus production and transduction (Canté-
Barrett et al., 2016; Kumar et al., 2001). However, CDH5 promoter analysis by 
Gory et al. (1999) suggests that the main transcriptional machinery binding 
region is within +24 base pair (bp) and -139 bp, in relation to transcription start 
site, followed by the major specific inhibitory region to -289 bp, and both of 
these promoter regions were included in the promoter construct as shown in 
Figure 32. Similarly, promoter analysis performed by Prandini et al. (2005) 
demonstrated the presence of two critical endothelium specific promoter region 
within -1135/-744 bp and -166/-5 bp and these regions were also included in the 
promoter constructs and have been used in other published CDH5 reporter 
constructs of a similar size (Schmeckpeper et al., 2009). 
Previously published murine ETV2 GFP reporter construct used 5 kbp upstream 
region (Wareing et al., 2012), while here 0.8 kbp fragment was used rationalising 
that it would include the previously described fragments required for the 
promoter activity. Analysis of the murine ETV2 promoter by De Haro and 
Janknecht (2005) demonstrated promoter activity when -466/+51 bp promoter 
sequence was used, furthermore basal transcription was driven by a shorter 
promoter sequence of -85/+51 bp. These sequences were also present in the 
generated ETV2 reporter construct (Figure 32) and, thus, should ensure 
functionality of the promoter region. However, two cAMP response elements 
have been described as a regulatory sequences for PKA mediated ETV2 induction 
(Yamamizu et al., 2012b) and only one of these sites was included in the 
promoter reporter construct. In murine undifferentiated ESC, absence of the 
second cAMP response element significantly reduced the expression of a 
163 
 
luciferase reporter gene (Yamamizu et al., 2012b). Therefore, it cannot be 
excluded that the absence of this regulatory fragment contributed to the lack of 
pLR-ETV2 reporter construct functionality. 
Similarly, a 3 kbp sequence is required for full ROBO4 promoter functionality 
(Okada et al., 2007), while approximately 1 kbp fragment was used in the 
pLG-ROBO4 construct. The shorter promoter fragment does not include 
enhancers present near -2.5kbp (Figure 32) and, thus, two fold reduction is 
promoter activity is expected (Okada et al., 2007). While this can potentially 
explain the lack of functionality of the ROBO4 reporter construct, the observed 
lack of CDH5 and ETV2 reporter functionality suggests an issue with the plasmid 
backbone used for the generation of reporter constructs and requires further 
investigation. 
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Figure 32: Promoter structures of CDH5, ETV2 and ROBO4 promoters. The key 
regulatory fragments reported in literature (De Haro and Janknecht, 2005; Gory et 
al., 1999; Okada, 2012; Prandini et al., 2005; Yamamizu et al., 2012b) are shown, 
shaded for those included and in white for those omitted from the generated 
constructs.  
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Limitations of the employed experimental approach for the validation of 
the generated reporters. 
There are multiple other shortcomings which need to be addressed. The 
successful titration of the generated viruses confirms the presence of late 
reverse transcription products (Butler et al., 2001) but not integration of the 
lentivirus in the genome. To confirm the reporter integration in the genome, 
qPCR using an integration specific set of primers (Butler et al., 2001) or 
sequencing of the infected cell lines is required. It would also be important to 
use RFP+ in addition to used GFP+ controls, in order to exclude any technical 
errors during FC analysis. Alternatively, the reporter gene mRNA expression 
could be confirmed using qRT-PCR. 
Furthermore, not all cells are successfully transduced, thus, selection of cells 
carrying the reporter constructs might be required. Similarly, generation and 
selection of monoclonal cell lines might be required to obtain high quality 
reporter lines. Additionally, GFP may provide insufficient signal for low gene 
expression levels, and additional quantification using GFP antibodies or 
proximity ligation qPCR assay may be required (Ståhlberg et al., 2012; Swenson 
et al., 2007), however, these approaches are not suitable for live cell imaging. 
In addition, thorough testing of the plasmid backbone should be performed to 
ensure functionality of the reporter gene and other plasmid components. In 
order to validate the functionality of the plasmid backbones, a constitutively 
active promoter, for example SFFV or CMV, should be cloned in the plasmid and 
reporter gene expression should be confirmed in vitro. This would clarify if the 
plasmid backbone is fully functional and indicate whether there are any issues 
with the chosen promoter fragments. Extensive control restriction digests 
performed using the original pLenti plasmids revealed unexpected fragments 
(personal communication, Dr Raquel Garcia, University of Glasgow), further 
implicating issues with the plasmid backbone. Therefore, work with the 
generated reporter constructs was not continued. 
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Preliminary validation of the outsourced CDH5 reporter construct. 
The optimisation of hESC-EC differentiation protocol could also be performed 
using only two reporter constructs – ETV2 reporter and CDH5 reporter construct. 
It was speculated that these reporters could be outsourced and used for the 
optimisation of hESC-EC differentiation. Therefore, an ETV2 (HPRM12894-
LvPF02, GeneCopoeia, US), here GC-ETV2-GFP, and a CDH5 reporter (Sahara et 
al., 2014), here SM-CDH5-GFP, constructs were obtained. Control digests 
generated fragments of expected sizes and this was followed by generation of 
lentiviral vectors carrying the constructs of interest.  
Preliminary validation of the SM-CDH5-GFP construct was attempted during 
hESC-EC differentiation with RC-11 and H9 hESC and showed a large percentage 
of cells expressing GFP but not staining positive for CD144+. Furthermore, when 
H9 hESC were infected with the SM-CDH5-GFP lentivirus, expression of GFP in 
the absence of CD144 staining was observed in pluripotent hESC. While transient 
GFP expression upon lentiviral integration cannot be excluded, expression of 
GFP after prolonged culture suggests non-specific GFP expression. More repeats, 
if possible using monoclonal cell lines created after selection in antibiotic 
containing media, are required to confirm these observations and this is only 
preliminary validation, therefore, no reliable conclusions can be drawn.  
In the original publication (Sahara et al., 2014), multiple clonal cell lines were 
created and one of these cell lines was selected for further experiments after 
testing reporter gene expression during spontaneous differentiation. 
Interestingly, a population of cells expressing GFP but not staining positive for 
CD31 can be observed in the published FC plots (Sahara et al., 2014). It can be 
speculated that the CD31- cells also were CD144-. If so, this is in line with the 
non-specific GFP expression reported here. It is also likely that CD144+ GFP- 
cells reported here were not been transduced with the construct. Thus, it can be 
speculated that selection in antibiotic containing media followed by creation of 
clonal reporter lines would result in a more accurate reporter expression. 
However, the non-specific GFP expression remains a significant limitation of this 
construct and alternative CDH5 reporter constructs should be considered. 
Therefore, the work with the SM-CDH5-GFP was not continued to focus on the 
outsourced ETV2 reporter construct. 
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Preliminary validation of the outsourced ETV2 reporter construct. 
For validation of the GC-ETV2-GFP construct, RC-11 hESC were transduced on 
day 0 of hESC-EC differentiation. GFP reporter expression was observed on day 4 
of the differentiation and, unexpectedly, increased further by day 7. This is in 
contrast with the expected expression pattern, and suggests that the reporter 
construct was not specific for ETV2 expression. Infection on day 0 of hESC-EC 
differentiation might have a negative effect on hESC-EC differentiation, as 
suggested by the low CD144 expression at the end of the differentiation. In 
addition, not all cells will be transduced with the reporter construct, further 
complicating monitoring of ETV2 expression early in hESC-EC differentiation. 
Thus, this experiment was not repeated and an alternative experimental setup 
was selected for the following experiments. 
To ensure that all cells carry the construct and to prevent any detrimental 
effects of lentiviral transduction on hESC-EC differentiation, pluripotent RC-11 
hESC were transduced with lentiviral vectors carrying GC-ETV-GFP construct, 
followed by selection in puromycin containing media before hESC-EC 
differentiation. Here, a majority of cells expressed GFP on day 0. This might be 
explained by the low basal ETV2 expression levels, as seen in the RT-PCR data. 
However, the percentage of GFP+ cells decreased during hESC-EC 
differentiation, once again not matching the expected expression pattern of 
increased ETV2 expression by day 3 of hESC-EC differentiation. The lack of 
reporter specificity was further confirmed by immunostaining, where cells 
expressing GFP but not staining positive for ETV2 could be identified. Taken 
together, this indicates that GC-ETV2-GFP construct does not specifically report 
ETV2 expression and, thus is not suitable to be used for optimisation of hESC-EC 
differentiation. 
It is difficult to speculate about the mechanisms underlying non-specific 
expression of the reporter gene without further analysis. As above, it is likely 
that testing of multiple clonal cell lines carrying the construct could be used to 
select a cell line with more specific ETV2 reporter expression. Interestingly, 
while this construct included a larger (1.5 kbp) ETV2 promoter fragment, it did 
not contain the second cAMP response element binding site implicated in 
expression regulation during endothelial differentiation (Yamamizu et al., 
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2012b) discussed previously. This might explain the lack of reporter upregulation 
during hESC-EC differentiation. Therefore, it can be proposed that a reporter 
construct including both cAMP response element binding sites, in addition to the 
basal expression sequences (De Haro and Janknecht, 2005), would be required 
for efficient monitoring of early endothelial differentiation. However, the 
presence of other, yet not described, negative regulatory elements in the 
promoter of ETV2, cannot be excluded. Therefore, further characterisation of 
the ETV2 promoter is necessary. 
 
Limitations of the chosen strategy for the optimisation of hESC-EC 
differentiation. 
It is clear that there are multiple possible complications with the chosen 
approach for reporter cell line generation. Firstly, it is difficult to capture the 
complexity of gene expression regulation within a relatively short promoter 
fragment. Additionally, the use of lentiviral vectors further complicates 
generation of the reporter cell lines as the exact integration site and copy 
number cannot be easily controlled (Charrier et al., 2011; Sakuma et al., 2012). 
Various methods for precise genome editing have been developed, for example, 
zinc finger nucleases (Urnov et al., 2010), TALEN - transcription activator-like 
effector nucleases (Hockemeyer et al., 2011; Joung and Sander, 2013) and 
CRISPR - clustered regularly interspaced short palindromic repeats systems (Cong 
et al., 2013; Mali et al., 2013). These systems allow precise insertion of a 
fluorescent reporter sequence in the genome. The main advantage of such 
approach is that all the regulatory regions controlling gene expression would be 
preserved and, thus, the reporter would be highly specific and expressed at near 
native levels. 
However, while fluorescent proteins are highly suitable for live cell imaging and 
can be easily coupled to the protein of interest, the large size of fluorescent 
proteins may interfere with the protein function (Toseland, 2013). Therefore, a 
thorough comparison of wild type and cells carrying the fusion protein construct 
should be undertaken, or alternatively bicistronic vectors can be used to obtain 
separate proteins (Sakuma et al., 2012). Additionally, various fluorescent 
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proteins should be carefully considered (Shaner et al., 2007, 2005), and if 
possible, a fluorescent protein with minimised oligomerization should be used to 
minimise the risk of any alteration of protein function. 
 
Generation of reporter cell lines for monitoring of hESC-EC differentiation - 
summary. 
In summary, the data presented in this chapter shows temporary ETV2 
expression upregulation during the mesodermal induction phase and progressive 
ROBO4 expression upregulation as hESC-EC differentiation progresses. This 
suggests that reporter constructs of these two genes would be useful in addition 
to CDH5 reporter for the optimisation of hESC-EC differentiation. Here, ETV2, 
ROBO4 and CDH5 reporter constructs were generated and preliminary validation 
was attempted in NCI60 cancer cell lines, HUVECs and HSVECs, and during hESC-
EC differentiation. No reporter expression was observed, possibly due to issues 
with the plasmid backbone used. However, these experiments were not 
continued and thus this data remains preliminary and no reliable conclusions can 
be drawn. This was followed by preliminary validation of outsourced CDH5 and 
ETV2 reporter constructs during hESC-EC differentiation. Non-specific reporter 
gene expression was observed in cell lines carrying either of the constructs and, 
thus, the work with these constructs was discontinued. Similarly, further 
research is required for robust conclusions and this remains preliminary data. 
However, there’s still scope to optimise hESC-EC differentiation. Therefore, the 
following chapters investigate the role of cAMP signalling and angiotensin 
signalling during hESC-EC differentiation. 
  
170 
 
Chapter 5: Manipulation of cAMP signalling to 
increase hESC-EC differentiation yield and induce 
arterial phenotype. 
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5.1 Introduction 
A range of methods have been published describing endothelial differentiations 
of hESCs and hIPSCs as introduced in 1.8. While the angiogenic properties of 
these cells have been demonstrated and significant advances have been made in 
developing differentiation protocols suitable for clinical use, further 
specification of the differentiated cells has received relatively little attention.  
Indeed, the recent research has focused on generating cells expressing EC 
markers CD144 and/or CD31 (Orlova et al., 2014, 2013; Patsch et al., 2015; 
Prasain et al., 2014; Sahara et al., 2014; Wu et al., 2015), while only some have 
attempted differentiating arterial endothelium (Rufaihah et al., 2013; 
Sivarapatna et al., 2015; Sriram et al., 2015). Given that evidence has been 
presented suggesting that arterial EC have superior angiogenetic capacity 
compared to venous EC (Rufaihah et al., 2013; Sriram et al., 2015), it became 
apparent that it is important to investigate further endothelial specification 
during hESC-EC differentiation and consider approaches for increasing arterial 
commitment of the differentiated cells.  
Arterial specification is mostly mediated via NOTCH-VEGF signalling axis, as 
described in 1.7.3, however, manipulation of cyclic adenosine monophosphate  
(cAMP) signalling is another promising approach for arterial specification as 
described by Yurugi-Kobayashi et al. (2006). cAMP is a second messenger 
molecule involved in various cellular processes in mature endothelial cells, 
including proliferation (Aslam et al., 2014; Favot et al., 2004), apoptosis (Kumar 
et al., 2009), CDH5 junction formation (Fukuhara et al., 2005; Kooistra et al., 
2005) and angiogenesis (Namkoong et al., 2009).  
As illustrated in Figure 33, the intracellular levels of cAMP are increased after 
activation of transmembrane adenylyl cyclases which are regulated by various 
G-protein coupled receptors and, additionally, soluble adenylyl cyclases  
generate intracellular cAMP pools (Kamenetsky et al., 2006). The intracellular 
cAMP gradients are further regulated by phosphodiesterases (PDEs), which are 
responsible for cAMP hydrolysis (Mika et al., 2012). More importantly, spatially 
anchored cAMP effectors protein kinase A (PKA) (Walsh et al., 1968) and 
exchange protein directly activated by cAMP (EPAC) (de Rooij et al., 1998) 
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produce specific downstream signals and gene expression changes (Baillie, 2009; 
Du and Montminy, 1998). 
 
Figure 33: Overview of cAMP signalling. Intracellular cAMP pools are generated 
after activation of adenylyl cyclases. The two main effectors of cAMP are PKA and 
EPAC, however, other targets have been described, for example, NICD. PDE are 
responsible for hydrolysis of cAMP, further regulating cAMP signalling. Adapted 
from: Murray (2008). 
While the role of cAMP signalling has been extensively researched in mature 
endothelial cells, the role of cAMP in endothelial cell development and 
specification remains to be explored. One of the regulatory targets of PKA is 
cAMP response element binding protein also known as CREB (Du and Montminy, 
1998). Mice homozygous for truncated form of CREB show decrease in CD31+ cell 
numbers and lack of vascular networks (Oike et al., 1999). Additionally, CREB 
has been shown to alter CD144+ cell phenotypes in vivo (Kim et al., 2015). 
Therefore, it can be speculated that cAMP also may play a role in EC 
development and specification. 
173 
 
Indeed, early observations using mESC endothelial differentiation models have 
uncovered a range of processes that are modulated by cAMP. Yurugi-Kobayashi 
et al. (2006) demonstrated that 8-bromo-cAMP aided endothelial specification of 
CD309+ cells and induced arterial specification. It was speculated that this may 
be due to direct activation of NOTCH signalling, which is at the core of current 
arterial specification model (Corada et al., 2014). 
Later observations suggested that cAMP activated PI3K and subsequently 
suppressed GSK3B, thus, proposing β-catenin as the complimentary signal for 
cAMP induced arterial specification (Yamamizu et al., 2010). Indeed, a complex 
consisting of NICD, RBPJ and β-catenin was purified from both embryonic and 
adult murine arteries but not veins, providing further evidence for the role of 
cAMP and β-catenin axis in arterial specification (Yamamizu et al., 2010). 
Further research also demonstrated that cAMP contributed to endothelial 
differentiation via PKA and ETV2 axis (Yamamizu et al., 2012b) and later CREB 
interaction was also demonstrated to be crucial for ETV2 activation (Shi et al., 
2015).  
Moreover, research has provided preliminary evidence that cAMP can induce 
NOTCH signalling and arterial phenotypes in sorted CD31+ cells derived from 
hiPSC  (Rufaihah et al., 2013; Sivarapatna et al., 2015). However, both reports 
used low efficiency hIPSC differentiation protocols that were not optimised for 
clinical purposes, thus, these observations needs to be validated using clinically 
relevant differentiation protocols and “gold standard” hESC lines. 
Aranguren et al. (2013) have proposed a set of 8 transcription factors (AFF3, 
HEY2, SOX17, MSX1, EMX2, NKX2-3, TOX2, PRDM16) which act complimentary to 
induce full arterial gene expression program in addition to NOTCH signalling. Out 
of these, we decided to focus on EMX2, PRDM16, MSX1 and TOX2 as these TF 
induced the highest levels of phenotype changes when expressed in HUVECs 
(Aranguren et al., 2013). Interestingly, promoter analysis data reported by Zhang 
et al. (2005) revealed a presence of a full, conserved CREB binding sequence in 
the promoter of EMX2 and an incomplete CREB  binding sequence in the 
promoter of MSX1. Thus, the transcription of some or all of these genes might be 
activated by cAMP (Mayr and Montminy, 2001), while other targets could be 
regulated by cAMP indirectly via mechanisms downstream from PKA or EPAC. 
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Therefore, we hypothesised that an increase in intracellular cAMP levels would 
promote endothelial differentiation by potentiating signalling pathways already 
targeted in our hESC-EC differentiation, for example ETV2 activation, and might 
also drive arterial specification by inducing NOTCH signalling and expression of 
TF contributing to arterial phenotype. Here, Forskolin was used to activate 
transmembrane adenylyl cyclases (Kamenetsky et al., 2006; Seamon and Daly, 
1981) and increase intracellular cAMP levels in hESC-EC differentiation system, 
followed by endothelial, arterial and arterial phenotype associated gene 
expression analysis by qRT-PCR, as well as EC and EPC marker expression 
analysis by FC.  
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5.2 Aims 
The aims of this chapter were: 
 To evaluate arterial and venous marker expression during hESC-EC 
differentiation. 
 To test a range of Forskolin doses for increasing intracellular cAMP levels 
during hESC-EC differentiation. 
 To assess endothelial, arterial and arterial phenotype related gene 
expression changes during hESC-EC differentiation on Day 5 and Day 7 
after Forskolin treatments. 
 To assess EC and EPC surface marker expression changes in Forskolin 
treated differentiations on Day 5 and Day 7 of hESC-EC differentiations. 
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5.3 Results 
5.3.1 Arterial and venous gene expression during hESC-EC 
differentiation. 
Firstly, endothelial commitment during hESC-EC differentiation was evaluated. 
For gene expression analysis during hESC-EC differentiation, H1 hESC and RC-11 
hESC were differentiated as described in the Methods chapter, section 1.1, and 
RNA was collected on Day 0, and Days 2 - 7 of the differentiation. All 
differentiations yielded >20% CD31+ CD144+ cells on Day 7 of the differentiation. 
As shown in Figure 34a and 1b, expression of venous gene EPHB4 remained 
steady throughout the differentiation both in H1 and RC-11 with Ct values of 
26.5 ±0.5 and 28.2 ±2.5 on day 7 respectively. In contrast, arterial gene HEY2 
expression was slightly upregulated as early as Day 3 (p<0.05 vs Day 0) in H1, 
with two fold upregulation between Days 4 to 6 (p<0.001 vs Day 0) and more 
than 4-fold upregulation on Day 7 (p<0.001 vs Day 0) with Ct values of 25.7 ±0.5. 
In RC-11, HEY2 was upregulated two fold on Day 6 (p<0.01 vs Day 0), reaching 
three fold upregulation on Day 7 (p<0.001 vs Day 0), with Ct values of 28.6 ±1.7 
respectively. 
5.3.2 Changes in the intracellular cAMP levels during hESC-EC 
differentiation in response to Forskolin treatments. 
In order to evaluate effects of intracellular cAMP changes during 
differentiations, it was necessary to determine the appropriate Forskolin 
concentrations to be used for low, submaximal and maximal intracellular cAMP 
level increase. To evaluate this, Forskolin was applied to Day 3 EBs during 
hESC-EC differentiation, followed by analysis using Promega cAMP-Glo kit. A 
dose dependent increase in intracellular cAMP levels was observed as expected 
(Figure 34c). Maximal intracellular cAMP levels were reached at 5µM Forskolin 
concentration and three concentrations were selected for further experiments - 
1µM Forskolin for low increase in intracellular cAMP levels, 2.5µM Forskolin for 
submaximal increase in intracellular cAMP levels and 10µM Forskolin for a full 
response. 
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Figure 34: Arterial and venous gene expression and Forskolin dose response 
curve during hESC-EC differentiation. RNA was collected on Day 0, and 
Days 2 - 7 of A. H1 B. RC-11 hESC-EC differentiation (n=3, independent 
experiments). Expression of venous gene EPHB4 and arterial gene HEY2 was 
quantified using qRT-PCR. Statistical significance was measured using repeated 
measures ANOVA with Tukey’s post hoc comparisons, * p<0.05, ** p<0.01, *** 
p<0.001 when compared to d0 hESC control. Data shown as RQ ± RQ max and 
min. C. Day 3 EBs were incubated with 0.1µM - 50 µM of Forskolin (n=3, 
independent experiments) and relative intracellular cAMP levels were measured. 
Response expressed as % Max response observed.  
ANOVA p>0.5 ANOVA p<0.001 
*** 
ANOVA p>0.5 ANOVA p<0.001 
*** 
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5.3.3 Gene expression profiles during hESC-EC differentiation 
after Forskolin treatments. 
To assess endothelial, arterial and arterial phenotype related gene expression 
changes after Forskolin treatments, hESC-EC differentiation media was 
supplemented with 1µM, 2.5µM or 10µM Forskolin on Day 3 and 5 of the 
differentiation. RNA was collected on Day 0, 3, 5 and 7 of the differentiation for 
qRT-PCR analysis. 
Expression of EC and EPC markers CD34, PECAM and CDH5 was not detected in 
pluripotent Day 0 H9 cultures. As expected, expression of all these markers was 
upregulated as early as Day 3 during hESC-EC differentiation (p<0.001 vs Day 0 
control). Further increase of expression was observed as the differentiations 
progressed and on Day 7 Ct of CD34 was 33.6 ±0.4 (p<0.01 vs Day 0 control), Ct 
of PECAM was 31.0 ±0.7 and Ct of CDH5 was 28.3 ±0.8. KDR was expressed on 
Day 0 (Ct 28.6 ±0.5) and its expression increased significantly 13-fold on Day 3 
(p<0.001 vs Day 0, Ct 26.2 ±0.9) and remained steady till the end of the 
differentiation. 
Genes used as markers for arterial commitment were detected in pluripotent 
cultures on Day 0 with Ct values of 27.4 ±0.2 for HEY2, 34.7 ±0.6 for DLL4, and 
28.1 ±0.3 for EFNB2. In contrast to the H1 and RC-11 differentiation data 
presented in the previous section, HEY2 expression remained comparable 
throughout the differentiation. DLL4 expression increased approximately 100-
fold on Day 5 and 200-fold on Day 7 with Ct values decreasing to 27.8 ±0.9. 
EFNB2 expression increased 6-fold on Day 3 (p<0.001 vs Day 0) and remained 
steady till Day 7 with Ct values of 27.2 ±0.2. In contrast, venous commitment 
gene EPHB4 expression increased only slightly after day 0 of hESC-EC 
differentiation with Ct values between 30.1 ±0.4. 
The data presented in this chapter shows that expression of MSX1 was not 
detected in pluripotent cells and was strongly upregulated more than 200-fold 
on Day 3 of hESC-EC differentiation (p<0.01 vs Day 0, Ct of 31.1 ±0.5) and 
remained upregulated till Day 7 albeit at lower levels with Ct of 33.7 ±0.7. In 
contrast, both PRDM16 and TOX2 had low expression levels in pluripotent H9, 
and their expression was further reduced 4-fold (p<0.01 vs Day 0) and 2-fold 
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(p<0.05 vs Day 0) accordingly during mesoderm induction on Day 3. PRDM16 was 
upregulated on Day 7 4-fold (p<0.001 vs Day 0, Ct 32.3 ±0.9), while TOX2 was 
upregulated 3-fold on Day 3 (p<0.001 vs Day 0) and 8-fold on Day 7 (p<0.001 vs 
Day 0) reaching Ct of 28.0 ±0.3. 
Overall, Forskolin treatments did not significantly alter PECAM, CDH5, KDR, 
DLL4, EFNB2, EPHB4, PRDM16, TOX2 and NANOG gene expression levels on Day 5 
and 7 of the differentiation. A trend of increased CD34 expression was observed 
in Forskolin treated differentiations with Ct values of 31.7 ±1.0 vs 30.8 ±1.0 on 
Day 5 and 33.6 ±0.4 vs 32.0 ±0.6 on Day 7 in control vs 10µM Forskolin treated 
differentiations accordingly). HEY2 expression was steady during the 
differentiation, which is in contrast to observations in H1 and RC-11, and was 
significantly reduced two-fold on Day 7 in differentiations treated with 10µM 
Forskolin (Ct 28.1 ±0.5  vs 29.6 ±0.6, p<0.05 vs control). 
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Figure 35: Gene expression changes in response to Forskolin treatment in H9. 
The differentiation media was supplemented with 1µM, 2.5µM or 10µM Forskolin on 
Day 3 and 5 of the differentiation. RNA was collected on Day 0, 3, 5 and 7 of the 
differentiation, followed by qRT-PCR analysis. Statistical significance was measured 
using repeated measures ANOVA with Tukey’s post hoc comparisons, # p<0.05, 
## p<0.01, ### p<0.001 when compared to D0, all non-significant when compared 
to D5 or D7 control, as appropriate. Data shown as RQ to Day 0 ± RQ max and min. 
Continued on the next page. 
For all graphs, unless indicated 
otherwise:  
 
ANOVA p<0.001 when comparing day of 
the differentiation. 
 
ANOVA p>0.05 for Forskolin treatments. 
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Figure 35 (cont.): Gene expression changes in response to Forskolin 
treatment in H9. The differentiation media was supplemented with 1µM, 2.5µM or 
10µM Forskolin on Day 3 and 5 of the differentiation. RNA was collected on Day 0, 
3, 5 and 7 of the differentiation, followed by qRT-PCR analysis. Statistical 
significance was measured using repeated measures ANOVA with Tukey’s post hoc 
comparisons, # p<0.05, ## p<0.01, ### p<0.001 when compared to D0, * p<0.05, 
** p<0.01, *** p<0.001 when compared to D5 or D7 control, as appropriate. Data 
shown as RQ to Day 0 ± RQ max and min. Continued on the next page.  
  
For all graphs, unless indicated 
otherwise:  
 
ANOVA p<0.001 when comparing day of 
the differentiation. 
 
ANOVA p>0.05 for Forskolin treatments. 
 
 
 
 
ANOVA day p>0.05 
 
 
 
ANOVA treatment p<0.05 
 
 
 
# 
 
 
 
ANOVA day p<0.05 
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Figure 35 (cont.): Gene expression changes in response to Forskolin 
treatment in H9. The differentiation media was supplemented with 1µM, 2.5µM or 
10µM Forskolin on Day 3 and 5 of the differentiation. RNA was collected on Day 0, 
3, 5 and 7 of the differentiation, followed by qRT-PCR analysis. Statistical 
significance was measured using repeated measures ANOVA with Tukey’s post hoc 
comparisons, # p<0.05, ## p<0.01, ### p<0.001 when compared to D0, * p<0.05, 
** p<0.01, *** p<0.001 when compared to D5 or D7 control, as appropriate. Data 
shown as RQ to Day 0 ± RQ max and min. 
  
 
 
 
For all graphs, unless indicated 
otherwise:  
 
ANOVA p<0.001 when comparing day of 
the differentiation. 
 
ANOVA p>0.05 for Forskolin treatments. 
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5.3.4 Effect of Forskolin on EC marker expression during hESC-
EC differentiation. 
While no gene expression changes in response to Forskolin treatment were 
observed, it cannot be excluded that hESC-EC differentiation cell phenotypes 
were altered via posttranscriptional mechanisms. Therefore, EC and EPC surface 
marker expression changes in response to increased intracellular cAMP levels 
were assessed. In these experiments, hESC-EC differentiation media was 
supplemented with 1µM, 2.5µM or 10µM Forskolin on Day 3 and 5 of the 
differentiation. Surface marker expression was analysed by FC on Day 5 and 7 of 
the differentiation. 
On Day 5, 19.9 ±3.1 % of cells stained double-positive for EPC markers CD34 and 
CD309 and 19.9 ±2.0 % cells expressed EC markers CD31 and CD144 (Figure 36). 
Forskolin treated cultures showed a trend of increased % of cells expressing EPC 
markers, reaching 30.6 ±1.2 % CD34+ CD309+ cells in 10µM Forskolin treated 
differentiations (p=0.07 vs DMSO). EC marker expression was significantly 
increased in 2.5µM and 10µM Forskolin treated cultures, reaching 32.0 ±1.8 % 
cells expressing both CD31 and CD144 (10µM Forskolin, p<0.01 vs DMSO). 
As shown in Figure 37a, around 18.1 ±5.0 % of cells expressed EPC markers in 
control and the marker expression was comparable between each of the 
experimental conditions on Day 7. In contrast, increased EC marker expression 
was observed with Forskolin treatments and reached 31.4 ±3.9 % CD31+ CD144+ 
cells in 10µM Forskolin treated differentiations, compared to 19.4 ±0.8 % in 
DMSO control (p<0.01). It was observed that the increase in CD31+ CD144+ % was 
mainly due to increase in cells expressing CD144 at a low level as illustrated in 
Figure 38. The analysis of this population (Figure 37b) confirmed a dose 
dependent Forskolin effect increasing % of Cd144low CD31+ cells (4.4 ±0.5 % 
control to 12.8 ±2.4 % 10µM Forskolin, p<0.01). However, 10µM Forskolin 
treatments, but not lower concentrations, also showed a trend of increased 
Cd144high CD31+ % (15.7 ±0.4 % vs 21.1 ±3.5 %, p=0.15 vs control). 
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Figure 36: Endothelial marker expression changes in response to Forskolin 
treatments in H9 on Day 5 of hESC-EC differentiation. The differentiation media 
was supplemented with 1µM, 2.5µM or 10µM Forskolin (FSK) on Day 3 of the 
differentiation. Surface marker expression was analysed by FC on Day 5 (n=3, 
independent experiments) of the differentiation. 
ANOVA p>0.05 
 
 
 
ANOVA p<0.01 
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Figure 37: Endothelial marker expression changes in response to Forskolin 
treatments in H9 on Day 7 of hESC-EC differentiation. The differentiation media 
was supplemented with 1µM, 2.5µM or 10µM Forskolin (FSK) on Day 3 and 5 of the 
differentiation. A. EC (n=5, independent experiments) and EPC (n=3, independent 
experiments) surface marker expression was analysed by FC on Day 7 of the 
differentiation. B. CD144+ CD31+ population observed on Day 7 can be subdivided 
in two populations with low CD144 expression (CD144low) and high CD144 
expression (CD144high) as illustrated. Statistical significance was measured using 
repeated measures ANOVA with Tukey’s post hoc comparisons, * p<0.05, 
** p<0.01, *** p<0.001 when compared to DMSO control. 
ANOVA p>0.05 
 
 
 
ANOVA p<0.01 
 
 
 
ANOVA p<0.01 
 
 
 
ANOVA p>0.05 
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Figure 38: Endothelial marker expressing populations observed on Day 7 in 
H9 hESC-EC differentiations treated with Forskolin. The differentiation media 
was supplemented with 1µM, 2.5µM or 10µM Forskolin (FSK) on Day 3 and 5 of the 
differentiation. Surface marker expression was analysed by FC on Day 7 of the 
differentiation (n=3, independent experiments) as shown in Figure 37, 
representative plots shown. Two populations were observed with low CD144 
expression (CD144low) and high CD144 expression (CD144hi) as illustrated.  
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5.4 Discussion 
In summary, the data presented in this chapter showed that arterial marker 
HEY2 but not venous marker EPHB4 expression was upregulated during hESC-EC 
differentiations in H1 and RC-11. Increase in intracellular cAMP levels after 
Forskolin treatments was evaluated in H9. This was followed by gene expression 
analysis, which showed that Forskolin treatments did not increase endothelial, 
arterial or arterial associated gene expression during hESC-EC differentiations 
with H9. Finally, surface marker comparison between Forskolin treated and 
untreated differentiations was performed and showed that Forskolin treatments 
increased % cells expressing EC markers, mainly via increase in Cd144low CD31+ 
population. 
HESC-EC differentiation protocol generates cells expressing EC markers CD144 
and CD31 in clinically relevant conditions. It has been speculated, that these 
cells would be superior to mixed adult cell populations currently trialled for 
therapeutic angiogenesis. However, EC further sub-specify in arterial and venous 
phenotypes, which differ in their gene expression profiles (Aranguren et al., 
2013; Chi et al., 2003), responses to vascular growth factors (Blebea et al., 
2002) and secretory profiles (Sriram et al., 2015). It can be proposed that some 
endothelial phenotypes might be superior for therapeutic angiogenesis. This is 
further supported by previous observations showing that arterial EC outperform 
venous EC in in vitro scratch wound assays (Sriram et al., 2015), and form denser 
capillary networks than mixed EC populations in in vivo Matrigel plug assays 
(Rufaihah et al., 2013). Therefore, inducing arterial phenotypes during hESC-EC 
differentiation represents an attractive approach for therapeutic angiogenesis. 
NOTCH signalling is essential for arterial specification and mice mutant for 
components of NOTCH signalling pathway display abnormal vascular 
development and lack arterial marker expression (Krebs et al., 2010, 2000; 
Swiatek et al., 1994). HEY2 acts downstream from NOTCH1 in vascular 
remodelling (Fischer et al., 2004) and activates arterial gene expression (Chi et 
al., 2003). Additionally, Aranguren et al. (2013) has showed that HEY2 is one of 
the key TF for restoring arterial phenotype lost upon in vitro culture. A 
preliminary analysis of arterial gene HEY2 expression was performed in H1 and 
RC-11, and EPHB4 expression was used as a control measure for venous 
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differentiation (Gerety et al., 1999). In both cell lines, EPHB4 expression 
remained steady throughout differentiation. In contrast, three to four fold 
increase in HEY2 expression was seen on Day 7. This suggests induction of 
arterial phenotype and activation of NOTCH signalling, however, it is not known 
how the HEY2 expression level compares to expression levels in tissue, and 
further confirmation using a panel of arterial probes, both at gene and protein 
level is required.  
While the role of cAMP signalling has been extensively researched in mature 
endothelial cells, the role of cAMP in endothelial cell development and 
specification remains to be explored. A role for PKA has been suggested in germ 
layer differentiation and downregulation of pluripotency (Yamamizu et al., 
2012a) and cAMP signalling has been reported to contribute to endothelial 
differentiation via ETV2 activation (Shi et al., 2015; Yamamizu et al., 2012b). In 
addition, Yurugi-Kobayashi et al. (2006) presented evidence showing that 
8-bromo-cAMP was required in addition to VEGF for activation of NOTCH 
signalling and subsequent arterial induction during mESC differentiation towards 
endothelial lineages. Later observations proposed catenin beta-1 as the 
complimentary signal for cAMP induced arterial specification (Yamamizu et al., 
2010) and demonstrated a complex consisting of NICD, RBPJ and β-catenin in 
both embryonic and adult murine arteries but not veins (Yamamizu et al., 2010).  
Therefore, it was hypothesised that intracellular cAMP level manipulation could 
be exploited to enhance endothelial differentiation and also drive arterial 
specification in hESC-EC differentiation system. To test this, increase in 
intracellular cAMP levels was evaluated after Forskolin treatments levels during 
hESC-EC differentiation and three Forskolin concentrations (1µM, 2.5µM and 
10µM) were selected for low, submaximal and maximal increase in intracellular 
cAMP. A panel of genes was chosen to investigate pluripotency, endothelial, 
arterial and arterial phenotype related gene expression by qRT-PCR.  
The analysis of gene expression changes during hESC-EC differentiations with H9 
shows that endothelial gene CD31, CD144, CD34 and CD309 expression was 
upregulated during the differentiation, while pluripotency gene NANOG 
expression was strongly downregulated by Day 5, in line with observations 
reported in Chapter 3.  
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In contrast to preliminary data in H1 and RC-11, HEY2 expression remained 
steady in H9 throughout the differentiation. Somewhat unexpectedly, HEY2 was 
expressed in pluripotent hESC in all three cell lines. However, NOTCH pathway 
genes have been reported to be active in pluripotent hESC (Walsh and Andrews, 
2003) and HEY2 expression has also been previously observed in pluripotent H9 
(Yu et al., 2008). It can be speculated that the increase in HEY2 expression was 
lacking in H9 due to higher baseline expression (Ct of 27), when compared to RC-
11 and H1 (Ct of 28 and 29 accordingly), however, it would be important to have 
a comparison to gene expression levels in primary arterial cells. In addition, 
expression of other arterial (EPHB4, DLL4) and venous (EFNB2) markers was 
quantified to gain further insight into endothelial specification during hESC-EC 
differentiation. 
The receptor tyrosine kinase EPHB4 and its ligand ephrinB2 (EFNB2 gene) can be 
used to distinguish between arterial and venous endothelium in the earliest 
stages of the development (Wang et al., 1998). Expression of both EFNB2 and 
EPHB4 was detected in the pluripotent H9. Previously, expression of ephrin 
receptors and ligands has been reported in pluripotent mESCs (Nunomura et al., 
2005), however, the expression and role of EFNB2 and EPHB4 in hESC is unclear 
and was not investigated further as this was not within the scope of this project. 
The expression of EFNB2 was upregulated before plating out on Day 3 of the 
differentiation, while EPHB4 expression increased non-significantly. These 
increases in expression by Day 3 are in line with the reported roles of EFNB2-
EPHB4 axis in EB formation during stem cell differentiations (Li et al., 2009; Z. 
Wang et al., 2004), and primary germ layer separation (N. Rohani et al., 2014). 
Neither the expression of EFNB2 nor EPHB4 was further upregulated later during 
the differentiation with the appearance of the first EC like cells. It is likely that 
EC like cells remain of an embryonic phenotype, indeed, expression of both 
ENFNB2 and EPHB4 has been reported in other differentiation systems 
(Aranguren et al., 2007; Orlova et al., 2013). Additionally, Orlova et al. (2013) 
also observed expression of both EFNB2 and EPHB4 in both cultured HUVECs and 
human umbilical artery endothelial cells, therefore, it can be suggested that 
EFNB2 and EPHB4 expression patters alone are not sufficient to determine 
endothelial specification in in vitro differentiation systems. 
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Observed changes in DLL4 expression might provide additional insight into 
arterial commitment during hESC-EC differentiation. DLL4 marks arterial 
endothelium (Shutter et al., 2000) and is the first NOTCH ligand detected in 
early arterial cells (Chong et al., 2011). DLL4 was strongly upregulated during 
vascular specification phase, when high levels of VEGF are present in the 
differentiation media and this is in line with the proposed role of VEGF in 
inducing DLL4 expression (Wythe et al., 2013). Yet, the increase in DLL4 
expression was not followed by an increase in HEY2 and EFNB2 expression as 
expected (Iso et al., 2006; Li et al., 2007; Rufaihah et al., 2013).  
As discussed above, this could be due to the somewhat higher than expected 
baseline expression of HEY2 and early upregulation of EFNB2. Perhaps the 
heterogeneous nature of the differentiation populations limits the conclusions 
that can be drawn from these observations. To gain a better insight in the 
endothelial specification during hESC-EC differentiation, arterial marker 
expression should be evaluated in a selected population of interest (CD144+). 
Alternatively, it could indicate that the differentiated cells remain embryonic 
and uncommitted to a particular phenotype. Analysis of other markers such as 
SOX17 and NRP-1 for arterial and COUP-TFII and NRP-2 for venous commitment 
(Corada et al., 2013; Herzog et al., 2001; You et al., 2005) is required to confirm 
this. 
Culture in vitro alters endothelial cell phenotype (Müller et al., 2002), and this 
was further confirmed by Aranguren et al. (2013) who demonstrated loss of 
arterial marker expression when comparing freshly isolated and cultured ECs. In 
addition, a range of TFs with altered expression profiles were also identified and 
EMX2, PRDM16, TOX2 and MSX1 were shown to act complimentary to induce near 
full arterial phenotype mimicking freshly isolated cells (Aranguren et al., 2013). 
Therefore, expression of these arterial phenotype associated TF was also 
analysed.  
The data presented in this chapter shows that expression of MSX1 was not 
detected in pluripotent cells and was strongly upregulated on Day 3 of hESC-EC 
differentiation. This is in line with observations describing MSX1 as being 
expressed in mesoderm with roles in extracellular matrix organisation and 
blocking cardiac differentiation (Rao et al., 2016). EMX2 was expressed at a low 
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level on Day 0, was upregulated on Day 5 and this expression was maintained on 
Day 7. The observed expression pattern suggests a role for EMX2 during vascular 
specification. While previously, EMX2 has been described to regulated by WNT 
and BMP signalling in neuronal development (Theil et al., 2002), the role of EMX2 
in vascular development remains to be investigated. 
In contrast, both PRDM16 and TOX2 were expressed in pluripotent H9, and their 
expression was reduced 4-fold and 2-fold accordingly during mesoderm induction 
on Day 3. Roles of PRDM16 and TOX2 in germ layer development have not been 
described, and this data suggests that they might be negatively regulated during 
mesodermal commitment. However, further research into the role of Prmd16 
and TOX2 during mesodermal differentiation was not undertaken as this was not 
within the scope of this project. Expression of both PRDM16 and TOX2 was 
upregulated on Day 5 and 7 of the differentiation, suggesting maintained arterial 
associated phenotype. 
To sum up, upregulation of arterial phenotype associated TF expression was 
observed during hESC-EC differentiation without requiring Forskolin treatments. 
Taken together with the observed DLL4, EFNB2 and HEY2 expression, it can be 
suggested that this indicates an inclination towards a full arterial phenotype, 
however, a more thorough phenotype analysis would be needed to investigate 
this. Additionally, a direct comparison to freshly isolated arterial cells, as well 
as arterial cells after prolonged culture would be needed to confirm that these 
expression levels are relevant to in vivo arterial phenotype described previously 
(Aranguren et al., 2013). 
When evaluating the effects of Forskolin treatments on hESC-EC differentiations, 
the gene expression data reported here shows that 10µM Forskolin treatments 
reduced EMX2 expression 4-fold on Day 5. The presence of a conserved CRE 
sequence in EMX2 gene (Zhang et al., 2005) suggests transcriptional activation by 
cAMP. In addition, EMX2 expression has been reported to be activated by BMP 
and WNT signalling (Theil et al., 2002), both of which are positively regulated by 
cAMP (Hino et al., 2005; Ohta et al., 2008). In contrast, the data reported in this 
chapter shows no positive effect of Forskolin on EMX2 expression levels. This 
suggests that cAMP alone is not sufficient to induce EMX2 expression during 
hESC-EC differentiation. Given that EMX2 expression is comparable between 
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treated and untreated differentiations on Day 7, it can be suggested that the 
observed decreased expression on Day 5 is not biologically relevant. Further 
research is required to evaluate the mechanisms underlying this and confirm this 
observation in other hESC cell lines. 
In addition, 10µM Forskolin treatments reduced HEY2 expression two-fold on 
Day 7. Interestingly, a similar trend was observed in 1µM and 2.5µM treated 
differentiations. Taken together with the lack of EFNB2 upregulation and EPHB4 
downregulation, it appears that NOTCH signalling by cAMP and did not induce 
arterial phenotype in hESC-EC differentiation. This is in contrast to previous 
reports showing increased expression of NOTCH1 in response to cAMP stimulation 
(Rufaihah et al., 2013; Sivarapatna et al., 2015), yet, expression of HEY2, which 
is downstream from NOTCH1 (Fischer et al., 2004), was not reported. 
Additionally, cAMP has been reported to activate NOTCH signalling in mature 
human monocytes (Larabee et al., 2013), suggesting that cAMP-NOTCH axis is 
conserved across multiple cell types.  
The observed differences can be explained by the differentiation systems used. 
Indeed, serum was used both in human (Rufaihah et al., 2013; Sivarapatna et 
al., 2015) and murine (Yamamizu et al., 2012a; Yurugi-Kobayashi et al., 2006) 
differentiation systems reporting cAMP induced NOTCH activation. Recently it 
has been demonstrated that expression of HEY1 and HEY2, but not other NOTCH 
target genes such as EPFNB2 and DLL4, is induced by serum via activation of BMP 
signalling in endothelial cells (Wöltje et al., 2015). This raises an interesting 
possibility (Figure 39) that cAMP simulation acts in addition to BMP to induce 
HEY2 expression and promote arterial phenotype and, possibly, activate NOTCH 
signalling (Hermkens et al., 2015; Rowlinson and Gering, 2010). As serum was 
not used in hESC-EC differentiation system (Figure 39a), such effect would be 
absent, explaining the lack of NOTCH and arterial phenotype gene upregulation. 
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Figure 39: Proposed relationship between intracellular cAMP and induction of 
NOTCH signalling and subsequently arterial phenotypes. A. In the absence of 
serum cAMP suppresses SHH signalling, inhibiting HEY2, resulting in insufficient 
NOTCH signalling activation for induction of arterial phenotypes. B. When serum is 
present in the differentiation media, expression of HEY2 is upregulated, possibly via 
BMP4 signalling, subsequently contributing to NOTCH signalling activation and 
induction of arterial phenotype. 
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Indeed, sonic hedgehog (SHH) - VEGF axis activates NOTCH signalling during 
vascular development in zebrafish (Lawson et al., 2002) and VEGF signalling also 
contributes to the expression of HEY2 directly by activating HEY2 promoter 
(Hayashi and Kume, 2008). It has been previously demonstrated that increased 
cAMP levels can inhibit SHH signalling (Noveen et al., 1996), thus, it can be 
proposed that, in the absence of serum, increased intracellular cAMP levels 
reduce HEY2 expression levels via inhibition of SHH and subsequently VEGF 
signalling. In contrast, in the presence of serum (Figure 39b), cAMP potentiates 
BMP4 signalling (Ohta et al., 2008; Wöltje et al., 2015) which induces Hey2 
expression that can subsequently induce NOTCH as seen in hematopoietic 
differentiation systems. In addition, cAMP can also increase RBPJ expression 
(Larabee et al., 2013), potentially further aiding induction of arterial phenotype 
together with NOTCH and VEGF signalling (Yamamizu et al., 2010).  
In contrast, a trend of increased CD34 expression was observed in Forskolin 
treated cultures, however, this did not reach statistical significance and surface 
marker expression data is needed to draw any conclusions. No other significant 
differences were seen in endothelial progenitor (KDR), endothelial (PECAM, 
CDH5), arterial (HEY2 and EFNB2) and arterial phenotype associated (DLL4, 
EMX2, PRDM16, TOX2) gene expression. Venous (EPHB4) and pluripotency 
(NANOG) gene expression was also comparable between the experimental 
conditions. Taken together, this suggests that an increase in intracellular cAMP 
levels does not induce NOTCH signalling and arterial phenotype, nor activate 
expression of arterial associated genes in this differentiation system with H9. 
This differs from observations using mESC differentiation models (Yamamizu et 
al., 2012b, 2010; Yurugi-Kobayashi et al., 2006) and a report using hIPSC cells, 
where Rufaihah et al. (2013) demonstrated that high concentrations of VEGF 
upregulate arterial gene expression and downregulate venous gene expression 
during endothelial hIPSC differentiation, and that this effect was amplified in 
8-bromo-cAMP treated cultures. More recently, Sivarapatna et al.(2015) reported 
similar observations in another hIPSC differentiation model and showed that 
8-bromo-cAMP increased KDR, EFNB2 and expression while reducing the 
expression of EPHB4.  
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There are multiple differences between the experimental approaches that could 
explain this. First and foremost, both reports evaluated sorted CD31+ cells that 
had been differentiated for at least 14 days. These cells represent a homogenous 
cell population that might exhibit a more mature phenotype and different gene 
expression profiles, potentially including expression of NOTCH pathway related 
genes. In addition, the mixed nature of hESC-EC differentiation increases the 
variability and background noise in qRT-PCR experiments, possible masking any 
effect that Forskolin had on the endothelial marker expressing cells present in 
the differentiation culture. To draw conclusions from these observations, 
changes in gene expression would need to be evaluated in sorted cells after 
Day 7 of hESC-EC differentiation. 
In addition, both differentiation approaches used serum in the differentiation 
media. Serum can contribute to signalling during the differentiation and has 
been shown to interact with NOTCH signalling in endothelial cells (Wöltje et al., 
2015). It can be speculated that cAMP acts complimentary to growth factors 
present in serum to induce arterial phenotype. As serum was not used during 
hESC-EC differentiations, the increased intracellular cAMP levels alone would not 
be sufficient for such effect.  
Alternatively, it has to be considered that Forskolin activates adenylyl cyclase to 
increase intracellular cAMP levels and, thus, depends on its expression and 
activity, while cell membrane soluble cAMP analogues used in the previous 
publications can active downstream effectors, for example PKA and EPAC, 
directly (Insel and Ostrom, 2003; Lane-Ladd et al., 1997). Absolute intracellular 
cAMP levels here were not measured after Forskolin treatments during hESC-EC 
differentiation, therefore, it cannot be excluded that the intracellular cAMP 
levels were lower than in the previously reported experiments and not sufficient 
to induce arterial phenotype gene expression. Repeating the experiments using 
comparable 8-bromo-cAMP concentrations to the ones reported in the previous 
publications would be necessary to confirm this. Additionally, to account for any 
off target effects of Forskolin, a biologically inactive Forskolin analogue 
1,9-Dideoxyforskolin should also be included as an additional control. 
An increase in endothelial surface marker expression was observed in Forskolin 
treated cultures. To gain a better insight, additional analysis of Day 5 and 7 
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surface marker expression was performed. A trend of increased EPC marker CD34 
and CD309 expression was observed on Day 5 and, in contrast to gene expression 
data discussed above, increased EC marker CD144 and CD31 expression was 
observed on both Day 5 and Day 7. The CD144+ CD31+ population observed on 
Day 7 could be further subdivided in two separate populations, depending on 
CD144 expression levels. The increase in CD31+ CD144+ cell % was mainly due to 
increase in Cd144low cell %, even though a trend of increased CD144high cell % was 
observed increase in the 10µM Forskolin treated differentiations.  
A non-significant increase EPC marker CD34 and CD309 expression was observed 
in Forskolin treated hESC-EC differentiation cultures both at gene and protein 
level. This is in line with the gene expression data reported in this chapter and 
previously described role of cAMP response element in ETV2 activation (Shi et 
al., 2015), which subsequently induces expression of endothelial gene expression 
programmes (Elcheva et al., 2014; Lee et al., 2008; Morita et al., 2015; Shi et 
al., 2014). In addition, Negrotto et al. (2006) have shown that cAMP acts via PKA 
and PI3K to prevent apoptosis of human umbilical blood derived CD34+ 
progenitor cells, in line with the observed increase in CD34+ CD309+ % on Day 5 
of hESC-EC differentiation. 
Previously, Forskolin treatments have been reported to increase EC gene PECAM  
and CDH5 mRNA expression in hIPSC differentiation model, however, surface 
marker expression was not reported (Rufaihah et al., 2013). More recently, 
Forskolin has also been used to facilitate highly efficient EC differentiation, 
however, the underlying mechanisms were not investigated (Patsch et al., 2015). 
Interestingly, the data reported in this chapter does not show an increase in 
PECAM and CDH5 gene expression levels, while increase in % cells expressing 
these markers was observed using FC. This suggests that increase in the 
intracellular cAMP levels alter post-transcriptional processes altering cell surface 
marker expression. 
The previously described VEGF, CD144 and cAMP interactions could be used to 
explain this observation. High levels of VEGF have been reported to disrupt 
endothelial adherens junctions (Mirzapoiazova et al., 2006) and stimulate CD144 
endocytosis (Gavard and Gutkind, 2006), without altering intracellular cAMP 
levels (Mirzapoiazova et al., 2006). Forskolin mediated activation of adenylyl 
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cyclase stimulates both PKA and EPAC (de Rooij et al., 1998), and EPAC aids 
endothelial CD144 junction formation (Fukuhara et al., 2005; Kooistra et al., 
2005). Thus, it can be proposed that the increased intracellular cAMP levels 
countered the negative effects of high VEGF concentrations on CD144 cell 
surface expression resulting in higher CD144 surface expression as observed in 
Forskolin treated differentiations both on Day 5 and Day 7 of the differentiation. 
It can be speculated that the observed Cd144low population becomes CD144- in 
the absence of Forskolin. 
In addition, CD144 plays a critical role in VEGF mediated endothelial cell survival 
(Carmeliet et al., 1999a). Thus, cAMP mediated CD144 surface expression and 
stabilised junctions could contribute to explaining the higher % of CD31+ and 
CD144+ cells observed at the end of hESC-EC differentiation. This is also in line 
with very recent observations by Saxena et al. (2016) who demonstrated that 
EPAC inhibition reduces endothelial cell yield in a hematopoietic hIPSC 
differentiation system. To confirm the role of EPAC in these observations, these 
experiment should be repeated using EPAC specific cAMP analogues, and ICC 
staining should be undertaken to evaluate CD144 internalisation and cell 
apoptosis. 
However, VEGF-CD144-cAMP axis can also have a detrimental effect on mature 
EC proliferation (Caveda et al., 1996; D’Angelo et al., 1997). Whether this 
applies to immature hESC-EC remains unknown, yet, the observed increase in 
CD31+ CD144+ % cells suggests that increased intracellular cAMP levels did not 
inhibit cell expansion. However, cells counts and proliferation should be 
evaluated to confirm this. 
Responses to intracellular cAMP levels are further regulated by PDEs (Mika et al., 
2012). Given the positive effects of Forskolin on EC marker expression in hESC-
EC differentiation system, it would be interesting to investigate which PDEs are 
involved in regulating this response. It can be speculated that selectively 
inhibiting PDE isoforms could enhance the differentiation process either in 
addition to or independently from Forskolin stimulation.   
In summary, the data reported in this chapter shows expression of arterial 
markers HEY2, EFNB2 and DLL4 during hESC-EC differentiation. Increase in 
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intracellular cAMP levels did not further enhance the expression of these arterial 
markers, nor TF associated with arterial phenotype. It is speculated that this 
was due to lack of serum in the differentiation media and BMP signalling is 
proposed as a complimentary signal provided by serum required for induction of 
NOTCH signalling and arterial phenotype. 
However, a trend of increase EPC gene CD34 and KDR expression was observed 
and was confirmed by FC. Interestingly, increase in intracellular cAMP levels 
during hESC-EC differentiation, resulted in higher % of cells expressing both EC 
markers CD31+ CD144+. It was observed that this was mostly due to increase in 
Cd144low population. Here it is proposed that cAMP-CD144-VEGF axis could 
underlie the observed effect. While other methods to induce arterial 
specification in a clinically relevant manner are required, manipulation of 
intracellular cAMP levels represents an attractive approach in enhancing the 
efficacy of this clinically relevant hESC-EC differentiation protocol. 
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Chapter 6: The role of the renin angiotensin 
system in hESC differentiation towards endothelial 
lineages. 
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6.1 Introduction 
The description of a pressor compound present in renal extracts marks the 
discovery of the first renin angiotensin system (RAS) component more than 100 
years ago (Basso and Terragno, 2001; Tigerstedt and Bergman, 1898). Years of 
research has uncovered the complexity of the RAS and established it as a central 
circulating hormone system controlling blood pressure, fluid homeostasis and 
cardiovascular disease pathogenesis, that has been successfully targeted 
pharmacologically in various disease processes, reviewed in (Bader, 2010).  
Angiotensin II (Ang II) is the main effector in the RAS and is generated in 
successive steps starting from angiotensinogen, which is constitutively produced 
in liver (Matsusaka et al., 2012). Reduction in fluid volume and subsequent 
changes in sodium chloride concentration are sensed by juxtaglomerular 
apparatus in the kidney and, in response, renin is secreted (Schnermann and 
Briggs, 2013). The enzymatic cleavage of angiotensinogen by renin produces 
angiotensin I which is then converted to Ang II by angiotensin converting enzyme 
(ACE) expressed on the EC surface (Skeggs et al., 1956). 
The majority of the effects of Ang II, such as fluid retention and constriction of 
vascular smooth muscle, are mediated via the classical and predominant 
angiotensin II receptor type 1 (AT1R), a G protein coupled receptor ( Figure 40). 
An alternative receptor, the angiotensin type 2 receptor (AT2R) has a low 
sequence homology (Mukoyama et al., 1993) to the AT1R, yet, has Ang II has a 
similar binding affinity to both AT2R and the AT1R (Dasgupta and Zhang, 2011). 
The AT2R is expressed in the embryo during development and rapidly reduces to 
negligible levels in terminally differentiated adult tissues, however it can be 
re-expressed in adults during pathological processes (de Gasparo et al., 2000; 
Kaschina and Unger, 2003; Santos et al., 2013). The AT2R is reported to 
counteract the actions of AT1R signalling, for example AT2R signalling is 
vasodilatory and also mediates anti-growth effects (Chow and Allen, 2016; 
Nakajima et al., 1995).  
Alongside the classical RAS a counter-regulatory axis has been identified, 
centred on an ACE homologue, angiotensin converting enzyme 2 (ACE2) (Tipnis 
et al., 2000). ACE2 cleaves Ang I generating Angiotensin-(1-9) which is then 
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converted to Angiotensin-(1-7) [Ang-(1-7)] by ACE (Donoghue et al., 2000). 
Alternatively ACE2 can also convert Ang II directly to Ang-(1-7) (Vickers et al., 
2002). While the reports of the biological activity of Ang-(1-7) are more than two 
decades old (Schiavone et al., 1988), Mas, the receptor for Ang-(1-7), has been 
identified only more recently (Santos et al., 2003). The ACE2/Ang-(1–7)/Mas axis 
not only counters the effects of Ang II/AT1R signalling, but also has a range of 
independent cardiovascular, renal and metabolic effects (Santos et al., 2013). 
Given the central role of the RAS in regulation of cardiovascular homeostasis, it 
is not surprising that pharmacological approaches targeting the RAS have been 
widely successful. ACE inhibitors were the first to be introduced clinically with 
the discovery of captopril (Ferguson et al., 1977) and still remain the first line 
choice for the treatment of hypertension. Later, Losartan was the first AT1R 
antagonist introduced (Duncia et al., 1992), and more recently the first non-
peptide renin inhibitor, aliskiren, has been developed (Stanton et al., 2003). 
These drugs have been widely used for treatment of hypertension and have been 
shown to reduce the mortality and morbidity in congestive heart failure and 
chronic renal diseases (Bader, 2010; Williams, 2016). Furthermore, new 
generation angiotensin receptor blockers offering higher potency and longer 
effect duration have reached the clinic, for example fimasartan which is a 
derivative of Losartan (Lee and Oh, 2016), and novel therapeutic approaches 
exploiting the RAS are being actively pursued with novel compounds, for 
example dual-acting angiotensin receptor-neprilysin inhibitors, holding a lot of 
promise for future therapies (Gori et al., 2016). 
RAS components have also been described in various organs and tissues, for 
example, brain, kidney and heart, defining a local RAS as reviewed by Bader et 
al. (2010) and might underlie some of the observed therapeutic benefits of ACE 
inhibitors and AT1R blockers (Campbell, 2014; De Mello and Frohlich, 2014). 
Indeed, the efficacy of treatments targeting cardiac RAS has been demonstrated 
in a clinical setting supporting the use of ACE inhibitors in the treatment of 
myocardial infarction (Düsing, 2016; Pfeffer et al., 1992). 
Additionally, it can be suggested that a local RAS also is formed in the 
vasculature as angiotensinogen has been described to be expressed in the rat 
aorta (Campbell and Habener, 1986), the presence of renin has been 
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demonstrated in endothelial cells (Lilly et al., 1985) and is closely associated 
with angiogenesis during development (Rider et al., 2015), while ACE has been 
described as an early marker for lymphatic, hematopoietic and endothelial cell 
development (Jokubaitis et al., 2008; Sinka et al., 2012; Zambidis et al., 2008). 
Additionally, intracellular synthesis of Ang II has been described in endothelial 
cells (Kifor and Dzau, 1987), therefore, it is likely that the RAS is active both 
during endothelial development, as well as during endothelial differentiation in 
vitro. 
Ang II receptors are differentially expressed during development. In general, the 
AT2R is expressed during development in cardiovascular and renal tissues and 
gets downregulated after birth, while AT1R expression appears in late foetal 
development and is further upregulated during maturation (Vinturache and 
Smith, 2014). This also holds true during the development of vasculature and 
expression of the AT2R has been demonstrated in foetal but not adult microswine 
and rat aorta, while AT1R expression progressively increased with age (Bagby et 
al., 2002; Shanmugam et al., 1996).  
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Figure 40: Overview of the renin angiotensin system. The majority of Ang II 
effects are mediated via Angiotensin II receptor type 1 (AT1R), however Angiotensin 
II receptor type 2 (AT2R) and Mas receptor (MasR) are expressed in various 
developmental and pathological processes and form a counter-regulatory 
angiotensin signalling axis. Adapted from: Gaspari et al. (2012). 
The presence of an active RAS in blood vessels and differential regulation of Ang 
II receptor expression during development suggests that the RAS may also 
regulate endothelial developmental processes. While no abnormalities in 
vascular development and angiogenesis have been reported in AT1R and AT2R 
knockout mice (Biermann et al., 2012; Tsuchida et al., 1998), a role for the RAS 
has been described in mesodermal development, with Ang II increasing KDR 
expression in a murine iPSC differentiation model (Ishizuka et al., 2012), and 
hematopoietic lineage development, with ACE inhibition resulting in diminished 
erythropoiesis (Savary et al., 2005). In addition, Zambidis et al.(2008) have also 
reported that the local RAS can be manipulated in a hESC haematopoietic 
differentiation system to induce endothelial phenotypes. They showed that a 
majority of re-plated hemangioblast colonies generated endothelial colonies 
after AT2R antagonist PD-123319 treatment, while the AT1R antagonist Losartan 
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generated hematopoietic colonies in treated cultures (Zambidis et al., 2008). 
However, further research is necessary to confirm and expand on these 
observations. 
Observed effects of a local RAS on EPC in bone marrow provide further evidence 
for a role in progenitor cell biology. RAS components have been demonstrated in 
bone marrow (Strawn et al., 2004) and the effects of angiotensin signalling on 
hematopoietic and EPC have been receiving increasing attention (Durik et al., 
2012). Signalling via AT1R appears to have a dual effect on the EPC, depending 
on the duration of the stimulation. Acute activation of the AT1R in addition to 
VEGF signalling has been reported to increase proliferation, reduce apoptosis 
and upregulate KDR expression in bone marrow-derived EPC, mostly mediated 
via PI3K/AKT and nitic oxide signalling (Fujiyama et al., 2001; Imanishi et al., 
2004; Yin et al., 2008).  
However, chronic AT1R stimulation induces apoptosis and senescence, reduces 
EPC outgrowth from isolated progenitor cells, and reduces the angiogenic 
potential of the EPC, mediated via increased oxidative stress and activation of 
apoptosis signalling, for example Caspase-3 (Endtmann et al., 2011; Imanishi et 
al., 2008, 2005). Taken together, it can be speculated that a local RAS may 
mediate similar effects on endothelial progenitors during development or hESC 
differentiation and, thus, acute activation of the AT1R could aid hESC-EC 
differentiation by upregulating KDR expression and increasing EPC proliferation, 
while intrinsic autocrine Ang II production should be limited to minimise 
oxidative stress and apoptosis. 
Similarly, members of the counter-regulatory axis of the RAS may also contribute 
to endothelial differentiation. This is supported by recent observations by 
Ikhapoh et al. (2015) who reported that signalling via AT2R potentiates VEGF 
signalling and induces endothelial phenotypes in microswine bone marrow 
derived MSCs. However, signalling via AT2R has been shown to decrease AKT and 
eNOS phosphorylation in endothelial cells and exert anti-growth effects 
(Benndorf et al., 2003; Kou et al., 2007; Stoll et al., 1995). 
Furthermore, Ang-(1-7) signalling via the Mas receptor and downstream 
signalling via PI3K/AKT has been shown to increase CD34+ cell proliferation and 
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survival, and counteract the negative effects of Ang II by reducing oxidative 
stress and restoring nitric oxide production (Heringer-Walther et al., 2009; 
Jarajapu et al., 2013; Papinska et al., 2015; Singh et al., 2015; Y. Wang et al., 
2010; Xiao et al., 2015). Therefore, it can be proposed that both AT2R and Mas 
receptor signalling can also be exploited to enhance hESC-EC differentiation.  
In summary, the observations described above suggest that a local RAS is active 
during endothelial development and can potentially alter the differentiation of 
EPC and EC. Therefore, we hypothesised that targeting components of the RAS 
could be exploited during hESC-EC differentiation to increase endothelial cell 
yields and give further insight into its role during endothelial development. 
Here, we evaluated the expression of RAS components during hESC-EC 
differentiation and compared endothelial marker expression and cell numbers 
after the use of Ang II, Ang-(1-7) and the AT2R agonist CGP-42112A (Hines et al., 
2001), the AT1R inhibitor Losartan and the AT2R inhibitor PD-123319 (Dudley et 
al., 1990) during hESC-EC differentiation.   
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6.2 Aims 
The aims of this chapter were: 
 Measure the expression of AT1R, AT2R and Mas RNA levels during hESC-EC 
differentiation. 
 Evaluate the effects of Ang II, Ang 1-7 and CGP-42112A treatments during 
hESC-EC differentiation. 
 Examine the role of the AT1R and AT2R during hESC-EC differentiation 
using the receptor-specific antagonists losartan, PD-123319 and PD-12377. 
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6.3 Results 
6.3.1 Expression of the RAS receptors during hESC-EC 
differentiation. 
To assess the RAS component gene expression during hESC-EC differentiation, 
hESC were differentiated as described (Methods section 2.3), and RNA was 
collected for RT-PCR analysis on day 0, and days 2 - 7 for H1 and RC-11, and on 
day 0 and days 3, 5 and 7 for H9.  
In RC-11, AT1R expression was detected at a low level (Figure 41a). In contrast, 
the expression of AT1R was not detected on day 0 of the differentiation in both 
H1 and H9 (Figure 41b and Figure 41c respectively). Low expression of AT1R was 
detected on day 2 in H1 and day 3 in H9. During the hESC-EC differentiation, 
AT1R expression was progressively upregulated reaching statistical significance 
on day 3 in H9 (7-fold upregulation, p<0.05 vs day 0), day 5 in H1 (12-fold 
upregulation, p<0.05 vs day 0) and day 6 in RC-11 (6-fold upregulation, p<0.05 vs 
day 0). By day 7 of the differentiation, AT1R was expressed in all three cell lines, 
reaching 36-fold upregulation in RC-11 (Figure 41a, Ct 32.0 ±0.3), 460-fold 
upregulation in H1 (Figure 41b, Ct 31.8 ±1.3) and 150-fold upregulation in H9 
(Figure 41c, Ct 33.4 ±0.3), all these changes were statistically significant when 
compared to day 0 (p<0.001). 
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Figure 41: Expression of the AT1R during hESC-EC differentiation. RNA was 
collected on day 0, and days 2 - 7 of hESC-EC differentiation with RC-11 (n=3, 
independent experiments) and H1 (n=3, independent experiments), and on day 0, 3, 
5 and 7 of hESC-EC differentiation with H9 (n=3, independent experiments). 
Expression of the AT1R was quantified using qRT-PCR. Statistical significance was 
evaluated using repeated measures ANOVA with Tukey’s post hoc comparisons, 
* p<0.05, ** p<0.01, *** p<0.001 when compared to d0 hESC control. Data shown is 
RQ ± RQ max and min. 
  
ANOVA p<0.001 
 
 
 
ANOVA p<0.001 
 
 
 
ANOVA p<0.01 
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AT2R expression was detected in all three cell lines at a low level. The 
expression of the AT2R was strongly upregulated 15-fold on day 3 in RC-11 
(Figure 42a, p<0.001 vs day 0) and 60-fold on day 3 in H9 (Figure 42c, p<0.001 vs 
day 0) reaching Ct values of 34.4 ±1.1 and 31.6 ±0.7 respectively. This was 
followed by a rapid downregulation on day 4 in RC-11 (p<0.01 vs day 3) and 
day 5 in H9 (p<0.01 vs day 3) returning to baseline expression levels which 
remained stable till the end of the differentiation. In contrast, in H1 (Figure 
42b) AT2R expression was strongly upregulated 30-fold on day 2 (Ct 32.2 ±0.4, 
p<0.01 vs day 0) and, although slightly lower, upregulation was observed on day 
7 (Ct 33.5 ±0.5, p<0.05 vs day 0).  
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Figure 42: Expression of the AT2R during hESC-EC differentiation. RNA was 
collected on day 0, and days 2 - 7 of hESC-EC differentiation with RC-11 (n=3, 
independent experiments) and H1 (n=3, independent experiments), and on day 0, 3, 
5 and 7 of hESC-EC differentiation with H9 (n=3, independent experiments). 
Expression of the AT2R was quantified using qRT-PCR. Statistical significance was 
evaluated using repeated measures ANOVA with Tukey’s post hoc comparisons, 
* p<0.05, ** p<0.01, *** p<0.001 when compared to d0 hESC control, unless 
indicated otherwise. Data shown is RQ ± RQ max and min. 
  
ANOVA p<0.001 
 
 
ANOVA p<0.001 
 
 
ANOVA p<0.01 
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Mas was expressed in all three hESC cell lines with Ct values of 31.9 ±0.1 in 
RC-11 (Figure 43a), 24.7 ±0.3 in H1 (Figure 43b), and 31.7 ±0.1 in H9 (Figure 
43c). The expression of Mas remained comparable throughout the 
differentiation. 
 
 
Figure 43: Expression of the Mas receptor during hESC-EC differentiation. 
RNA was collected on day 0, and days 2 - 7 of hESC-EC differentiation with RC-11 
(n=3, independent experiments) and H1 (n=3, independent experiments), and on 
day 0, 3, 5 and 7 of hESC-EC differentiation with H9 (n=3, independent 
experiments). Expression of the Mas receptor was quantified using qRT-PCR. 
Statistical significance was evaluated using repeated measures ANOVA with 
Tukey’s post hoc comparisons, all non-significant when compared to d0 hESC 
control. Data shown is RQ ± RQ max and min.  
  
ANOVA p>0.05 
 
 
 
ANOVA p>0.05 
 
 
 
ANOVA p>0.05 
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6.3.2 Angiotensin peptide stimulation during hESC-EC 
differentiation. 
To evaluate effects of RAS receptor activation during hESC-EC differentiation, 
H9 were differentiated towards endothelial lineage (n=3, independent 
experiments) and Ang II (100nM or 1μM, as indicated) or Ang-(1-7) (1μM) 
treatments were applied on days 3 and 5 of hESC-EC differentiation, followed by 
EC (CD31 and CD144) and EPC (CD34 and CD309) surface marker expression 
analysis using FC on day 7. Total cell counts and viability were also assessed.  
On average, 28.8 ± 8.0 % cells expressed both CD144 and CD31 at the end of the 
control differentiations. Data is presented normalised to control differentiations 
to account for the variability between the experiments. There were no 
significant differences in EC, EPC surface marker expression or total counts 
between the treated and control differentiations (Figure 44a-c). 
Additionally, Ang II (100nM) or, to study the role of AT2R, the AT2R agonist 
CGP-42112A (Hines et al., 2001) (100nM) treatments were applied on 
days 0, 2, 3, 5 of H9 hESC-EC differentiation (n=3, independent experiments), 
followed by surface marker expression analysis using FC on day 7 (Figure 44d-f). 
It was observed that 36.9 ±5.1 % of cells expressed EC markers CD31 and CD144 
in control differentiations on day 7. EC, EPC marker expression and total cell 
numbers were not different between control and Ang II or CGP-42112A 
treatment. 
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Figure 44: Assessment of Ang II, Ang-(1-7) and CGP-42112A treatments during 
hESC-EC differentiation. A-C. Angiotensin II (Ang II, 100nM or 1μM) or 
angiotensin-(1-7) (Ang-(1-7), 1μM) treatments were applied on days 3 and 5 of 
hESC-EC differentiation with H9 (n=3, independent experiments) or D-F. 
Angiotensin II (Ang II, 100nM) or the selective AT2R agonist CGP-42112A 
(CGP, 100nM) treatments were applied on days 0, 2, 3, 5 of hESC-EC differentiation 
with H9 (n=3, independent experiments). Populations expressing both EC markers 
CD31 and CD144 or EPC markers CD309 and CD34 were compared using FC on 
day 7 of the differentiation. Statistical significance was evaluated using repeated 
measures ANOVA, all non-significant (ANOVA p>0.05) when compared to d0 hESC 
control. 
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6.3.3 AT1R inhibition during hESC-EC differentiation. 
To examine the role of the AT1R during hESC-EC differentiation, Ang II and the 
AT1R antagonist Losartan (Duncia et al., 1992) alone or in combination were 
added to the differentiation media from day 0 onwards (Figure 45a). Total cell 
counts, viability and EC and EPC surface marker expression was evaluated on day 
5 and day 7 of the differentiation by FC. 
Addition of Ang II did not change EPC/ EC marker expression, total cell counts or 
viability, when compared to the control (Figure 45b). Incubation with Losartan 
only did not change total cell counts and viability compared to controls. 
However, a reduction in the percentage of cells expressing EPC markers CD309 
and CD34 on day 5 in Losartan treated differentiations was observed (10.9 ±1.6 % 
vs 16.9 ± 2.1 %, p<0.05 vs Control, Figure 45c). No differences in expression of 
the EC markers CD144 and CD31 was observed on day 7 (Figure 45b), when 
comparing Losartan treatment to control (24.6 ± 2.1 % vs 28.1 ± 4.9 %, p=0.76).  
Incubation of the cultures with Ang II and Losartan also reduced the percentage 
of cells expressing EPC markers on day 5 in comparison to Ang II alone (15.9 
±3.4 % vs 10.1 ±0.8 %, p<0.05 vs Ang II only, Figure 45c), and a similar reduction 
in the percentage of cells staining positive for EC markers CD144 and CD31 was 
observed on day 7 (18.3 ±2.3 % vs 24.6 ±2.8 %, p<0.05 vs Ang II only, Figure 45b). 
Total cell counts and viability remained comparable between the conditions. 
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Figure 45: Assessment of the effects of blocking the AT1R during hESC-EC 
differentiation. A. Treatment schematic. B-E. Losartan (10μM) and angiotensin II 
(Ang II, 100nM) treatments were applied on days 0, 2, 3, 5 of hESC-EC 
differentiation with H9 (n=3, independent experiments). Populations expressing EPC 
markers CD309 and CD34 were compared using FC on day 5 of the differentiation. 
Total cell counts, viability and populations expressing EC markers CD31 and CD144 
were compared on day 7 of the differentiation. Statistical significance was evaluated 
using repeated measures ANOVA with Tukey’s post hoc comparisons, * p<0.05 
when compared to control, unless indicated otherwise. 
ANOVA p<0.05 
 
 
 
ANOVA p>0.05 
 
 
 
ANOVA p>0.05 
 
 
 
ANOVA p<0.05 
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To confirm the observed effect of the AT1R antagonist Losartan on EPC marker 
expression and to investigate the effect of addition of Losartan earlier during 
differentiation Losartan was added at various time points, followed by EPC and 
EC marker analysis on day 7 (Figure 46a). On average, 34.5 ±4.3 % cells 
expressed EC markers CD31 and CD144 and 30.6 ±1.1 % cells expressed EPC 
markers CD309 and CD34 on day 7 of the control differentiations. In contrary to 
the observed reduction in EPC (day 5) and EC (day 7) marker expressing cell 
percentages in the previous experiment (Figure 45), no other significant 
differences were observed in EC and EPC marker expression or total cells counts 
and viability (Figure 46b-e). 
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Figure 46: Assessment of the effects of blocking the AT1R during various 
stages of hESC-EC differentiation. A. Treatment schematic. B-E. Losartan (Los, 
10μM) treatments were applied as indicated during hESC-EC differentiation with H9 
(n=3, independent experiments). D0 – day 0, D5 – day 5, D7 – day 7 of the 
hESC-EC differentiation. Total cell counts, viability and populations expressing EPC 
markers CD309 and CD34 and EC markers CD31 and CD144 were compared on 
day 7 of the differentiation. Statistical significance was evaluated using repeated 
measures ANOVA with Tukey’s post hoc comparisons, all non-significant. 
ANOVA p>0.05 
 
 
 
ANOVA p>0.05 
 
 
 
ANOVA p>0.05 
 
 
 
ANOVA p>0.05 
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It has been previously suggested that when AT1R is blocked, Ang II may stimulate 
AT2R (Chow and Allen, 2016). To investigate if the observed reduction in the 
percentage of cells expressing EC and EPC markers in differentiations treated 
with Losartan and Ang II was due to signalling via AT2R, an AT2R antagonist 
PD-123319 (Dudley et al., 1990) was added to the differentiation media in 
addition to Ang II and Losartan from day 0 of the differentiation.  
Expression of EC markers CD144 and CD31 was reduced by a fifth on day 7 from 
20.5 ±2.8 % to 16.5 ±3.2 % in differentiations treated with Ang II and Losartan 
(p<0.05 vs Ang II, Figure 47c), and was not significantly different when compared 
to the combination of Ang II, Losartan and PD-123319 (18.3 ±2.7 %, p=0.18 vs Ang 
II and Losartan, Figure 47c). Percentage of cells expressing EPC markers, total 
cell counts and viability remained comparable between the conditions (Figure 
47b, d-e). 
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Figure 47: Effect of antagonism of the AT1R and the AT2R during hESC-EC 
differentiation. A. Treatment schematic. B-E. Losartan (Los, 10μM), angiotensin II 
(Ang II, 100nM) and PD-123319 (PD, 500nM) treatments were applied as indicated 
during hESC-EC differentiation with H9 (n=3, independent experiments). Total cell 
counts, viability and populations expressing EPC markers CD309 and CD34 and EC 
markers CD31 and CD144 were compared on day 7 of the differentiation. Statistical 
significance was evaluated using repeated measures ANOVA with Tukey’s post hoc 
comparisons, * p<0.05 when compared to control. 
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To account for possible differences in the half-life of the added drugs in cell 
culture, differentiations were repeated, with the exception that each drug was 
replenished every 24hr (Figure 48a). A comparable percentage of cells 
expressing EC markers was observed in Ang II and Losartan treated 
differentiations on day 7 (20.4% ±2.4 vs 23.7% ±2.4, p=0.2 vs Ang II only, Figure 
48c). In contrast, the percentage of cells expressing EC markers was significantly 
reduced in differentiations where PD-123319 was added in addition to Ang II and 
Losartan when compared to Ang II treated differentiation (17.4% ±0.7 vs 23.7% 
±2.4, p<0.05 vs Ang II only, Figure 48c). However, the difference was not 
significant in comparison to Ang II and Losartan treated differentiations (17.4% 
±0.7 vs 20.1% ±2.4, p=0.25). Percentage of cells expressing EPC markers, total 
cell counts and viability were comparable between conditions (Figure 48b, d-e). 
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Figure 48: Effect of daily antagonism of the AT1R and the AT2R during 
hESC-EC differentiation. A. Treatment schematic. B-E. Losartan (Los, 10μM), 
angiotensin II (Ang II, 100nM) and PD-123319 (PD, 500nM) treatments were applied 
daily as indicated during hESC-EC differentiation with H9 (n=3, independent 
experiments). Total cell counts, viability and populations expressing EPC markers 
CD309 and CD34 and EC markers CD31 and CD144 were compared on day 7 of 
the differentiation.  Statistical significance was evaluated using repeated measures 
ANOVA with Tukey’s post hoc comparisons, * p<0.05 when compared to control. 
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6.3.4 AT2R inhibition during hESC-EC differentiation. 
To investigate the role of the AT2R during hESC-EC differentiation, the AT2R 
antagonist PD-123319 and Ang II, alone or in combination, were added to the 
differentiation media from day 3 onwards (Figure 49a). Total cell counts, 
viability, EC and EPC surface marker expression was evaluated on days 5 and 7 of 
the differentiation by FC.  
Analysis on day 5, as shown in Figure 49b, revealed that PD-123319 treatment 
did not significantly alter EPC surface marker expression on day 5, with 
12.4 ±0.4 % and 13.5 ±2.0 % cells staining positive for CD309 and CD34 in control 
and PD-123319 treated differentiations respectively. In addition, a slight trend 
for increased total cell numbers was observed on day 5 in Ang II treated 
differentiations (2.1 x106 in Control differentiations vs 2.7 x106 in Ang II treated 
differentiations, Figure 49c), however only two cell counts were taken so more 
repeats are needed to confirm this and determine the statistical significance. 
On day 7, 17.4 ± 3.2 % cells expressed CD144 and CD31 in control (Figure 49d). In 
contrast to the observations on day 5, a significant reduction of total cell 
numbers was observed in Ang II and PD-123319 treated differentiations on day 7 
(1.3 ±0.3 x106 vs 2.7 ±0.3 x106 cells, p<0.05 vs Ang II only, Figure 49e). Thus, the 
total EC yield at the end of the protocol was reduced from 0.5 ± 0.1 x106 cells in 
Ang II treated differentiations to 0.2 ± 0.04 x106 cells in Ang II and PD-123319 
treated differentiations. The viability was 94.0 ±0.8 % in the control and 
remained comparable between the conditions. 
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Figure 49: PD-123319 treatments during hESC-EC differentiation. A. Treatment 
schematic. PD-123319 (PD, 500nM) and angiotensin II (Ang II, 100nM) treatments 
were applied on days 3 and 5 of hESC-EC differentiation with H9 (n=3, independent 
experiments). B-C. Total cell counts# and populations expressing EPC markers 
CD309 and CD34 were compared using FC on day 5 of the differentiation. D-E. 
Total cell counts and populations expressing markers CD31 and CD144 were 
compared on day 7 of the differentiation. Statistical significance was evaluated using 
repeated measures ANOVA with Tukey’s post hoc comparisons, * p<0.05 when 
compared to control, unless indicated otherwise. #n=2 for cell counts on day 5 only 
as first count was not taken. 
ANOVA p>0.05 
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To account for possible off-target effects of PD-123319 (Daugherty et al., 2013; 
Lautner et al., 2013; Tetzner et al., 2016), total cell counts, viability and EC and 
EPC marker expression was compared between differentiations treated with Ang 
II and PD-123319 as above and differentiations treated with Ang II and the 
alternative AT2R antagonist PD-123177 (Wong et al., 1990) (Figure 50a).  
Total CD144+ CD31+ cell counts were significantly reduced on day 7 of the 
differentiation from 0.8 ±0.1 x106 in Ang II treated differentiations to 0.4 ±0.1 
x106 in Ang II and PD-123177, and to 0.4 ±0.004 x106 Ang II and PD-123319 
treated differentiations (both p<0.05 vs Ang II only, Figure 50b). This was mainly 
due to a significant reduction in total cell counts was observed in both Ang II and 
PD-123319 treated differentiations (4.2 ± 0.6 x106 vs 3.0 ± 0.4 x106, p<0.05 vs 
Ang II only) and Ang II and PD-123177 treated differentiations (2.9 ± 0.5 x106 vs 
4.2 ± 0.6 x106, p<0.05 vs Ang II only) (Figure 50c). Viability was comparable 
between the conditions and was 92.8% ± 2.2 in control. EC marker expression 
remained comparable with 20.4 ± 4.1 % cells expressing CD144 and CD31 in Ang II 
only control differentiations, compared to 14.5 ±1.0 % (p=0.37) and 14.9 ±1.8 % 
(p=0.32) in Ang II and PD-123319 or Ang II and PD-123177 treated differentiations 
respectively (Figure 50d). Similarly, EPC surface marker remained comparable 
with 25.0±7.8 %  CD309+ CD34+ cells in Ang II treated differentiations compared 
to 17.4 ±3.1 % (p=0.48) and 15.3 ±0.9 % (p=0.33) CD309+ CD34+ in 
differentiations treated with Ang II and PD-123319, or Ang II and PD-123177 
respectively (Figure 50e).  
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Figure 50: Comparison of PD-123319 and PD-123177 treatments during 
hESC-EC differentiation in the presence of added Ang II. A. Treatment 
schematic. B-E. PD-123319 (PD-319, 500nM), PD-123177 (PD-177, 1μM) and 
angiotensin II (Ang II, 100nM) treatments were applied on days 3 and 5 of hESC-EC 
differentiation with H9 (n=3, independent experiments). Total cell counts, viability 
and populations expressing EC markers CD31 and CD144 and EPC markers 
CD309 and CD34 were compared on day 7 of the differentiation. Statistical 
significance was evaluated using repeated measures ANOVA with Tukey’s post hoc 
comparisons, * p<0.05 when compared to Ang II only control. 
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Next, the experiment was repeated with replenishment of the drugs every 24hrs 
to account for any reduced effects through breakdown of the added drugs. In 
contrast to the data previously described (Figure 49 and Figure 50), CD144+ 
CD31+ cell yield remained comparable between the conditions and was 1.1 ±0.1 
x106 cells in the Ang II treated control differentiations, 0.9 ±0.2 x106 cells in the 
And II and PD-123319 treated differentiations (p=0.33 vs Ang II only) and 1.1 ±0.1 
x106 cells in the Ang II and PD-123177 treated differentiations (p=0.83 vs Ang II 
only) (Figure 51b). Total cell numbers were not decreased by PD-123319 or 
PD-123177 treatments in combination with Ang II, with 4.5 ±0.6 x106 cells in Ang 
II, 4.1 ±0.6 x106 in Ang II and PD-123319, and 4.6 ±0.7 x106 in Ang II and PD-
123177 treated differentiations (Figure 51c).  
Both EC marker CD31 and CD144 expression remained comparable between the 
conditions with 25.4 ±0.9 % in Ang II, 23.1 ±1.3 % in Ang II and PD-123319 and 
23.6 ±2.7 % in Ang II and PD-123177 treated differentiations (Figure 51d). 
Similarly, EPC marker CD309 and CD34 expression was comparable between each 
experimental condition with 25.4 ±0.69 %, 23.6 ±2.7 % and 23.1 ±1.3 % CD309+ 
CD34+ cells in Ang II, Ang II and PD-123319, and Ang II and PD-123177 treated 
differentiations respectively (Figure 51e). The viability was comparable between 
the each experimental condition and was 87.9 ±1.0 % in Ang II treatment group.  
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Figure 51: Comparison of daily PD-123319 and PD-123177 treatments during 
hESC-EC differentiation in the presence of added Ang II. A. Treatment 
schematic. B-E. PD-123319 (PD-319, 500nM), PD-123177 (PD-177, 1μM) and 
angiotensin II (Ang II, 100nM) treatments were applied daily between days 3 to 7 of 
hESC-EC differentiation with H9 (n=3, independent experiments). Total cell counts, 
viability and populations expressing EC markers CD31 and CD144 and EPC 
markers CD309 and CD34 were compared on day 7 of the differentiation. Statistical 
significance was evaluated using repeated measures ANOVA with Tukey’s post hoc 
comparisons, all non-significant when compared to Ang II only control. 
ANOVA p>0.05 
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6.4 Discussion 
In summary, the data presented in this chapter revealed upregulated AT2R 
expression between day 2 and 3 of hESC-EC differentiation and progressive AT1R 
upregulation, suggesting that components of the RAS may play a role in 
endothelial differentiation. However, addition of exogenous Ang II at two 
different concentrations to the differentiation media did not alter total cell 
numbers and/ or the differentiation efficiency. Utilising the AT1R antagonist 
Losartan from day 0 of the hESC-EC differentiation had a limited effect on 
hESC-EC differentiation and thus was not investigated further. Blocking the AT2R 
from day 3 of the differentiation using PD-123319 (Dudley et al., 1990) also did 
not have an effect on hESC-EC differentiation. However, when PD-123319 was 
added in the presence of Ang II, reduced differentiation efficiency and reduced 
total cell numbers at the end of the hESC-EC differentiation were observed. 
Taken together, it can be suggested that, in the absence of AT2R signalling, AT1R 
signalling is detrimental to hESC-EC differentiation.  
Ang II receptors are differentially regulated during endothelial development with 
the AT2R expressed in the foetal cardiovascular and renal tissues and the AT1R 
upregulated during maturation (Bagby et al., 2002; Shanmugam et al., 1996; 
Vinturache and Smith, 2014). Additionally, ACE is regarded as one of the early 
markers of endothelial development (Jokubaitis et al., 2008; Sinka et al., 2012; 
Zambidis et al., 2008). However, while the observations during hematopoietic 
differentiation suggest a role for Ang II signalling in establishing endothelial 
phenotypes (Zambidis et al., 2008), the effect of Ang II signalling during 
endothelial development remains unclear.  
First, expression of the RAS receptors was quantified during hESC-EC 
differentiation with H1, H9 and RC-11. Expression of the AT1R could not be 
detected in pluripotent H1 and H9 hESC, and was detected at low levels in 
RC-11. However, progressive upregulation and high AT1R expression levels were 
observed in all three cell lines by day 7 of the hESC-EC differentiation. The AT2R 
expression was low in hESC and peaked during mesoderm induction on day 2 in 
H1, and day 3 in H9 and RC-11. This is in line with the reported AT1R and AT2R 
expression patterns during development (Bagby et al., 2002; Shanmugam et al., 
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1996; Vinturache and Smith, 2014) and suggests that Ang II signalling may be 
exploited during endothelial differentiation. 
In contrast, expression of the Mas receptor remained comparable throughout the 
hESC-EC differentiation – it was highly expressed in H1, while expression levels 
in H9 and RC-11 were lower. Currently there are no reports on the role of Mas 
receptor in pluripotency. Underlying reasons for the high Mas expression were 
not investigated further as no effect of added Ang-(1-7), the natural Mas agonist 
(SANTOS 2003), could be detected. Therefore, although it would be interesting 
to further study the role of Mas in hESC-EC differentiation in the future, the 
work here focused on the role of Ang II and the AT1R and AT2R.  
To confirm the RNA expression data, protein expression levels of AT1R and AT2R 
could be evaluated. Previously, antibodies that can reliably discriminate 
between the receptor subtypes (Gao et al., 2012; Liles et al., 2015) have been 
described and could be used to investigate AT1R and AT2R expression levels. The 
interpretation of RNA expression data is further complicated by the presence of 
other cell types in the mixed differentiation system. For example, it cannot be 
excluded that fibroblasts, which express angiotensin receptors (Gray et al., 
1998), may also be present in the mixed cell population and contribute to the 
observed receptor expression patterns. 
Ideally, the expression of AT1R and AT2R should be measured in sorted cell 
populations of interest, for example the CD309+ population. To confirm the 
receptor expression in mesodermal and early endothelial progenitors, CD87+ 
(Drukker et al., 2012) or CD56+ CD326- (Evseenko et al., 2010) populations could 
be analysed. Fluorescence or magnetic activated cell sorting could be used to 
obtain 90%+ pure populations of interest which would provide a more accurate 
insight in the RAS receptor expression profiles. 
To investigate whether Ang II signalling had an effect on the endothelial 
differentiation, Ang II treatments were applied from day 0 or day 3 of the 
hESC-EC differentiation. Ang II treatments did not alter EC and EPC marker 
expression and total cell counts during the differentiation. The lack of effect 
suggests that either the hESC-EC differentiation system was already saturated by 
Ang II produced by the differentiating cells, that Ang II activated both AT1R and 
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the AT2R which can antagonise each other (Nakajima et al., 1995), or that Ang II 
does not alter the hESC-EC differentiation process. It would be critical to 
measure Ang II levels in the differentiation media, using mass spectrometry or 
commercially available enzyme-linked immunosorbent assay kits (Chappell, 
2015), to clarify this. Here, receptor-specific antagonists were used to evaluate 
the role of the AT1R and the AT2R during the endothelial differentiation. 
While observations from human peripheral blood EPC studies, suggest that Ang II 
signalling via the AT1R has been induces oxidative stress and accelerates EPC 
senescence (Endtmann et al., 2011; Imanishi et al., 2008, 2005). Treatments 
with the AT1R antagonist Losartan (Duncia et al., 1992) from day 0 of the 
hESC-EC differentiation did not have significant effects on the total cell counts, 
or percentage of cell expressing EPC an EC markers. However, oxidative stress 
and cell senescence was not measured in this experiment. 
When Ang II was added to the differentiation media in addition to Losartan, a 
significant reduction in the percentage of cells expressing EPC markers on day 5 
and EC markers on day 7 was observed, however no changes in total cell counts 
were observed. To confirm whether the observed effect was due to AT1R 
inhibition alone or AT2R activation in the presence of the AT1R blockade, the 
AT2R inhibitor PD-123319 (Dudley et al., 1990) was added to the differentiation 
media in addition to Losartan and Ang II. A reduction in the percentage of cells 
expressing EC markers was seen in Losartan and Ang II treated differentiations, 
as observed in the previous experiment. This was also not significantly different 
from the Losartan, Ang II and PD-123319 treated differentiations, implying that 
the observed effect was due to AT1R blockade, not preferential AT2R signalling. 
To account for possible loss of the drug potency due to degradation during the 
time course following a single treatment, the experiment was modified to 
include daily treatments. No significant differences were seen in EC marker 
expression at the end of the differentiation in Ang II and Losartan treated 
differentiations. Given that the effect of Losartan treatments, alone or in 
combination with Ang II, on the hESC-EC differentiations was limited, further 
experiments focused on investigating the effects of AT2R signalling during hESC-
EC differentiation instead. 
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To examine the role of the AT2R during hESC-EC differentiation, the AT2R agonist 
CGP-42112A (Hines et al., 2001) was added from the day 0 of the hESC-EC 
differentiation. No significant differences were seen in EC and EPC marker 
expression, while a non-significant reduction in total cell numbers was seen and 
needs to be confirmed in additional experimental repeats. Signalling via the 
AT2R has been shown to exert anti-growth effects in endothelial cells via 
decrease of AKT and eNOS phosphorylation (Benndorf et al., 2003; Kou et al., 
2007; Stoll et al., 1995), which is in line with this observation. To confirm this, 
changes in nitric oxide production could be measured using the commercially 
available nitric oxide kits. In contrast, Ikhapoh et al. (2015) suggested that 
signalling via the AT2R potentiates VEGF signalling and induces endothelial 
phenotypes in microswine bone marrow derived MSCs, while no changes in cell 
numbers were reported. This discrepancy might be explained by cell type-
specific differences. Alternatively, as the role of the AT2R was inferred from 
experiments using Ang II in combination with PD-123319 (Ikhapoh et al., 2015), it 
could be suggested that AT1R activation in the absence of AT2R, or blocking of 
Mas or MrgD receptor signalling (Lautner et al., 2013; Tetzner et al., 2016) could 
also be responsible for the reported effects.  
To investigate the effect of blocking the AT2R during the hESC-EC 
differentiation, PD-123319 was added from day 3 of the hESC-EC differentiation 
when AT2R expression was upregulated. PD-123319 treatments alone did not 
alter the percentage of cells expressing EC and EPC markers and total cell 
counts. This suggests that AT2R signalling does not have a beneficial effect 
during hESC-EC differentiation. However, when Ang II was added to the 
differentiation media in combination with PD-123319, a significant reduction in 
total cell counts was observed, while viability remained unchanged. As Ang II 
treatments in the previous experiments were not detrimental to the hESC-EC 
differentiation, it can also be suggested that AT1R activation in the absence of 
compensatory AT2R signalling may be responsible for the observed decrease in 
total cell numbers. A similar pattern was observed in Ang II and PD-123177 
treated differentiations, supporting the conclusion that this was a specific effect 
of AT2R blockade and not an off target effect of PD-123319 (Daugherty et al., 
2013; Lautner et al., 2013; Tetzner et al., 2016).  
232 
 
Taken together, this data supports the observation that AT1R signalling in the 
absence of AT2R signalling during hESC-EC differentiation is detrimental to the 
total cell numbers and the efficiency of EC differentiation. This also mimics the 
observations in the MSC differentiation system, where combined VEGF, Ang II 
and PD-123319 treatments significantly reduced EC marker expression (Ikhapoh 
et al., 2015), however, the data presented here suggests that this is due to 
detrimental effects of AT1R signalling, when compensatory AT2R-mediated 
effects are absent. 
Additionally, while signalling via the AT2R does not appear to have any beneficial 
effects on its own, as suggested by the experiments utilising the specific AT2R 
agonist CGP-42112A, it seems to be required to counterbalance the negative 
effects of the AT1R as the detrimental effects were not observed in Ang II only 
treated differentiations. The mechanisms underlying this were not investigated 
due to time constraints. However, as the cell viability remained comparable, it’s 
likely that the reduced cell growth is due to AT1R effects on cell proliferation or 
senescence as discussed above. 
Furthermore, one of the potential targets of Ang II signalling is VEGF signalling, 
which forms a central signalling axis during endothelial differentiations as 
described in section 1.7.2, with a range of effects on endothelial differentiation 
and cell survival. Ang II signalling via AT1R and PKC has been demonstrated to 
increase VEGF receptor CD309 expression in EPCs (Imanishi et al., 2004) and 
retinal microcapillary endothelial cells (Otani et al., 1998). Signalling via AT1R 
has also been shown to aid differentiation of CD309+ mesodermal cells in mouse 
iPSC (Ishizuka et al., 2012) and haemangioblast colonies preferentially 
differentiate towards endothelial progenitor cells after PD-123319 treatment 
(Zambidis et al., 2008), suggesting that similar effects may be observed in hESC 
endothelial differentiation.  
However, here Ang II treatment alone did not increase the percentage of cells 
expressing EPC and EC markers, and Losartan treatments alone, did not 
consistently have a detrimental effect on the EPC and EC populations. In 
contrary, when Ang II was added in addition to PD-123319, a trend for a reduced 
percentage of cells expressing EC and EPC markers was observed, perhaps due to 
the detrimental effects of AT1R signalling on EPC growth. 
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Interestingly, when this experiment was repeated with daily replenishment of 
the agonists/ antagonists this effect was abolished. While direct comparison of 
these experiments cannot be made as only two of the three experimental runs 
were done in parallel, this observation suggests that AT1R activation in the 
absence of AT2R activation may induce paracrine secretion of a growth factor 
affecting cell proliferation and survival which is then removed during media 
changes. In order to identify the growth factor responsible for the observed 
effects, growth factor RNA expression and protein level expression should be 
determined.  
Shi et al. (2009) reported that Ang II signalling via AT1R and ERK/AKT induces 
paracrine secretion of VEGF in a MSC differentiation system. Additional evidence 
has been provided from in vivo observations showing Ang II and AT1R dependent 
upregulation of VEGF expression (Amaral et al., 2001; Tamarat et al., 2002). 
However, increased VEGF signalling would be a positive regulator for hESC-EC 
differentiation. Furthermore, while here changes in VEGF expression were not 
evaluated, it is unlikely that changes in the VEGF secretion would have 
significant effects on the hESC-EC differentiation due to the high concentrations 
of VEGF added to the differentiation media.  
While, without further experimental evidence, it is impossible to be certain of 
the growth factors responsible for the observed effects, TGFB is an obvious 
candidate. Indeed, TGFB signalling can negatively affect both EC proliferation, 
viability and specification (Asano and Trojanowska, 2009; Castañares et al., 
2007; James et al., 2010; Sahara et al., 2014) as described previously in section 
3.1. In addition, Ang II acts on fibroblasts to induce TGFB secretion in 
myofibroblast cultures (Campbell and Katwa, 1997; Gray et al., 1998) and also 
induces TGFB in vascular smooth muscle cultures (Gibbons et al., 1992; Itoh et 
al., 1993). It remains unclear, whether TGFB expression is also induced in 
endothelial progenitor cells, however, given the mixed nature of hESC-EC 
differentiation, the presence of other secretory cell types is likely.  
To confirm that the detrimental effects are indeed mediated via the AT1R, it 
should be confirmed that adding Losartan, in addition to Ang II and PD-123319 
reversed the observed effects. Previous experiments using combined Ang II, 
Losartan and PD-123319 reported in this chapter demonstrated a trend for 
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reduced percentage of EC cells, but not reduced total cell numbers. However, 
treatments were applied from day 0 of the differentiation in these experiments, 
and thus are not directly comparable. 
Alternatively, AT1R or AT2R-specific knock out cell lines could be used to gain 
insight into the role of these receptors during hESC-EC differentiations. To do 
this, clustered regularly interspaced short palindromic repeats systems (Cong et 
al., 2013; Mali et al., 2013) could be employed for precise genome editing, and 
inducible gene knockout systems have also been described (Chen et al., 2015) 
allowing for differentiation stage specific gene editing. The knock out cell lines 
could be differentiated towards endothelial lineages in the presence or absence 
of added Ang II and the cell phenotypes throughout the differentiation could be 
evaluated and compared with wild type cells. 
Additionally, it is required to confirm these observations in a range of cell lines 
and further research is required to investigate the underlying mechanisms using 
high efficiency differentiation cultures, if possible. The activation of 
downstream signalling pathways, for example ERK, AKT/eNOS, and oxidative 
stress should also be evaluated to gain further insight into the downstream 
effectors of RAS signalling during the endothelial differentiation. 
Here the functional effects of RAS manipulation were not evaluated, however, it 
is likely that the RAS could alter the functionality of the differentiated cells 
without obvious changes in EC and EPC marker expression in line with the 
previously described effects of the RAS on nitric oxide production. For example, 
AT1R mediated eNOS induction has been extensively reported to enhance 
angiogenesis in vitro and in vivo (Imanishi et al., 2004; Otani et al., 1998; 
Tamarat et al., 2002), with the AT2R reported to have opposing actions 
(Benndorf et al., 2003; Kou et al., 2007).  Alternatively, more recently Ang II 
pretreatments have been reported to enhance BM-MNC angiogenic capacity via 
the AT2R induced eNOS induction (Xu et al., 2013) and MSC angiogenic capacity 
via increased paracrine VEGF secretion (C. Liu et al., 2015) in in vivo myocardial 
infarction models, thus, any beneficial or detrimental effects of RAS signalling 
on the functional characteristics of the derived hESC-EC cells remain to be 
clarified. 
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In summary, the data presented in this chapter demonstrated differential 
expression of RAS receptors during hESC-EC differentiation, suggesting that Ang 
II signalling may be active during endothelial differentiation. Ang II treatments 
alone did not alter cell numbers and EC marker expression at the end of the 
differentiation. To investigate the roles of the AT1R and the AT2R during hESC-EC 
differentiation, receptor specific antagonists were used alone or in combination 
with Ang II. The AT1R antagonist Losartan had a limited effect on the hESC-EC 
differentiation and thus was not investigated further. When PD-123319 was 
added to the differentiation system alone, no significant changes were observed 
in the total cell numbers and marker expression profiles. However, when PD-
123319 was used in addition to Ang II, a significant reduction in the total cell 
numbers and EC marker expression was observed. This effect was consistent 
when the alternative AT2R antagonist PD-123177 was used, suggesting that 
unopposed AT1R activation is detrimental to hESC-EC differentiation. 
Additionally, the data also demonstrates that the effect was abolished by daily 
treatments, suggesting that a secreted growth factor might mediate the 
observed effects. Further research is required to investigate this and identify the 
secreted factor. This highlights the complex role of the RAS during endothelial 
differentiation and suggests that Ang II signalling should be limited during hESC-
EC differentiation.  
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Chapter 7: General Discussion. 
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7.1 Discussion 
Cardiovascular disease represents a significant socio-economic burden and 
minimally invasive therapies that address the needs of patients suffering with 
PAD and CLI are needed. Cell therapies have been proposed as an alternative to 
pharmacological and surgical treatments, yet, have demonstrated somewhat 
limited efficacy. Therefore, it has been speculated that differentiation of hESC 
towards endothelial lineages, could provide well defined cell populations with 
superior angiogenic profile. 
While numerous endothelial differentiation protocols have been published 
(Descamps and Emanueli, 2012) and, more recently, high differentiation 
efficiencies have been achieved (Patsch et al., 2015; Prasain et al., 2014; Sahara 
et al., 2014), most of these approaches are not optimised for clinical purposes 
due to the use of poorly defined, non cGMP compatible reagents, or require 
additional processing steps, such as cell sorting to remove undefined cell 
populations which can pose a teratoma risk. This complicates the clinical 
approval and increases the therapy cost, representing a significant hurdle that 
needs to be overcome in order to use differentiated endothelial cells for the 
future angiogenesis therapies. 
Therefore, here it was aimed to develop and optimise a clinically compatible 
hESC-EC differentiation protocol that avoids using poorly defined reagents, and 
yields high percentages of cells expressing EC markers without the use of cell 
sorting. While not all reagents used in the experimental work were cGMP grade 
due to cost implications, for example Lonza EGM-2 and VEGF, clinical grade 
versions of these reagents are available, if required. Use of cGMP compatible 
reagents simplifies the bench to bedside translation of this differentiation 
protocol, reducing the time and cost of bringing hESC-EC cell therapies to clinic. 
Initially, as described in Chapter 3, the hESC-EC differentiation protocol was 
optimised to reduce the cost of the differentiation by using Pluronic F-127 
(Ungrin et al., 2008) coated instead of low adherence wells, while retaining the 
differentiation efficiency. Inhibition of TGFB signalling using SB431542 was 
evaluated as a cGMP compatible approach for increasing EC marker expressing 
cell yields (James et al., 2010; Sahara et al., 2014), yet, no additional benefit 
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was observed. Thus, TGFB inhibitors were not included in the hESC-EC 
differentiation protocol described here. The optimised protocol consists of 
dissociating pluripotent hESC on day 0 of the differentiation and generation of 
controlled size EB in 96 well tissue culture plates coated with Pluronic F-127 
(Ungrin et al., 2008) in mesodermal specification media developed in the group 
(Olivier et al., 2016). On day 3 of the differentiation, the EBs are plated in 
Gelatin coated 6 well tissue culture plates in vascular specification media 
supplemented with VEGF. Gene expression profiling showed a peak of 
mesodermal gene Brachyury expression on day 2 of the differentiation, followed 
by upregulation of endothelial gene KDR and CDH5 expression. By day 7, cells 
with endothelial morphology can be observed and approximately 30% of the 
differentiated cells express both endothelial markers CD31 and CD144.  
While gene and surface marker expression patterns showed endothelial 
commitment of the differentiated cells, the functional characteristics, and the 
in vitro and in vivo angiogenic potential of the differentiated cells was not 
evaluated in this thesis. However, hESC-EC differentiated cell in vitro Matrigel 
tubule formation and AcLDL uptake assays have been performed in the group 
(personal communication, Dr Alison Condie, University of Glasgow) and 
confirmed the functionality of the differentiated cells. It would be beneficial to 
also perform the widely used nitric oxide production and matrigel plug in vivo 
assays, in addition to other functional tests suggested for extensive EC function 
testing, for example, vascular structure formation in coculture with pericytes, 
and incorporation in the vasculature of zebrafish xenografts (Orlova et al., 
2014).  Such testing would provide the much needed insight of the functionality 
of the generated cells and would allow for comparison to other endothelial cell 
types, for example NRP1+ CD31+ cells (Prasain et al., 2014) or EC expressing 
arterial markers (Rufaihah et al., 2013), reported to have superior in vivo vessel-
forming ability. 
The developed hESC-EC protocol yields a reasonable percentage of cells 
coexpressing EC markers CD31 and CD144 after 7 days of differentiation, without 
out the use of cell sorting or undefined reagents, such as Matrigel and serum, 
which sets it apart from other endothelial differentiation approaches. Yet, it is 
clear that there is scope for further optimisation with focus on the use of small 
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molecule drugs to enhance the differentiation efficiency and avoid the need of 
sorting prior to the clinical use. Therefore, it was hypothesised that high 
throughput screening could be used to optimise the hESC-EC differentiation 
protocol.  
While various approaches can be employed for high throughput optimisation of 
the endothelial differentiation, the use of fluorescent reporter cell lines offers a 
highly specific and flexible way to monitor the progression of the differentiation. 
Therefore, as described in Chapter 4, work was undertaken for generation of 
reporter cell lines suitable for monitoring both mesodermal induction and 
vascular specification phase of the hESC-EC differentiation. ETV2 plays a central 
role in endothelial development - it induces vascular mesoderm (Kataoka et al., 
2011) and is required for endothelial and hematopoietic development (Ferdous 
et al., 2009; Shi et al., 2014). ETV2 expression profiling revealed transient ETV2 
mRNA expression at the end of the mesodermal specification phase of the 
hESC-EC differentiation. Therefore, ETV2 was selected as an early endothelial 
commitment reporter gene. For monitoring of the endothelial commitment 
during the vascular specification phase of the differentiation, CDH5 (Dejana et 
al., 1999) and ROBO4 (Huminiecki et al., 2002; Huminiecki and Bicknell, 2000) 
genes were selected as both of these genes are specifically expressed in mature 
endothelium and were shown to be progressively upregulated during the hESC-EC 
differentiation.  
Reporter constructs where cognate ETV2, CDH5 or ROBO4 promoter fragments 
drive the expression of GFP or RFP fluorescent proteins were generated. 
Preliminary validation was attempted both using the generated plasmids, and, in 
addition, lentiviral vectors carrying the constructs were generated and used for 
validation in HUVECs, HSVECs and during the hESC-EC differentiation. Reporter 
gene expression was not observed during the validation, suggesting that the 
generated reporter constructs were not functional, however, further validation 
is required. Instead, it was decided to obtain a commercially available ETV2 
reporter construct and a previously published CDH5 reporter construct (Sahara et 
al., 2014), and use these for the optimisation of hESC-EC differentiation. 
Preliminary validation of the lentiviruses carrying either of the obtained reporter 
constructs suggested non-specific reporter gene expression. This highlights the 
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complexity of gene expression regulation and suggests that there are additional 
regulatory elements that were not included in the chosen promoter sequences. 
While reporter cell line generation for high throughput screening was not 
pursued further, the use of reporter cell lines for high throughput screens 
remains an attractive approach for the optimisation of the hESC-EC 
differentiation. It can be suggested that the recent advances in precise genome 
editing, for example TALEN (Hockemeyer et al., 2011; Joung and Sander, 2013) 
and CRISPR (Cong et al., 2013; Mali et al., 2013), should be considered as an 
alternative strategy for reporter generation, allowing for creation of endogenous 
reporter constructs. However, here it was proposed that rational targeting of 
novel signalling pathways could be employed as an alternative approach for the 
optimisation of hESC-EC differentiation.  
Furthermore, it became clear that arterial endothelial cells may offer higher 
efficacy for clinical angiogenesis (Rufaihah et al., 2013; Sriram et al., 2015). 
Indeed, limited efficacy has been one of the key issues with the adult BM-MNC 
therapies (Teraa et al., 2015) and, thus, the prospect of differentiating EC 
populations with superior angiogenic characteristics is highly appealing. 
Preliminary gene expression analysis during the hESC-EC differentiation 
suggested induction of arterial gene HEY2 but not venous gene EPHB4 expression 
during the hESC-EC differentiation. However, there is scope for more robust 
induction of arterial phenoytpes. Therefore, the potential targets to induce 
arterial phenotypes and to increase the arterial marker expressing cell 
percentages during the hESC-EC differentiation were investigated.  
The central role for NOTCH and VEGF signalling in arterial specification is well 
established (Corada et al., 2014; Lawson et al., 2001), however, research using 
mESC differentiation models suggests that intracellular cAMP levels also 
contribute to arterial phenotypes, possibly via activation of NOTCH signalling 
(Yurugi-Kobayashi et al., 2006), and forming of NICD, RBPJ and β-catenin 
complexes (Yamamizu et al., 2010). Additionally, targeting cAMP signalling has 
also been reported to increase EC differentiation efficiency via targeting ETV2 
(Shi et al., 2015; Yamamizu et al., 2012b). Therefore, in Chapter 5, it was 
hypothesised that intracellular cAMP levels could be targeted pharmacologically 
to increase the differentiation efficiency, and to induce complete arterial 
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phenotype, including the expression of arterial phenotype associated genes 
(Aranguren et al., 2013). This could not only reduce the need for cell sorting 
before clinical use, but also could potentially deliver a clinically superior cell 
population for therapeutic angiogenesis. 
Forskolin treatments increased intracellular cAMP levels during the hESC-EC 
differentiation, however, no significant increases in arterial or arterial 
associated gene expression were observed. The lack of arterial gene expression 
was in contrast to the previous observations using mESC differentiation systems 
(Yamamizu et al., 2012b; Yurugi-Kobayashi et al., 2006) and more recent 
publications using hESC differentiation models (Rufaihah et al., 2013; 
Sivarapatna et al., 2015). Here, it was speculated that this discrepancy could be 
due to use of serum in the previously published differentiation protocols, which 
may supplement the differentiation media with BMP4 (Wöltje et al., 2015) that, 
in the presence of increased intracellular cAMP levels, may induce arterial 
phenotype. Further research is required to confirm this, and comparing the 
effects of increased cAMP levels during hESC-EC differentiation in presence and 
absence of serum would provide a valuable validation of this hypothesis. 
However, serum products are not well defined, can display batch variability and, 
thus, present unnecessary complications for clinical translation of cell therapies. 
Therefore, it would be required to identify and validate the active compound in 
serum that is essential in addition to cAMP for the induction of arterial 
phenotype and use it for hESC-EC arterial differentiation instead. 
However, a trend of increased EC marker CD31 and CD144 expression was 
observed and was shown to be mediated mostly via higher percentage of 
CD144low CD31+ cells. This supports the use of Forskolin in recently developed 
endothelial differentiation methods (Patsch et al., 2015; Sahara et al., 2014), 
however, the effects and mechanisms of Forskolin treatments were not 
investigated in these publications. ETV2 mediated effects may contribute to the 
increased EC percentage at the end of the differentiation (Shi et al., 2015; 
Yamamizu et al., 2012b). However, here it was also observed that the increased 
differentiation efficiency was mediated via increase in CD31+ CD144low cell 
population. Therefore, it was proposed that higher intracellular cAMP levels may 
contribute to the stabilisation of the CD144 junctions via EPAC (Fukuhara et al., 
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2005; Kooistra et al., 2005) and, thus, increasing CD144 expression levels and 
promoting EC survival (Carmeliet et al., 1999a). To confirm this, these 
experiments should be repeated using EPAC specific cAMP analogues (Carmeliet 
et al., 1999a) and a detailed CD144 expression analysis should be performed. 
The observed increase in the differentiation efficiency highlights the value of 
using small molecule drugs for the optimisation of hESC-EC differentiation. Such 
treatments can be easily added to the differentiation protocols without 
significantly increasing the differentiation cost, and are compatible with the 
clinical requirements for cell therapies. 
The renin angiotensin system (RAS) may play a role in the hESC-EC 
differentiation, yet, that has not been described in publications investigating 
endothelial differentiation of hESC. Indeed, evidence suggests a presence of a 
local RAS in the vasculature (Campbell and Habener, 1986; Lilly et al., 1985; 
Rider et al., 2015), ACE has been described as an early marker for lymphatic, 
hematopoietic and endothelial development (Jokubaitis et al., 2008; Sinka et 
al., 2012; Zambidis et al., 2008), and AT1R and AT2R signalling manipulation has 
been shown to induce endothelial phenotypes in a hESC hematopoietic 
differentiation system (Zambidis et al., 2008). Additionally, active Angiotensin II 
(Ang II) signalling via AT1R may also mediate a range of detrimental effects on 
EPC growth and proliferation (Endtmann et al., 2011; Imanishi et al., 2008, 
2005). Therefore, in Chapter 6, it was hypothesised that Ang II signalling is 
active during the hESC-EC differentiation and that this axis may be exploited to 
enhance the hESC-EC differentiation.  
Differential RAS receptor expression was demonstrated during hESC-EC 
differentiation, supporting the hypothesis and suggesting a role for the Ang II in 
the differentiation. Ang II and Losartan treatments, alone or in combination, did 
not consistently alter the percentage of endothelial cells and total cell counts at 
the end of the differentiation. However, when PD-123319 was used together 
with Ang II, a significant reduction in total cell numbers and a trend of reduced 
percentage of cells expressing EC markers CD31 and CD144 at the end of the 
differentiation was observed. This suggests that unopposed AT1R activation is 
detrimental for hESC-EC differentiation. Further research is required to confirm 
the mechanisms underlying this during the hESC-EC differentiation. In particular, 
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the role of AT1R induced oxidative stress and senescence, and the role of AT2R in 
counteracting these effects needs to be investigated. While here AT1R blocking 
did not have a robust beneficial effect, it cannot be excluded that in other 
differentiation systems AT1R signalling mediated effects hinder EC 
differentiation efficiency. Thus, the use of clinically available AT1R antagonists 
may be an attractive, low cost and cGMP compliant way to enhance the 
differentiation efficiency of clinical grade endothelial differentiation protocols. 
Taken together, the work described in this thesis has contributed to the current 
knowledge of processes underlying endothelial differentiation and has suggested 
approaches for development and optimisation of clinically compatible 
endothelial differentiation protocols. Indeed, while hESC and hIPSC derived 
endothelial cell therapies for therapeutic angiogenesis remain an area of active 
research and higher differentiation efficiencies have been achieved (Patsch et 
al., 2015; Prasain et al., 2014; Sahara et al., 2014), there is a lack of focus on 
novel approaches to increase endothelial differentiation efficiency and most of 
the published protocols employ highly similar differentiation strategies. Here it 
was shown that the intracellular cAMP levels can be manipulated to increase the 
percentage of cells expressing endothelial markers at the end of the 
differentiation and suggests mechanisms responsible for these effects. 
Furthermore, the negative effects of the AT1R signalling during the hESC-EC 
differentiation were demonstrated. Both of these signalling systems have 
received little attention and research focus during hESC-EC differentiation, and 
therefore represent novel targets for optimisation. Therefore, it can be 
proposed that evaluation of other signalling pathways, for example sphingosine 
1-phosphate signalling (Schuchardt et al., 2011), may reveal additional targets 
that can be used to further enhance the endothelial differentiation in a clinically 
compatible manner. 
Furthermore, while the developed hESC-EC differentiation protocol is clinically 
compatible, as it does not use poorly defined reagents, there is scope for 
additional optimisation to ensure the reliability, cGMP compatibility and 
affordability of the differentiated endothelial cell therapies. Firstly, 
optimisation of pluripotent hESC and hIPSC derivation and culture conditions is 
required. Various methods for cGMP compatible hESC and hIPSC derivation have 
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been described (Baghbaderani et al., 2015; Tannenbaum et al., 2012), and 
therefore, if possible, clinical grade hESC and hIPSC should be used. Here 
research grade hESC cell lines H1 and H9, as well as clinical grade hESC cell lines 
RC-11 and RC-9 were cultured in StemPro media in tissue culture vessels coated 
with CellStart or Vitronectin XF. While this culture method is clinically 
compatible, other commercially available, simplified and highly defined culture 
media, for example, Essential 8 medium (Chen et al., 2011; Wang et al., 2013) 
and L7 hPSC medium (Baghbaderani et al., 2016), may be more suitable for 
clinical grade hESC culture. More recently, human serum derived protein inter-α-
inhibitor (IαI) has been identified as supporting feeder free, hESC and hIPSC 
culture on uncoated tissue culture plastic (Pijuan-Galitó et al., 2016), if 
recombinant IαI can be developed, it would represent a significant advance for 
future large scale, simplified, clinically compatible hESC culture systems.  
Undefined reagents which may contribute to cell signalling, for example 
Matrigel, are often used for hESC and hIPSC culture in the recently reported 
endothelial differentiation methods (Patsch et al., 2015; Prasain et al., 2014; 
Sahara et al., 2014). Ideally, the developed endothelial differentiations 
protocols, including the hESC-EC differentiation protocol described here, should 
be developed, optimised and evaluated using multiple hESC and hIPSC lines 
derived and cultured following the latest clinically compatible methods. This 
would ensure the reproducibility of the developed differentiation methods and 
also would simplify the clinical translation.  
Safety of the proposed cell therapies is another key aspect that has to be 
considered during preclinical development. The use of hESC and hIPSC derived 
cell therapies carries a tumorigenicity risk due to undifferentiated cells 
remaining in the final cell therapy product and due to genetic instability of the 
cells (Knoepfler, 2009). Such concerns represent an important roadblock in 
getting stem cell therapies to clinical practice and, indeed, unexpected 
mutations have been observed in the first hIPSC clinical trial where 
differentiated retinal pigment epithelium cells were used to treat age-related 
macular degeneration, resulting in temporary suspension of the trial (Garber, 
2015). These safety concerns can be addressed by using extensive cell therapy 
quality control testing for genetic abnormalities and ensuring the absence of any 
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residual pluripotency cells. To address the concerns of residual pluripotency, 
characterisation of the non-EC marker expressing cells present after hESC-EC 
differentiation has been performed in our group (personal communication, Dr 
Alison Condie, University of Glasgow) and confirmed lack of pluripotent cells, 
which is crucial for translation of this method to clinical therapy.  
Other methods for ensuring differentiated hESC cell therapy safety include 
isolating the cells from the rest of the body, as done with the insulin producing 
islet replacement product developed by Viacyte (Agulnick et al., 2015), 
however, this would not be a suitable approach for therapeutic angiogenesis, 
where the therapeutic cells support angiogenesis and integrate in the 
vasculature. Alternatively, introducing inducible suicide genes mediating 
apoptosis by caspase-9 (Ando et al., 2015; C. Wu et al., 2014; Yagyu et al., 2015) 
has been proposed as an additional safety feature for hESC and hIPSC cell lines 
which, if required, would allow for efficient clearance of the transplanted cells. 
However, such approaches require genetic manipulation of the cell lines, which 
introduces additional risks and further complicates clinical approval of such cell 
products.   
With the key signalling pathways for endothelial differentiation being well 
described and widely targeted, it can be suggested that future work should also 
evaluate using small molecule drugs to enhance these signalling pathways, and 
screen for non-peptide cytokine mimetics. Generally, small molecule drugs are 
more stable and easier to quantify, thus benefiting the robustness and 
reproducibility of the differentiation, and offer a cost advantage, when 
compared to recombinant proteins  (Feng et al., 2016). Indeed, small molecule 
GSK3B inhibitors have been used instead of WNT in multiple published 
endothelial differentiation methods (Patsch et al., 2015; Sahara et al., 2014). 
And, while the complex nature of cytokine receptor signalling poses significant 
challenges for pharmaceutical targeting of growth factor receptors (Boger and 
Goldberg, 2001), a small molecule sensitizer of BMP signalling has been shown to 
contribute to mesodermal induction (Feng et al., 2016) and induction of one of 
the BMP4 effectors (ID1) by small molecule flavonoids has been shown in human 
cervical carcinoma cell line (Vrijens et al., 2013), providing a proof of principle 
for this approach. 
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Once highly efficient, robust and cGMP compliant endothelial cell derivation 
methods are established, further research will be required to evaluate various 
other clinical aspects of endothelial cell therapies. For example, the required 
cell dose and the best administration route for therapeutic angiogenesis 
currently remains unclear. Indeed, the grafting efficiency is the key determinant 
of the required dose and insights from adult cell therapies suggest that the 
engraftment efficiencies can vary significantly depending on the route of the 
administration (de Silva and Lederman, 2004; Golpanian et al., 2016; Scudellari, 
2009). While intravenous injection is the least invasive method of cell delivery, 
other methods, for example, direct injection in the affected areas, may offer 
superior cell grafting (Freyman et al., 2006). Furthermore, the use of hydrogel 
based vehicles for cell therapy delivery allow for additional control of cell fate 
and behaviour (C. Wang et al., 2010) and perhaps the previously described 
hydrogel based local VEGF delivery systems (Silva and Mooney, 2007) could be 
combined with cell therapy products to enhance cell grafting and angiogenic 
activity.  
While currently the delivery of endothelial cells capable of directly contributing 
to therapeutic responses receives the majority of research focus, it can also be 
argued that hESC derived endothelial cells are crucial for the advancement of 
biotechnology and tissue engineering fields. Indeed, tissue vascularisation 
remains a key limitation for tissue engineering (Lovett et al., 2009; Mao and 
Mooney, 2015) and endothelial cell can be used to prevascularise the generated 
tissues before transplantation. For example, EC coated collagen rods have been 
used to create perfusable vessel networks for tissue engineering (McGuigan and 
Sefton, 2006), while endothelial cell coculture with osteoblasts (Unger et al., 
2007), myoblasts and fibroblasts (Levenberg et al., 2005), and keratinocytes and 
fibroblasts (Black et al., 1998) has been used to generate tissues containing 
capillary networks. The large number of endothelial cells required for 
vascularisation limits the use of adult cell types, thus, the prospect of large 
scale clinically compatible endothelial cell differentiation from hESC and hIPSC 
is particularly attractive. 
In summary, endothelial cell therapies hold a lot of promise not only for 
therapeutic angiogenesis, but also are a cornerstone for future developments in 
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tissue engineering. While adult cell sources can be used to obtain and expand in 
vitro endothelial cultures, these methods cannot provide the large number of 
cells required for therapeutic purposes and tissue engineering. Therefore, well 
characterised, highly efficient, robust, and cGMP compliant endothelial methods 
are required to facilitate the development of novel clinical therapies. The work 
described in this thesis contributes to the development of clinically compatible 
endothelial differentiation methods and suggests areas of future research for 
further advancement of endothelial differentiation methods. While multiple 
significant hurdles concerning cGMP compatibility and efficiency of the 
described endothelial differentiation methods remain to be overcome, the 
recent advances in hESC derivation and culture, and endothelial differentiation 
promise large scale, clinically compatible endothelial cell differentiation 
methods in the near future, representing an important milestone towards 
clinical cell therapies for angiogenesis and tissue engineering.  
 
7.2 Concluding remarks 
In conclusion, it was aimed to develop a clinically compatible endothelial 
differentiation protocol and optimise the developed differentiation method using 
reporter cell lines indicating early and late endothelial commitment. The 
reporter constructs could not be validated and, thus, high throughput 
optimisation was not performed. However, the use of reporter cell lines is a 
viable approach to screen for compounds increasing the yields of hESC-EC 
differentiation, this way avoiding the need for cell sorting prior to clinical use of 
the differentiated cells. Additionally, cAMP signalling was exploited during 
hESC-EC differentiation to increase the percentage of the EC at the end of the 
differentiation. Furthermore, the negative effects of AT1R signalling during 
hESC-EC differentiation were demonstrated. Both of these signalling systems can 
be easily manipulated in a clinically compliant manner, and therefore represent 
an attractive target during clinically compatible hESC-EC differentiation. Taken 
together, these studies have highlighted the difficulties of establishing efficient, 
clinically compatible hESC-EC differentiation methods, which are crucial for 
future therapeutic angiogenesis cell therapies and tissue engineering. 
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